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1. Abstracts 
 
1.1 Summary 
 
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer, with a 
medium overall survival of only six months. The standard of care treatment, consisting of 
surgical resection followed by adjuvant chemotherapy, which incidentally can be offered to 
as little as 20% of the newly diagnosed patients, shows only marginal benefit for patients 
and no significant improvements to PDAC therapy have been made over the past two 
decades. PDAC is currently treated as a single, homogenous disease. Recently, three 
molecular subtypes termed classical, exocrine-like and quasimesenchymal (QM) have been 
defined, based on transcriptomic profiling of micro-dissected cancer cells from primary 
tumors and commercially available cell lines. The newly defined molecular subtypes were 
associated with differences in patient overall survival and are suggested to predict response 
to different chemotherapeutical agents. However, no clinical markers are available for the 
stratification of patients according to these molecular subtypes. 
The aim of this study was the identification and validation of novel pan-PDAC as well as 
subtype-specific protein biomarker candidates, which can be employed in the development 
of novel clinical applications, such as diagnostics and/or targeted PDAC therapies. Using a 
panel of twelve patient derived primary pancreatic cancer cell lines, grown in a chemically 
defined serum free medium, we employed LC-MALDI-MS to identify novel cell surface and 
secreted PDAC protein biomarker candidates. Two commercially available healthy 
pancreatic cell lines served as controls. The cell surface proteome was analyzed following 
in vitro biotinylation and subsequent streptavidin pull down of the covalently biotin-labeled 
proteins, while the secreted proteome was analyzed by shotgun proteomics. In addition, we 
investigated in vivo vascular accessible PDAC biomarkers, by carrying out whole body 
perfusions of mice bearing orthotopic pancreatic tumors using a reactive biotin ester 
solution. Biomarker candidates of interest were selected after the proteomics discovery 
experiment and underwent thorough validations, using complementary antibody based 
(immunofluorescence, Western Blot) and antibody independent (single reaction monitoring, 
RT-qPCR) techniques. The validation experiments were performed both in vitro – using the 
PDAC cell culture model and in vivo – using tumor xenografts developed in immunodeficient 
mice. 
More than 2500 proteins were identified after completing the cell surface proteome analysis, 
and over 1700 proteins could be reported in the conditioned cell culture medium. We 
selected the two pan-PDAC biomarker candidates, protocadherin-1 (PCDH1) and lipocalin-
2 (LCN2), as well as the two exocrine-like biomarker candidates, cadherin-17 (CDH17) and 
galectin-4 (LGALS4), for further validations.  
In vitro immunofluorescence confirmed the exclusive presence of PCDH1 and LCN2 on the 
surface of primary patient-matched PDAC cell lines, which correlated with elevated levels 
of the corresponding mRNAs. The expression of the two exocrine-like protein biomarker 
candidates was restricted to the predicted subtype, as proven by immunofluorescence and 
single reaction monitoring. The secretion of the two exocrine-like proteins in the cell culture 
medium was additionally confirmed by single reaction monitoring. The regulation of the two 
exocrine-like PDAC biomarkers was at least partially due to the upregulation of the 
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corresponding mRNAs. Additionally, we could report that CDH17 and LGALS4 colocalize 
on the surface of cultured exocrine-like PDAC cells. In vivo immunofluorescence analyses 
corroborated the presence of PCDH1 and LCN2 on the surface of pancreatic cancer cells 
and in the tumor environment, while being completely absent in healthy human pancreata. 
Exocrine-like tumor xenografts expressed CDH17 and LGALS4 at high levels, as evaluated 
by immunofluorescence. However, a limited activation of the two putative exocrine-like 
biomarkers could be detected in vivo in some of the classical pancreatic tumors. Protein 
expression patterns correlated with reported levels of the respective mRNAs for all the 
investigated biomarker candidates, evaluated in both EpCam+ epithelial cells isolated from 
orthotopic xenografts and whole tumor tissue. 
Moreover, LCN2 and LGALS4 could be detected in the course of a proof-of-principle in vivo 
perfusion experiment using mice harboring orthotopic tumors. Therefore, we could conclude 
that the two proteins are accessible from the blood stream and could represent candidates 
for novel PDAC targeted therapies. 
Taken together, our study identifies novel pan-PDAC as well as subtype-specific protein 
biomarkers candidates, which can be used in clinical applications for patient stratification. 
Additionally, the proteins were secreted by pancreatic cancer cells, and could therefore 
represent the basis for developing novel non-invasive diagnostic tools. Importantly, the 
validated protein biomarker candidates were also accessible from the vascular system, 
making them eligible targets for novel antibody based therapies of PDAC.  
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1.2 Zusammenfassung 
 
Das duktale Pankreasadenokarzinom weist unter allen Krebserkrankungen eine der 
höchsten Mortalitätsraten auf, die mittlere Überlebenrate nach der Diagnose beträgt nur 6 
Monate. Die Standardbehandlung bestehend aus operativer Entfernung des Tumors gefolgt 
von adjuvanter Chemotherapie kann lediglich bei 20% der neu diagnostizierten Patienten 
angewandt werden und zeigt zudem nur geringen Nutzen für die Patienten. In den 
vergangenen zwei Jahrzehnten konnte die Therapie trotz intensiver Bemühungen sowohl 
seitens akademischer Forschungsstellen als auch seitens der pharmazeutischen Industrie 
nicht signifikant verbessert werden. Duktales Pankreasadenokarzinom wird derzeit bei allen 
Patienten einheitlich behandelt. Vor kurzem wurden, basierend auf Genexpressionsprofilen 
von durch Lasermikrodissektion aus humanem Tumorgewebe generierten Krebszellen 
sowie kommerziell erhältlichen Zelllinien, drei molekulare Subtypen des duktalen 
Pankreasadenokarzinoms (klassisch, exokrin-ähnlich und quasimesenchymal) 
beschrieben. Diese neu definierten molekularen Subtypen wurden mit unterschiedlichen 
Überlebensraten der Patienten assoziiert. Darüber hinaus können diese vermutlich zur 
Vorhersage des Behandlungserfolges mit verschiedenen Chemotherapeutika dienen. 
Jedoch gibt es noch keine klinischen Marker für die Stratifizierung von Patienten nach 
diesen molekularen Subtypen. 
Das Ziel dieser Studie war die Identifizierung und Validierung neuer Pan- und Subtyp-
spezifischer Protein-Biomarkerkandidaten des duktale Pankreasadenokarzinoms, welche 
zur Entwicklung neuer Diagnostika und zielgerichteter Therapien genutzt werden können. 
Anhand von zwölf aus Patientenmaterial abgeleiteten, primären Zelllinien, die in serum-
freiem Medium kultiviert wurden, konnten mittels LC-MALDI-MS neue Zelloberflächen- und 
sekretierte Biomarkerkandidaten idenfiziert werden.  Dabei dienten zwei kommerziell 
erhältliche, gesunde Pankreas-Zelllinien als Kontrollgruppe. Die Analyse des 
Zelloberflächenproteoms erfolgte durch in vitro-Biotinylierung der Zellen mit 
darauffolgender Affinitäts-basierter Anreicherung der kovalent markierten Proteine auf 
Streptavidin, wohingegen das sekretierte Proteom durch einen Shotgun-Ansatz untersucht 
wurde. Darüberhinaus wurden vaskulär erreichbare Biomarker durch in vivo-Perfusion von 
orthotop pankreastumortragenden Mäusen mit einem reaktiven Biotin-Ester Derivat 
markiert und analysiert. Aus den Proteom-Daten wurden daraufhin interessante 
Biomarkerkandidaten ausgewählt und mittels komplementären, auf Antikörpern 
basierenden Techniken (Immunfluoreszenz, Western Blot) sowie Antikörper-unabhängigen 
Techniken (Single Reaction Monitoring, RT-qPCR) validiert. Die Validierung erfolgte sowohl 
in vitro auf Zellkulturmodellen als auch in vivo mittels Tumor-Xenotransplantaten in 
immundefizienten Mäusen. 
Durch die Analyse des Zelloberflächenproteoms konnten mehr als 2500 Proteine 
identifiziert werden, im konditionierten Zellkulturmedium wurden über 1700 Proteine 
entdeckt. Zur weiteren Validierung wurden die zwei Pan-Biomarkerkandidaten 
Protocadherin-1 (PCDH1) und Lipocalin-2 (LCN2) sowie die zwei exokrin-ähnlichen 
Biomarkerkandidaten Cadherin-17 (CDH17) und Galectin-4 (LGALS4) ausgewählt. 
Durch Immunfluoreszenz wurde das spezifische Vorhandensein von PCDH1 und LCN2 auf 
der Zelloberfläche von Zelllinien, die von humanem duktalen Pankreasadenokarzinomen 
abgeleitet wurden, bestätigt, was darüberhinaus mit erhöhten Konzentrationen der 
korrepondierenden mRNAs korreliert. Wie durch Immunfluoreszenz und single reaction 
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monitoring gezeigt wurde, erwies sich die Expression der zwei exokrin-ähnlichen 
Biomarkerkandidaten wie vorhergesagt als beschränkt auf den exokrin-ähnlichen Subtyp.  
Die Sekretion der zwei exokrin-ähnlichen Subtyp-spezifischen Proteine in das 
Zellkulturmedium wurde darüber hinaus durch single reaction monitoring bestätigt. Die 
Regulation der zwei exokrin-ähnlichen Biomarker korrelierte dabei mit den erhöhten 
Konzentrationen der korrespondierenden mRNAs. Darüber hinaus konnte die 
Kolokalisierung von CDH17 und LGALS4 auf der Oberfläche von dem exokrin-ähnlichen 
Subtyp zugeordeten Zellen gezeigt werden. Die in vivo Immunfluoreszenz-Analysen 
konnten die Präsenz von PCDH1 und LCN2 auf der Oberfläche von Pankreastumorzellen 
und in der Umgebung des Tumors bestätigen, wohingegen die Biomarker in gesundem, 
humanen Pankreasgewebe nicht nachgewiesen werden konnten. Exokrin-ähnliche 
zugeordnete Xenotransplantate überexprimierten CDH17 und LGALS4 ebenfalls stark, wie 
durch Immunfluoreszenz gezeigt werden konnte. Jedoch konnte eine geringe Aktivierung 
der zwei mutmaßlich exokrin-ähnlichen Subtyp-spezifischen Biomarker in vivo auch im 
klassischen Subtyp detektiert werden. Die Proteinexpression korreliert für alle 
Biomarkerkandidaten stark mit den erhaltenen Konzentrationen der korrespondierenden 
mRNAs, welche in EpCam positiven Epithelzellen aus orthotopen Xenotransplantaten und 
Tumorgewebe evaluiert wurden. 
Darüber hinaus konnten LCN2 und LGALS4 in einem in vivo-Perfusionsexperiment mit 
orthotop tumortragenden Mäusen detektiert werden. Daraus lässt sich folgern, dass die 
zwei Protein-Biomarker vaskulär zugänglich und somit vielversprechende Kandidaten für 
neue zielgerichteten Therapien darstellen. 
In dieser Studie wurden neue Pan- und Subtyp-spezifische Protein-Biomarkerkandidaten 
für das duktale Pankreasadenokarzinom identifiziert, die klinisch zur Stratifizierung von 
Patienten genutzt werden können. Darüber hinaus werden diese Proteine von 
Pankreastumorzellen sekretiert und können daher auch als Basis für die Entwicklung 
neuartiger, nicht invasiver Diagnostika dienen. Die validierten Biomarkerkandidaten sind 
zudem durch das Blutgefäßsystem zugänglich, was sie zu geeigneten Zielstrukturen für 
neue Antikörper-basierte Therapien des duktalen Pankreasadenokarzinoms macht. 
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2. Introduction 
 
2.1 Pancreatic ductal adenocarcinoma 
Despite significant advancements made in the field of oncology, pancreatic ductal 
adenocarcinoma (PDAC) continues to represent one of the most lethal forms of cancer. 
Accounting for less than 5% of cancer cases, PDAC represents the fourth most common 
cause of cancer-related deaths in the United States (Figure 1) [1]. In Europe, in 2012 
pancreatic cancer was evaluated to be the fifth most common type cancer, with 
approximately 104’000 new cases reported per year. The high mortality rate reported for all 
patients made it the fourth cause of cancer related death in Europe [2]. The majority of 
patients succumb to the disease within 6 months from the time point of diagnosis, and the 
five year overall survival is a mere 5% [3, 4]. One of the main reasons for this devastating 
prognosis is that most patients, due to lack of early symptoms, present with an already 
advanced (i.e. metastatic disease) – and early pre-cancerous lesions are usually non-
detectable using standard imaging techniques [5]. Only a limited number of patients (~30%) 
present with resectable, localized pancreatic cancer. Surgical removal of the primary tumor, 
however, increases the five year survival rate to only 10-20% [5]. PDAC is the most common 
type of pancreatic cancer, accounting for approximately 90% of pancreatic malignancies. 
Interestingly, other types of pancreatic cancers, such as neuroendocrine tumors and even 
the less common cystic neoplasms (less than 1% of cases), exhibit better prognoses and 
improved responses to chemotherapy compared to PDAC [6].  
 
Figure 1: Predicted cancer statistics – estimated morbidities and cancer related deaths in the US for 
2014; derived from the American Cancer Society. 
Efforts to develop more efficient therapies have been mostly unsuccessful. No major 
breakthroughs have been made since gemcitabine was approved as the standard 
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chemotherapeutic agent for PDAC in 1997, when an only moderate overall survival could 
be reported, compared to 5-fluorouracil (5-FU) therapy [7]. The most recent advancement 
has been the introduction of the Epidermal Growth Factor Receptor (EGFR) inhibitor 
Erlotinib in parallel with gemcitabine treatment, extending the median survival by only14 
days [8].  
 
2.1.1 Molecular and genetic aspects of PDAC 
It is speculated that early detection and a better understanding of the particular molecular 
mechanisms driving pancreatic ductal adenocarcinoma could help thwart the current 
therapeutic challenges. Risk groups have been identified, based on environmental and 
genetic factors. Smoking and alcohol consumption have been linked to an increased risk of 
developing PDAC [4]. Diabetes patients are also more likely to be diagnosed with PDAC, 
although it is not yet clear whether their increased body index represents a risk factor – or 
early symptom of the malignancy [4]. The description of familial cases of PDAC has also 
suggested the presence of genetic predisposition factors. Members of families with a history 
of developing pancreatic cancer have a six-fold increased risk of developing the disease 
themselves, while living in families with sporadic PDAC cases also poses a twofold 
increased risk of being diagnosed with the same ailment [4]. Mutations in BRACA2, PALB2 
(partner of interaction for BRACA2), SERPIN B12, ATX, MLH1, as well as ARF/INK4A germ 
line mutations have been listed as putative genetic risk factors for PDAC familial cases [4, 
9].
 
Figure 2: KRAS driven metabolic reprogramming in PDAC: activated KRAS has been shown to 
facilitate glucose and glutamine via the upregulation of specific transporters. Phosphorylated glucose 
is also shunted into the non-oxidative pentose phosphate pathway, leading to increased nucleic acid 
production. Oncogenic KRAS has been involved in glutamine reprogramming, leading among others 
to increased maleate production, responsible for balancing the intracellular ROS levels. KRAS also 
influences autophagy in pancreatic tumor cells. Plasma membrane localization of Ras is regulated 
by specific farnesyl transferases. Adapted from Bryant et al. [10]. 
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The main genetic event driving PDAC progression, metabolism and proliferation appears to 
be KRAS mutation, described in approximately 95% of identified cases [10]. This small 
GTPase can be activated via a series of activating mutations, the most common ones being 
three point mutations, affecting the residues G12, G13 and Q61. These genetic activator 
mutations can either lead to the formation of steric hindrance, preventing GTPase activating 
proteins from binding to KRAS (the G12D amino acid substitution, occurring in 98% of 
PDAC cases), or the mutated amino acid prevents the correct coordination of a water 
molecule needed for the hydrolysis of bound GTP (Q61 substitutions) [10, 11]. Interestingly, 
KRAS mutation appears to be an early event in the progression of pancreatic cancer, since 
it has already been reported in over 90% of pancreatic intraepithelial neoplasia (PanIN) pre-
cancerous lesions [5, 10, 11]. KRAS mutation is subsequently followed by inactivation of 
cyclin-dependent kinase inhibitor 2A, p53 and SMAD4 [10, 11]. Oncogenic KRAS is 
involved in a plethora of signaling pathways responsible for increased proliferation and 
inhibition of apoptosis, altered metabolism and microenvironment, promotion of 
inflammation leading to metastasis and evasion of immune response (Figure 2) [10, 12].  
 
2.1.2 Extracellular matrix characteristics in PDAC 
One particular characteristic of PDAC is the highly fibrotic tumor microenvironment, created 
by a dense extracellular matrix (ECM), leading to increased interstitial fluid pressure and 
the subsequent collapse of many tumor-associated capillaries [8, 13]. Up to 80% of PDAC 
tumors are necrotic, with little vasculature and a highly expressed stromal compartment. 
The tumor-associated ECM is rich in collagen and glycosaminoglycans, among which 
hyaluronic acid is one of the major ingredients [8, 13]. Responsible for the matrix deposition 
are activated pancreatic stellate cells, which represent myofibroblast cells normally 
associated with the exocrine pancreas [14, 15]. These essential niche components typically 
switch between inactive (containing vitamin A lipid droplets) and active state (when they 
start expressing α-SMA), and can be activated by a plethora of factors, including 
transforming growth factor-β1 (TGF-β1), tumor necrosis factor α (TNFα), interleukins such 
as IL1, IL6, oxidative stress, etc. [14, 15]. In the active form, pancreatic stellate cells are 
responsible for the massive production and remodeling of ECM components, while they 
also release cytokines, chemokines and adhesion molecules. Moreover, they can perform 
phagocytosis, similar to liver Kupffer-cells [15].  
Although it may seem counter-intuitive, the abundance of hyaluronic acid in the tumor 
microenvironment and the increased interstitial fluid pressure – both leading to the formation 
of extended hypoxic areas in the pancreatic tumors, appear to benefit the progression of 
PDAC rather than inhibiting it [8]. One reason might be that hyaluronic acid and other ECM 
components can bind surface receptors and lead to the activation of signaling pathways 
responsible for cell proliferation and survival of cancer cells [13]. It has recently become 
acknowledged that hypoxia and ECM signaling play important roles in cancer metastasis, 
and intra-tumoral hypoxia appears to be a pathway for metastasis rather than an 
impediment [16]. Several speculations exist regarding the mechanisms employed by 
pancreatic cancer cells to tackle with the hypoxic and nutrient depleted environment: they 
could activate alternative metabolic pathways, increase their glucose intake, increase 
autophagy (see also Figure 2), etc. [10, 13]. 
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The hypo-perfusion of PDAC tumors also impends the diffusion of chemotherapeutic 
compounds, explaining the clinical failure of treatment agents that showed positive results 
in early in vitro and animal based in vivo tests [8]. Treatment with stabilized hyaluronidases 
has been shown to lead to increased perfusion of PDAC mouse tumors and improve 
response to chemotherapy. Simply treating tumor bearing mice with hyaluronidase 
prolonged the overall survival of the animals [8], which could be explained by improved 
infiltration of activated immune system components, or could be due to disruption of 
paracrine signaling in response to alterations of the tumor-associated ECM. Despite 
concerns that increasing tumor perfusion might lead to increased metastasis, no such 
observation could be reported in the initial experiments [8]. 
However, not all experimental data support the idea that stromal ablation is required for 
improved PDAC treatment. A recent report by Özdemir and colleagues pointed out that 
cancer-associated α-SMA positive myofibroblast depletion lead to the development of more 
invasive, non-differentiated tumors, with enhanced hypoxia, EMT and decreased survival 
of tumor-bearing mice compared to animals whose stromal compartment was intact [17]. 
Depletion of α-SMA positive cells correlated with decreased collagen I expression and 
general tumor ECM remodeling. The report suggested that the tumor-associated stromal 
compartment might represent a protective response of the organism rather than a tumor 
survival mechanism, and cautioned against stromal targeting therapies in PDAC until 
additional experiments are performed [17].  
 
2.1.3 Precursor lesions in PDAC 
Evaluation of pancreatic tissue collected from patients suffering from chronic pancreatitis, 
or PDAC patients who were eligible for surgical removal of the primary tumor, revealed the 
presence of histological abnormalities, representing early dysplastic lesions in the 
progression of pancreatic cancer. These observation come in agreement with observations 
that other adenocarcinomas also go through an adenoma to carcinoma progression, a 
stepwise process of accumulating genetic and morphologic abnormalities [5, 18, 19]. Three 
types of precursor lesions have been described, based on their morphological 
characteristics: pancreatic intraepithelial neoplasms (PanIN), and two type of cystic lesions 
– intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN) 
[5, 9]. A schematic representation of the three premalignant lesions is represented in 
Figure 3.  
PanINs represent the most common premalignant lesion of the pancreas [9, 19]. Usually 
asymptomatic, PanINs contain columnar cells which lose their cuboidal architecture and 
increase production of mucins, while exhibiting various levels of cytological and genetic 
abnormalities [5, 18]. When discovered in patients suffering from chronic pancreatitis, they 
are believed to signal a high risk of progression to carcinoma, but unfortunately the lesions 
can only be detected through invasive biopsy procedures, as they are invisible by cross-
sectional imaging or endoscopic ultrasound [5, 18]. Interestingly, PanINs have been 
described in as much as 30% of autopsy specimens collected from elderly patients [9]. 
Based on the cytological criteria, PanINs can be classified in three grades: low grade PanIN-
1A (flat), PanIN-1B (papillary), followed by intermediate grade PanIN-2 (displaying mild 
cytological atypia) and finally high grade PanIN-3 lesions, also described as ‘carcinoma in 
situ’, characterized by severe tissue abnormalities, although still confined by the basement 
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membrane [5]. KRAS mutation is an early event in the development of PanINs, activating 
mutations being already present in stage 1 lesions, and are followed, as the cellular atypia 
progresses, by loss of tumor suppressor genes such as p16, p53, SMAD4 [9]. Telomere 
shortening is also an early event and leads to the increased expression of telomerase by 
the dysplastic cells [5, 18]. Mouse models expressing mutated KRAS (G12D substitution) 
under the control of PDX1 transcription factor promoter (essential for the maturation of 
pancreatic and β cells), conditionally knocked out for p53, develop the full range of PanIN 
lesions, culminating with aggressive PDAC. Therefore, mouse models confirmed the 
hypothesis that PanINs represent precursor lesions of pancreatic cancer [11, 19].  
 
Figure 3: Precancerous lesions and the sequential accumulation of genetic abnormalities leading to 
the formation of PDAC. Adapted from Hezel et al. [9]. 
Of interest is the fact that morphological and gene expression changes specific for epithelial 
to mesenchymal transition (EMT) have been described early in the progression of PanIN 
lesions, raising concerns that metastatic spread in PDAC can represent an early event [11]. 
The results were confirmed using two mouse models harboring activated KRAS G12D 
mutations under the conditional control of two different promoters – the above mentioned 
PDX1, and the Mist1 transcription factor promoter, required for complete differentiation of 
acinar cells in mice [11]. Early accumulation of genetic and epigenetic abnormalities is 
accompanied by increased expression of atypical protein markers, which can be later found 
in fully developed PDAC and metastatic lesions, such as aberrantly glycosylated MUC1 
[20], or secreted protein lipocalin-2 (LCN2) [21]. This raises the prospect of using protein 
biomarkers for detection of early pre-cancerous lesions, with profound clinical applications. 
IPMNs are invasive carcinoma precursors, showing an increased incidence in recent years. 
IPMNs have been described as tumors of the duct epithelium, characterized by papillary 
epithelial proliferation, increased mucin production and cystic dilatation of affected ducts [5]. 
According to their site of origin, IPMNs are divided into main duct (MD-IPMN) or branch duct 
(BD-IPMN); when both duct types are involved, the lesions are termed “mixed duct type”. 
Based on the histological properties, IPMNs can be subdivided into intestinal, pancreato-
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biliary, oncocytic and gastric, with the first three types usually originating from the main duct, 
while the gastric subtype arises typically from branch ducts [5]. From the listed IPMN 
subtypes, the intestinal subtype is one of the most often described pre-malignant lesion, 
being characterized by tall columnar cells, elongated nuclei and amphophilic cytoplasm [5]. 
At a molecular level, many of the described genetic abnormalities are similar to those 
already identified in PanIN lesions. Additionally, a common mutation affects the GNAS locus 
[5]. Unlike the PanIN lesions, IPMNs developing from the branch duct can be detected by 
MRI, and early treatment for these aggressive lesions is therefore possible [5, 19]. 
MCNs represent the most uncommon type of pancreatic precancerous lesion, more often 
developing in women, which are usually located in the pancreatic body or tail [5]. The lesions 
are asymptomatic and usually discovered by accident; prognosis is usually good, but 
surgical removal is advised for all patients. If untreated or undiagnosed, MCNs can grow 
very large, and include calcifications. The presence of mural nodules signals a high risk of 
malignancy. Under the microscope, the cells underlying MCN lesions appear columnar and 
express abundant mucins, like all the previously described precursor lesions. KRAS 
mutations and inactivation of tumor suppression genes p16, p53 and SMAD4 are a common 
event [5, 18]. A characteristic of MCN is the presence of ovarian like stroma associated with 
the atypical epithelial structures, expressing progesterone and estrogen receptors [9]. 
Therefore, the stroma can undergo luteinization similar to that described in the normal 
ovarian stroma. Despite the low risk of malignancy, diagnosed MCNs are typically surgically 
removed [5].  
 
2.1.4 Molecular subtypes in PDAC 
Despite the increased understanding of the molecular mechanisms driving pancreatic 
cancer, novel therapies designed for PDAC continue to fail in clinical trials, and even 
response to standard therapy is extremely heterogeneous. One of the major problems is 
that PDAC has been long viewed as a homogeneous disease [8].  
This monodimensional approach has been challenged by Collisson et al., when the analysis 
of microdissected pancreatic cancer cells and commercially available cell lines revealed 
differences in their transcriptomic profiles, not described previously [3]. Based on the gene 
expression level, they were able to describe three molecular subtypes, differing in their 
response to chemotherapy and overall survival [3]. The three molecular subtypes were 
termed by the authors: classical, exocrine-like and quasi-mesenchymal. Furthermore, they 
discovered that the molecular subclassification can be achieved by performing gene 
enrichment analysis using only 62 gene signatures, which they designated as a PDA 
(pancreatic ductal adenocarcinoma assigner) [3].  
Based on the gene expression profiles, they observed that the classical subtype expresses 
high levels of epithelial-associated and adhesion molecules, the quasi-mesenchymal (QM) 
subtype is enriched in mesenchymal associated genes, while the exocrine-like subtype 
continues to express digestive enzyme genes [3]. In their initial study, patients harboring 
the classical subtype showed better overall survival than the other two subtypes, with the 
QM patients presenting the worst prognostic; the molecular subclassification of the patients 
correlated better with the overall survival than previously used factors, such as tumor size, 
degree of differentiation, etc. [3]. 
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The stratification of patients according to these three molecular subtypes proved to be 
beneficial for therapy selection as well. The classical subtype appeared to be more 
dependent on KRAS signaling than the other two described subtypes. It comes therefore 
as no surprise that the classical subtype responded best to EGFR inhibitory therapy with 
Erlotinib [3]. This addiction of the classical subtype to KRAS signaling could allow patients 
harboring the classical subtype to benefit from KRAS targeted therapies, which might one 
day become clinically available, considering the increased interest manifested in their 
development [3, 7, 22]. By contrast, the QM subtype responded best to gemcitabine 
treatment [3].  
The exocrine-like subtype response to chemotherapy could not be evaluated in vitro by 
Collisson et al., due to its complete absence from commercially available serum grown cell 
cultures [3]. Initial concerns that the exocrine-like subtype might represent an artifact 
introduced by the statistical analysis were refuted after additional in vivo analysis. Moreover, 
Dr. Christian Eisen (HI-STEM , DKFZ, Heidelberg, Germany) confirmed the existence of 
this subtype in vitro after developing serum-free cell culture methods (Noll, Eisen et al., 
manuscript in preparation). Furthermore, Eisen and collaborators established that the 
exocrine-like subtype pancreatic cancer cells exhibit increased resistance to several 
chemotherapeutic agents used for the treatment of PDAC, and this resistance could be 
linked to activation of detoxification pathways typically expressed by hepatocytes (Noll, 
Eisen et al., manuscript under preparation). Although at first disheartening, the proof that 
exocrine-like PDAC patients would not benefit from standard chemotherapies spells out the 
importance of developing optimal stratification strategies of PDAC patients, in parallel with 
the development of novel, targeted therapeutical strategies.  
 
2.1.5 PDAC therapies – standard of care and novel approaches 
Surgery continues to represent the best treatment, despite the fact that the overall survival 
of patients with resectable tumors does not raise above 20% [5]. The surgical approach is 
dependent on the location of the primary tumor. Patients with tumors situated in the head 
of the pancreas will typically undergo a Kausch-Whipple pancreatoduodenectomy. In 
contrast, pancreatectomy – together with hilar and spleen nodes removal is performed in 
patients with tumors present in the body or tail of the pancreas [23].  
Neoadjuvant therapies have been proposed in pancreatic cancer, as a means to shrink the 
primary tumor and allow surgical removal. Neoadjuvant therapy can be administered as 
soon as the tumor is diagnosed [24]. Examples of neoadjuvant therapies investigated in 
PDAC include: radiotherapy, chemotherapeutical agents – 5-FU, gemcitabine, cisplatin, 
used as monotherapies, or in combination [24]. A potential drawback of opting for 
neoadjuvant therapies is the fact that they delay surgical intervention [7, 25], thus potentially 
allowing the pancreatic tumor to advance to more aggressive and metastatic levels.  
Adjuvant therapies are administered to patients after undergoing surgical resection, and 
include radiotherapy, chemotherapy – or a combination of both [24]. Historically, 5FU has 
been the chemotherapeutic of choice, until in 1997 gemcitabine was proven to improve the 
overall survival (albeit moderately) and the five year survival rate [7]. Gemcitabine is a 
nucleoside analogue designed to trigger apoptosis in fast dividing cells by stalling DNA 
replication after its incorporation in place of a normal cytidine [26]. Novel therapies have 
been attempted in combination with gemcitabine, but despite early promising results in vitro 
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and in early clinical trials, they all failed to reach the goal of at least significantly improving 
patient survival [27].  
With such a dismal prognosis, even for patients diagnosed with resectable PDAC, efforts 
have been made recently to develop targeted therapies against pancreatic cancer. The 
tyrosine kinase inhibitor Erlotinib has been the only targeted therapy in combination with 
gemcitabine to receive FDA approval for the first line treatment of PDAC patients, after a 
small (about two weeks), but statistically significant increase in overall survival could be 
observed for the treatment arm receiving the combined therapy compared to gemcitabine 
treatment alone [7]. An alternative approach has been to target EGFR with the chimeric 
monoclonal antibody Cetuximab, but despite promising initial results, stage II and III trials 
failed [27]. 
One desired target for PDAC therapies is KRAS, since activator mutations are a common 
and early event in pancreatic cancer. However, the development of targeted therapies 
against KRAS are not trivial, and early attempts have failed in clinical trials. One such 
example is the use of farnesyltransferase inhibitors, aiming to disrupt the membrane 
association of KRAS [7, 22]. However, an additional mechanism of KRAS membrane 
association, through geranyl-geranylation can circumvent the farnesyl transferase 
inhibitors. Therapies aiming to inhibit both farnesylation and geranylation are prohibited by 
the anticipation of high toxicities [7]. Novel strategies are being currently considered, 
targeting specific pockets formed in G12C KRAS mutants [28], but the efficiency of these 
approaches remains to be tested in clinical trials. 
Vascular Endothelial Growth Factor (VEGF) inhibitors have also represented an area of 
interest for PDAC, since it is overexpressed in 93% of the patients [7]. However, clinical 
responses have not been encouraging, as both antibody based therapies with Bevacizumab 
and VEGF receptor inhibitors Sorafenib and Axitinib have failed to bring significant 
improvements in the overall survival when combined with gemcitabine and Erlotinib [7]. 
Some strategies aim to target the PDAC associated stroma. Examples include the use of 
Sonic Hedgehog (Shh) inhibitors (NCT01064622), and the engineered hyaluronidase 
PEGPH20 (NCT01839487) [7], which recently entered phase II clinical trials. 
Antibody-based therapies have also been considered, in combination with pre-existing 
chemotherapeutics or other targeted approaches. Emerging passive immunotherapies are 
targeting proteins overexpressed by PDAC, independent of their function in promoting 
carcinogenesis. One such example is the single chain Fv murine antibody SS1P 
recognizing mesothelin (NCT00006981), a glycosylphosphatidylinositol anchored protein 
overexpressed in 90-100% of PDAC cases [6, 7]. Immune checkpoints blocking therapies 
aiming to reverse tumor associated immune suppression are also currently tested in PDAC 
[29, 30]. The anti-CTLA4 antibody Ipilimumab, administered in combination with allogeneic 
pancreatic cancer cells transfected with GM-CSF, have revealed a slight increase in overall 
survival, compared to Ipilimumab treatment alone (NCT00836407).  
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2.2 Biomarker discovery and proteomics 
 
2.2.1 Molecular biomarkers – definition and identification 
According to the American National Institute of Health (NIH), a biomarker is defined as: “a 
characteristic used to measure and evaluate objectively normal biological processes, 
pathogenic processes, or pharmacological responses to therapeutic intervention” [31, 32]. 
Therefore, biomarkers represent valuable tools for early disease detection and differential 
diagnostic, providing prognostic and predictive information, while also allowing the 
monitoring of high-risk populations. Additionally, they also support the development and 
selection of targeted therapeutics [31]. 
Biomarkers can be classified according to different criteria. Based on their general 
characteristic, we can divide them in biomarkers for imaging and molecular biomarkers. 
Molecular biomarkers have biophysical properties allowing their detection and 
quantification, and include nucleic acid based biomarkers (DNA, RNA), peptides, proteins, 
lipids as well as small metabolites [32, 33]. Based on their utility, biomarkers can also be 
classified in diagnostic biomarkers, disease staging biomarkers, disease prognostic 
biomarkers, or biomarkers for monitoring of therapy response. Finally, the NIH ‘Biomarkers 
and Surrogate Endpoint Working Group’ has defined three types of biomarkers – type 0 
(markers of the natural history of a certain disease, correlating with clinical indices), type I 
(markers measuring drug activity) and type II (also known as surrogate markers) [33]. A 
surrogate marker is expected to be a reliable substitute for a morbid event end-point, and 
must act as both an epidemiologic marker as well as a therapeutic responder [34]. This 
subchapter will focus on molecular biomarkers and experimental screening procedures 
employed for their detection. 
Genomic approaches for biomarker investigation are typically evaluating differences in gene 
expression profiles or variation in the genetic sequence which can be associated with a 
particular pathological condition. For example, DNA-microarrays and next generation 
sequencing techniques allow the investigator to identify gene mutations, copy number 
variations and single nucleotide polymorphisms (SNP) [32, 35]. The field of transcriptomics, 
analyzing differences in RNA transcripts expression over time, and between healthy and 
diseased cells, has developed an array of sophisticated methods, widely used in biomarker 
discovery experiments. Several RNA species can be investigated, including mRNAs, non 
coding RNAs and small RNAs [36]. A series of techniques have been developed over the 
years and are being continuously optimized for the evaluation of mRNA levels such as: 
Northern Blot, serial analysis of gene expression (SAGE), RNA-seq; additionally, DNA-
microarrays can as well be used in transcriptomics experiments [35-37]. RNA-seq has the 
advantage that it does not require predefined probes, while the coverage of the whole 
transcriptome of an organism can be achieved. Moreover, it can also be used to distinguish 
between alternative-splicing products in various pathological or developmental conditions 
[35, 36]. Genomic approaches have the advantage of being suited for high-throughput 
investigations, while the overall cost of such approaches has decreased significantly over 
the last decade [38]. However, genomic experiments have several caveats. For example, 
single cell RNA sequencing has been associated with increased noise when estimating 
expression levels of low copy mRNA species, while at the same time being accompanied 
by the introduction of a 3’ end amplification bias [35]. Moreover, the quality control 
guidelines for many genomics methods are not clearly defined. For this reason, additional 
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validation techniques following transcriptomics-based discovery experiments, such as RT-
qPCR, are often mandatory [36]. But the most important draw-back of genomic approaches 
is the fact that variation in mRNA copy numbers or genetic mutations cannot always 
accurately predict the actual final gene product levels in the cell/tissue, nor can they predict 
the complex post-translational modifications (PTMs), alternative splicing, or allosteric 
interactions of the respective encoded proteins [39-41]. Nonetheless, the recent publication 
of the human proteome draft by Wilhelm et al. suggested that, at least for healthy tissues, 
the translation rate might represent a constant characteristic of a given transcript, implying 
that the mRNA levels can often be employed for predicting the abundance of the final protein 
product [42]. Of importance, some nucleic acid species can potentially be used as surrogate 
biomarkers, and they can be easily detected in biological fluids.  For example, microRNAs 
(miRNAs) represent small endogenous non-coding RNAs, responsible for the post-
transcriptional regulation of target genes, playing important roles in many physiological and 
pathological processes [43]. Several reports have indicated dysregulations of circulating 
miRNAs in the blood of patients suffering from different disorders, and miRNAs are currently 
intensely investigated as cancer prediction biomarkers [44]. 
Proteomics approaches for biomarker discovery include 2D-PAGE based methods, mass 
spectrometric identification, antibody microarrays and tissue microarrays. Differential Gel 
Electrophoresis (also known as 2D-DIGE) has been for almost a quarter of a century the 
work-horse in proteomics [45]. However, gel based methods are laborious, require high 
amounts of starting material, and have been plagued by problems associated with the 
solubility of hydrophobic trans-membrane proteins [46, 47]. Antibody based proteomics has 
traditionally been widely used, due to its rapid, sensitive, and high-throughput options [48]. 
However, antibody based techniques such as Enzyme-linked immunosorbent assay 
(ELISA), protein micro-arrays and immunohistochemistry (IHC) are dependent on the 
availability of highly specific antibodies, with the ability to recognize splice isoforms or PTMs 
[48]. In addition, ELISA and tissue micro array (TMA) based identifications are difficult to 
multiplex [39, 48]. Protein micro-array/protein chips represents a high-throughput method, 
developed on a technology similar to the DNA micro-array chips.  Protein chips can be 
grouped into analytical arrays, functional proteomics micro-arrays and reverse phase 
protein micro-array [49]. The difference between these array types is dictated by the nature 
of the macromolecule immobilized on the chip’s surface. Analytical arrays contain trapped 
antibodies, affibodies (small engineered affinity proteins) or aptamers (single stranded 
oligonucleotides which bind their target with high affinity and specificity), which will capture 
the corresponding proteins against which they were raised and detection can be achieved 
using ELISA type methods [31, 49]. Functional micro-arrays contain immobilized whole 
proteins which can be used for the investigation of protein-protein/protein-DNA or 
RNA/protein-phospholipid or protein-small molecule interactions. Finally, in reverse phase 
protein micro-arrays, complex protein extracts (such as cell lysates) are immobilized and 
detected by the use of an antibody [31, 49, 50]. Protein arrays suffer from the same limitation 
earlier mentioned for ELISA and TMA antibody based methods. Additionally, protein chips 
need to immobilize proteins on solid surfaces without leading to loss of tertiary and 
quaternary structures, and the subsequent recovery of the corresponding proteins from the 
chip for further analysis is difficult [49]. Moreover, considering the wide dynamic range of 
the proteome [51], it is difficult to construct protein arrays with a sufficient capacity for a 
complete proteome analysis.  
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Mass spectrometry has become the method of choice for the majority of proteomics based 
biomarker discovery projects. The development of the two stable soft ionization techniques 
– Electro Spray Ionization (ESI) and Matrix-Assisted Laser Desorbtion/Ionization (MALDI) 
– allowing the concurrent ionization and transfer of the biological analytes into the gas phase 
without extensive degradation, represented one of the major instrumentation 
advancements, leading to the development of modern day proteomics [45, 52]. Efforts made 
to improve the quality of digitally available databases for spectra identification, and the 
recent publication of the first drafts of the human proteome allow for advanced MS based 
proteomics biomarker identification [53]  Mass spectrometric based biomarker identification 
has the advantage that it can process complex biological samples, without the requirement 
of introducing any pre-analysis hypothesis, thereby eliminating any prespecification 
associated biases. However, the complexity of the samples analyzed, in particular the wide 
dynamic range of mammalian proteomes, affects the sensitivity of the method and leads to 
stochastic sampling [51, 54]. Instrumentation advancements over the last decade have also 
facilitated MS-based discovery experiments. Significant improvements in the acquisition 
rate translated in an increased number of identified proteins per minute. For example, a 
recent study by Hebert et al. reported the identification of over 4000 yeast proteins based 
on a 1.3 hours chromatographic-MS method, at an impressive identification rate of 67 
proteins per minute [55].  A summary of modern MS methods will be presented in the 
following chapter. 
Recently, a novel technique termed mass cytometry has been developed combining the 
advantages of fluorescence assisted cell sorting (FACS) and mass spectrometry. Briefly, 
the method utilizes antibodies labeled with lanthanide atoms (absent from biological 
samples), which recognize and bind their specific target, after which the cell is vaporized in 
a CyTOF analyzer and the corresponding atom is detected [56]. The method has been 
successfully used to detect differences in cell-surface protein expression under different 
treatment conditions and has the advantage of eliminating spectral overlap (a common 
problem in FACS sorting). On the down side, the sample is vaporized during the analysis, 
therefore no additional evaluations can be performed [56]. Additionally, the method does 
not address the problems associated with the use of antibodies, plaguing all antibody based 
detection techniques. 
The field of lipidomics investigates alterations in lipid compositions, biosynthesis or 
downstream metabolism. Lipids are complex macromolecules, exhibiting a high structural 
diversity, which can include neutral molecules (triglycerides, sterols), polar lipids 
(glycerophospholipids), and small signaling molecules, such as eicosanoides, comprising 
numerous isomers [36]. One of the most widely use lipidomics marker in the clinic is 
cholesterol, which, depending on its association with low-density or high-density 
lipoproteins, represents a prognosis marker for patients at risk of developing atherosclerosis 
[57]. Currently, lipidomics discovery experiments are mostly performed using MS based 
methods [36]. However, the coverage of the lipidome by mass spectrometry is limited by 
the scarcity of data bases and spectral libraries. The development of novel lipid based 
bioinformatics resources and software tools (e.g. the LIPID MAPS lipidomics gateway), is 
one step forward in the direction of improved lipidome discovery and quantification 
experiments [36]. 
Metabolomics is the field analyzing the whole metabolome under a given set of 
physiological, environmental, and/or clinical conditions [36]. An exact definition of the 
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metabolome is more difficult to pin down, however, it can be generally referred to as the 
“quantitative element of all the low molecular weight molecules present in a particular 
physiological and developmental state” [36]. Historically, two major techniques have been 
employed for identification experiments in the field: MS and NMR (nuclear magnetic 
resonance) [58]. MS based metabolomics techniques can analyze a large number of 
unrelated metabolites, with a wide range of chemical properties. Sample prefractionation by 
chromatographic methods is a prerequisite, and current platforms allow high resolution 
screening and quantification for a variety of metabolites. One limitation of LC-MS based 
metabolomics is the scarcity of tools for data annotations, and the fact that the high chemical 
variety of different metabolites makes it (at least at the moment) impossible to measure the 
entire metabolome of one sample [36]. An alternative approach has been to use MS based 
proteomics to investigate the PTMs and general expression patterns of proteins involved in 
known metabolic pathways [59]. NMR techniques have the advantage that they do not 
require any sample prefractionation prior to analysis. Additionally, it is a nondestructive, 
noninvasive technique, providing detailed information of the metabolite’s molecular 
structure, based on atom-centered nuclear properties and interactions [58]. However, the 
interpretation of NMR spectra is not trivial. For clinical applications, kit based technologies 
have also been developed [36]. 
 
2.2.2 Short introduction to proteomics and mass spectrometry  
Proteomics represents the large scale systematic study of protein structure and function in 
an organism, tissue, cell, organelle or specific pathway [54]. Several techniques can be 
employed for the study of proteins, however, currently mass spectrometry represents the 
most common methodological approach.  
All mass spectrometers use the analysis of a mass-to-charge ratio for the identification of 
proteins. The most important components of a mass spectrometer are the ion source, the 
mass analyzer and the data processing electronics [52].  
The polarity, volatility and thermal instability of proteins and peptides hindered for a long 
time their non-destructive transfer into the gas phase. Thus, the use of mass spectrometry 
in proteomics has been limited by the development of soft ionization techniques, compatible 
with these analytes. However, the development of two stable ionization techniques: ESI and 
MALDI in the late 1980’s has allowed for a more stable ionization of macromolecules and 
the subsequent development of MS based proteomics methods [45, 52, 60]. 
In MALDI, analytes are co-crystalized with a matrix (selected based on the purpose of the 
experiment). The matrix will absorb the energy of the laser and transfer it to the analyte, 
while the rapid pulsed laser heating leads to the desorption of the matrix and analyte ions 
into gas phase [52]. The development of robotic systems capable of performing automated 
mixture of the matrix of choice and analytes eluted from a chromatography column has 
simplified MALDI sample preparation, initially viewed as too laborious [45]. MALDI 
generated ions are usually single charged [52]. Several variations of matrix associated 
ionization techniques have been developed, including Surface-assisted laser 
desorption/ionization mass spectrometry (SALDI) and Desorption/ionization on silicon 
(DIOS), using porous graphite, and silicon, respectively, to increase the tolerance of MALDI 
MS methods to detergents and salts [52]. Another variation of the technique – termed 
Surface-Enhanced Laser Desorption/Ionization (SELDI), allowed evaluation of biochemical 
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activity and subsequent enrichment of a particular subset of the analyzed sample. In SELDI 
the proteins/peptides of interest are first deposited on a surface modified with a chemical 
functionality, allowing the selective binding of distinct target analytes. The corresponding 
matrix is added after non-bound peptides/proteins are washed away [61].  
On the other hand, in ESI, an electrically charged spray is created by applying a high voltage 
between an emitter at the end of a separation pipeline (e.g. a capillary chromatography 
column) and the inlet of the mass spectrometer [52]. ESI generated ions are usually multiply 
charged [52].  
Mass analyzers sort the analyte ions based of their mass-to-charge (m/z) ratio. Different 
mass analyzers have been built, employing different separation strategies. Ion trap, ion 
cyclotron resonance and orbitrap instruments analyze the resonance frequency of ions. 
Quadrupole systems use the stability given by m/z in an oscillating electric field to selectively 
stabilize the paths of distinct analyte ions. Finally, time of flight analyzers use the flight time 
of ions accelerated under the same potential to separate the different analytes. Hybrid mass 
analyzers have been built, increasing the versatility of the analysis [52]. ESI systems can 
be attached to a variety of mass analyzers and are often preferred due to the possibility of 
coupling them directly (online systems) to a liquid chromatographic separation system. 
MALDI systems are often coupled with time of flight (TOF) analyzers, and can only be used 
offline, which increases the overall analysis time. However, MALDI based analysis is highly 
stable and has the advantage of allowing long term storage and subsequent re-analysis of 
a sample of interest [45].  
Two types of distinct proteomic approaches can be used for protein identification: bottom-
up approach, and top down proteomics [52].  
Bottom-up approaches are currently the most popular tactic employed in proteomics, when 
dealing with complex samples. For this method, also known as shotgun proteomics, 
proteins are digested prior to performing the analysis and the resulting peptide masses and 
sequences represent the basis for protein identification, similarly to the DNA shotgun 
sequencing [52]. Peptides generated by enzymatic digestion are later dissociated into 
smaller fragments, using different dissociation methods, such as collision induced 
dissociation (CID) or electron transfer dissociation (ETD). The subsequent tandem mass 
spectrometric data (MS2 or MS/MS) are compared to in silico generated fragmentation 
patterns available in public databases [52, 62]. The bottom-up approach has the advantage 
of being highly sensitive, fully automatable and fractionation techniques are easily 
applicable for peptides. Drawbacks of the method include the possible loss of PTMs, 
ambiguity of the origin of redundant peptide sequences and limited sequence coverage, 
depending on the ionization method and the pre-fractionation/enrichment methods applied 
[45, 52].  
Top-down proteomic approaches are less commonly used, but have recently attracted more 
interest, after the development of highly sensitive mass analyzers. In top down proteomics, 
whole proteins are analyzed and tandem mass spectrometry is performed after using 
alternative fragmentation methods, such as ETD and electron capture dissociation (ECD). 
Advantages of top-down proteomics include a better sequence coverage, identification of 
specific isoforms and easier detection of complex PTMs. However, front end separation 
techniques are more challenging for intact protein mixtures, and the method is dependent 
on the development of high mass accuracy instruments, such as Fourier Transformation 
MS or Orbitrap instruments [52, 63].  
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The majority of tandem MS analyses are performed in a data dependent acquisition mode, 
meaning that the data collected after the first MS analysis is used for the selection of 
precursor ions that will be fragmented and are subject to a second round of MS analysis, 
following a dissociation step [64]. Lately, the lab of Rudi Aebersold, has been developing a 
data independent acquisition method, termed SWATH MS, in which all precursors 
contained in a predetermined window are fragmented and the resulting spectra are 
recorded [48, 64].The method promises to allow improved quantification for most of the 
proteins in a sample [64], but complicates the subsequent bioinformatics analysis.   
MS based proteomics can be used for the identification, and quantification of protein 
expression between complex biological samples, evaluation of PTMs and associated 
metabolic pathways, evaluation of protein-protein interactions, etc [41, 60]. Depending on 
the aim of the experiment, the general shotgun proteomics workflow includes sample 
selection, the preparation and optimization of whole protein extracts (which includes 
cell/tissue lysis, depletion of abundant proteins), enzymatic digestion, sample fractionation 
and finally the MS and MS2 analysis [52, 60]. A schematic representation of a typical 
shotgun MS proteomic workflow is represented in Figure 4. The previously mentioned steps 
are common for both discovery and targeted proteomics, which will be discussed in greater 
detail in the following chapters. 
 
Figure 4: Schematic illustration of the shotgun proteomics workflow. For simplification purposes, 
isotope labeling techniques used for the quantification steps are omitted. RP-LC = reverse phase 
liquid chromatography. 
Due to the high dynamic range of mammalian proteome, sample pre-fractionation is 
required in order to allow the mass spectrometric identification [45]. Some of the most 
commonly used prefractionation methods include reverse-phase chromatography and 
strong cation exchange chromatography. The two chromatographic methods can also be 
combined in a two dimensional prefractionation step (also known as multi-dimensional 
protein identification technology or MudPIT). Additionally, fractionation methods can enable 
the enrichment of a proteome subset, such as immobilized metal affinity chromatography 
(IMAC) for phosphorylated peptides, or lectin affinity chromatography for the enrichment of 
glycosylated proteins [47, 52, 62].  
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Finally, mass spectrometry based applications allow for the subsequent comparison and 
quantification of proteins from different samples. In order to obtain a snap shot of protein 
concentration characterizing different biological states, an experimenter can choose 
between label-based and label-free quantification methods [45, 52]. Label based methods 
make use of the ability of mass analyzers to distinguish between peptides containing 
different isotopic species. Heavy isotopes can be incorporated in peptide populations using 
metabolic, chemical or enzymatic methods, and a minimum of two distinct populations 
(labeled and unlabeled) can be analyzed in parallel. Relative quantification is done by 
comparing the intensity of co-eluting peaks, distinguished by their mass difference [45, 52]. 
Chemically labeling techniques commonly used are isobaric labeling for relative and 
absolute quantification (iTRAQ), isotope coded protein labelling (ICPL), etc [45]. Enzymatic 
labeling usually leads to the incorporation of 18O isotopes in digested peptides, and is 
currently less applied [52]. Metabolic labeling is today one of the quantification methods of 
choice, with the development of SILAC (stable isotope labeling by amino acids in cell 
culture) and super-SILAC (mix of SILAC labeled cell lines) by the group of Mathias Mann, 
allowing the quantification of complex biological samples, for which metabolic labeling 
would not be an option [65]. Label free quantification methods have required the 
development of proper bioinformatics tools, but represents an appealing alternative to 
isotope labeling, since they are cheaper and less laborious to use. For better quantification 
and peak accuracy measurement, added internal standards are recommended prior to MS 
analysis [45]. It is important to mention that the minimization of processing steps is 
recommendable for all relative and absolute quantification methods, as they can introduce 
experimental artifacts [45]. Also, the optimization of the enzymatic digestion is essential for 
bottom-up quantification experiments, and the protein to enzyme ratio, incubation time and 
temperature are just a few of the parameters that should be optimized in order to obtain 
accurate quantitative proteomic results [66].  
In conclusion, MS based proteomic approaches are versatile identification and 
quantification methodologies, although the high dynamic range of the eukaryote and 
especially mammalian proteome does not currently allow for the accurate simultaneous 
identification and quantification of all protein species. The experimenter must therefore 
optimize individual proteomic workflows, according to the aim of the experiment [54].  
 
2.2.3 Clinical proteomics in cancer diagnostic and therapy – functional 
and methodological requirements 
The field of clinical proteomics investigates the differences between healthy and diseased 
tissues/fluids, thus identifying and quantifying protein differences between the samples [54]. 
Consequently, clinical proteomics can help shed light on the pathology of the disease, 
enables better stratification of patients, while at the same time offering novel targets for the 
development of targeted therapies, thus aiding the development of 
customized/personalized medicine [48, 54].  
Clinical proteomics has the advantage that it can identify and quantify a large number of 
proteins in complex biological samples, without requiring any pre-specified theory; however 
the broad and unbiased approach comes with the cost of reduced sensitivity and 
reproducibility, the latter due to stochastic sampling [39, 54]. Current proteomic techniques 
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have been grouped into discovery and targeted methods, the latter being employed in the 
validation phase of a biomarker discovery experiment [48]. 
In order for a cancer protein biomarker to be approved for clinical use, it needs to fulfill 
several requirements. Diagnostic markers need to be released by the tumor into the general 
circulation at amounts high enough to allow detection, should be specific to the tissue of 
origin and should be detected in early stages of the disease [32]. Additionally, biomarkers 
developed for targeted therapies need to be accessible from the blood stream – and can 
include antigens expressed on the surface of cancer cells or the associated stroma, the 
extracellular matrix, or markers expressed by the tumor neo-vasculature [67]. When 
validating putative biomarkers it has to be analyzed whether their levels can be altered by 
non-cancerous pathologies [32]. Therefore, experimental procedures employed for the 
identification and subsequent validation of a protein cancer biomarker need to be rigorous 
and reproducible, in order to successfully develop and implement the discovery into clinical 
practice.  
The general protocols for biomarker discovery and validation include three important 
phases: the preanalytical phase (including sample collection), the analytical phase (the 
actual assay) and the postanalytical phase (data interpretation and subsequent validation 
strategies) [32]. Several precautions need to be taken in each phase in order to avoid 
investing time and resources in the development of an improper biomarker. During the 
preanalytical phase, proper controls need to be established and the cohort size should be 
sufficient to allow proper statistical prediction of putative biomarkers and avoid model 
overfitting. Sample handling and storage needs to be standardized and thoroughly planned, 
to avoid experimental artifacts, which could result from improper handling (such as proteins 
or other putative markers released by lysing blood cells) [32]. The proper selection and 
optimization of the proteomics protocol is crucial for the analytical phase. Sample pre-
fractionation is often essential for the detection of cancer biomarkers, otherwise their signal 
could be eclipsed by the most abundant proteins present in the raw sample [41]. The final 
mass spectrometric analysis needs to be performed on an instrument with an appropriate 
sensitivity and dynamic range [31, 48]. Data interrogation and statistical analysis performed 
in the post analytical phase needs to be rigorous and an adequate number of clinical 
samples of high quality need to be available for proper validation [32]. Sample prefiltering 
(using correction methods, or false discovery rates) are often used to reduce the size of the 
data set, but could lead to overly optimistic predictions of the efficiency of a putative 
biomarker [68]. Finally, proper validation techniques, highly reproducible and accurately 
quantifying the putative biomarker, should be employed and will be discussed in greater 
detail in a later subchapter.  
So far, the majority of the FDA approved biomarkers for cancer diagnosis include protein 
markers developed in the last decades of the 20th century such as: carcinoembriogenic 
antigen (CEA) for colorectal cancer, carbohydrate antigen 19-9 (CA 19-9) for PDAC, 
prostate specific antigen (PSA) for prostate cancer, carbohydrate antigen 125 (CA125) for 
ovarian cancer and human chorionic gonadotropin for seminoma [69]. However, each of the 
enumerated biomarkers has been reported to have limitations: either their levels are also 
elevated in benign diseases (e.g. PSA is upregulated in other benign prostate disorders), 
or their sensitivity is suboptimal  [70]. Several other biomarkers have been considered as 
putative diagnostic or metastasis markers. Examples include mucine-1 (MUC1) (elevated 
and abnormally glycosylated in many cancers, including PDAC) [20], HER-2 (proposed as 
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a marker for invasive breast cancer, currently used only as a predictive factor for 
Trastuzumab treatment), human epididimus protein 4 (HE4), etc. [69, 70]. Some of the novel 
diagnostic secreted biomarkers have been reported to have similar sensitivities to already 
existing clinical approved markers, which initially discouraged their adoption into clinical 
practice. However, for those biomarkers exhibiting an increase specificity compared to the 
already approved markers, testing a combination of both old and more recent biomarkers 
has been suggested. Recently, a combination of CA125 and HE4 has received FDA 
approval to be used for distinguishing between benign and malignant pelvic masses  [70]. 
Thus, combinational tests should also be considered when developing novel soluble 
diagnostic biomarkers for the clinic.  
Combining a set of biomarkers is especially important, since it is difficult to identify proteins 
showing absolute specificity to a given tumor tissue, with the exception of seldom PTMs 
(e.g.: pancreatic ribonuclease in PDAC and kallikrein in ovarian cancer) [32]. Cancer 
specific protein isoforms, recapitulating splice patterns specific for embryonic development, 
have also been described in malignancies and other pathologies (e.g. rheumatoid arthritis, 
endometriosis, atherosclerosis). For example, splice isoforms of tenascin-C and fribronectin 
are specifically expressed in the extracellular matrix of several tumors at the sub-endothelial 
level [67]. Once a vascular accessible protein biomarker has been properly validated, it can 
be used for the development of targeted therapies, such as antibody based therapy. Cancer 
specific antigens can be targeted with a monoclonal antibody in native state or armed 
(conjugated with cytotoxic drugs, cytokines, radionucleotides). Different antibody formats 
can also be investigated (e.g.: diabodies, small immune proteins, full IgGs). The choice for 
the optimal delivery agent is influenced by its uptake in the normal and diseased tissue and 
by the clearance profile [67]. An alternative to the use of antibodies as delivery agents has 
been the development of high affinity ligands-based targeted cytotoxics [71]. 
In the next subchapters we will discuss in greater detail the specific sample preparation 
methods reported in literature for secreted and cell surface protein discovery and 
quantification. Finally, the last subchapter will be dedicated to commonly used validation 
methods and recent developments in the field of targeted proteomics. 
 
2.2.4 Using mass spectrometry to identify membrane associated 
protein biomarkers 
The membrane proteome has been defined as the entire complement of membrane proteins 
present in a cell under specific conditions at a specific time [72]. Proteins associated with 
the cell and organelle membranes play important roles in cell-cell communication, signal 
transduction and the transport of metabolites, ions and other solutes [47].  
Membrane proteins can be classified based on different criteria. Based on their level of 
association with the plasma membrane, they can be divided into membrane spanning and 
peripheral membrane proteins. Based on their secondary structure, they have been 
classified into α-helix and β-barrel containing structures. And finally, based on the number 
of transmembrane helixes, membrane proteins can be classified into single pass proteins 
(further subclassified into type I, i.e. secreted proteins containing one transmembrane helix, 
and type II, i.e. non secreted) and multipass proteins [72].  
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It is approximated that 20-30% of all open reading frames in the human genome encode for 
membrane proteins [47]. However, due the amphipathic nature of transmembrane and 
membrane associated proteins, it has been notoriously difficult to study them using standard 
LC-MS methodologies [47, 72]. Membrane proteins represent attractive targets for 
biomarker and drug discovery, and they account for more than 60% of all approved 
therapeutic drug targets. For this reason, efforts are being made to optimize experimental 
methods that can allow the selective enrichment of membrane fractions and facilitate their 
proteomic analysis [72, 73]. 
Initial analysis of membrane proteins using 2D-PAGE have indicated that the method is not 
suitable for the investigation of the membrane proteome, due to solubility issues of these 
hydrophobic proteins in the buffers required for the first dimension of separation [47, 72]. 
For this reason, the majority of modern, large scale membrane proteomics experiments opt 
for gel free approaches [72]. The membrane enrichments methods summarized in this 
chapter will therefore refer to protocols tested and optimized for LC-MS based identification 
and quantification techniques. 
The most simple enrichment methods for membrane fractions are ultracentrifugation and 
gradient centrifugation. Unspecific, weakly bound proteins can be removed by including a 
sodium carbonate wash [47].  
Targeted enrichment strategies have also been developed, including – chemical labeling 
reagents (e.g. reactive ester derivatives of biotin), coating with colloidal silica particles, 
proteolysis approaches, or glycoprotein affinity enrichment strategies [47, 73, 74]. A 
schematic representation of the top three most commonly used plasma membrane 
proteome enrichment strategies for proteomic analysis are represented in Figure 5. 
The covalent labeling of cell surface proteins with biotin can be achieved by the use of 
chemical reagents containing biotin coupled to a reactive ester, which can covalently modify 
either protein associated amino groups (the case of N-hydroxysuccinimide esters, 
Figure 5), sulfhydryl residues (N-iodoacetyl or maleimide) and aldehydes (hydrazide 
groups). After the chemically labeling of the membrane proteome, affinity streptavidin pull-
down and stringent washes, ensure the enrichment of the membrane fraction and the 
subsequent removal of unspecifically bound proteins [47, 73, 75]. The spacer separating 
the biotin residue and the functional reactive group can be optimized in order to increase 
the hydrophilic nature of the biotinylation reagent (thus limiting cellular uptake of the biotin 
ester), or to allow a cleavable linker region (e.g.: sulfo-NHS-SS-biotin) [47, 73].  
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Figure 5: Targeted enrichment strategies for the analysis of plasma membrane proteome. 
A: Reactive ester derivatives of biotin are used for the tagging of proteins expressed on the cell 
surface and/or in the ECM, followed by streptavidin pull down and MS analysis. In this example, an 
N- hydroxysuccinimide ester was represented, reacting with primary amino groups present either at 
the N-terminal end of the proteins or in the amino acid side chain of lysine. Curtesy of Dr. C. Rösli 
B: Cationic silica beads can be applied to enrich the plasma membrane fraction, by taking advantage 
of the anionic nature of the cell surface. Anionic cross-linkers enable the formation of membrane 
fractions with increased partitioning density, which can be isolated by centrifugation. Adapted from 
Kornhuber et al. [76] C: Enzymatic digestion of intact cells can be used to obtain extracellular 
peptides. Adapted from Wu et al. [74]. 
Particle enrichment strategies rely on the anionic nature of the plasma membrane, which 
allows the electrostatic attachment of cationic colloidal silica beads. The addition of an 
anionic cross linker (e.g. polyacrilic acid) leads to the covalent association of the silica beads 
to the intact cell membrane (Figure 5). This covalent modification increases the partitioning 
density and facilitates sample collection by centrifugation. Following cell lysis, the desired 
membrane fraction can be pelleted from the crude extract, using a simple centrifugation 
technique [47].  
Another method to investigate transmembrane proteins consists in the use of short duration 
enzymatic treatment on intact cells, thus ‘shaving’ the exposed extracellular epitopes. The 
method circumvents problems associated with low soluble hydrophobic transmembrane 
originating peptides, but is dependent on membrane integrity (Figure 5) [47]. Wu and 
collaborators developed a method combining sequential enzymatic digestion that allows in 
parallel the characterization of the protein’s membrane topology. Intact cells are incubated 
first with the protease of choice and after the collection of extracellular shaved peptides, the 
plasma membrane integrity is compromised by homogenization at high pH, followed by a 
second enzymatic digestion [74].  
Given that a large number of extracellular protein domains are glycosylated, lectin pull-down 
can be used to enrich cell surface glycoproteins. Deglycosylation with peptide-N4-(N-acetyl-
beta-glucosaminyl) asparagine amidase (also known as PNGase F), or other specialized 
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enzymes can help improve the protein coverage following MS analysis [66, 77]. Additional 
use of glycoprotein enrichment methods in biomarker discoveries will be addressed in the 
following subchapter, concerning secreted protein biomarker discovery. 
Better protein sequence coverage for transmembrane proteins can be achieved by using 
solvents and/or detergents for increased solubilization of highly hydrophobic proteins. 
Historically, methanol has been the solvent of choice for protocols aiming to improve 
membrane proteome solubilization and subsequent identification. Solvent volatility is 
compatible with downstream mass spectrometric identification, permitting easy removal 
prior to analysis. The disadvantage of such methods is that enzymatic digestion efficiency 
is reduced and it requires constant addition of fresh proteases during the peptide generation 
step [47]. Using detergents to improve the solubilization of hydrophobic proteins has been 
the most widely adopted method, but their implementation is restricted by incompatibilities 
with the downstream chromatographic and mass spectrometric experiments. There is a 
large variety of detergents which can be used for proteomic protocols, including both 
denaturating (e.g. SDS) and non-denaturating reagents (e.g. Triton X-100, used when 
protein functionality and protein-protein interactions need to be preserved) [47]. A recent 
improvement (addressing the compatibility of MS and detergent) has been the development 
of acid-labile surfactants – such as sodium 3-[(2-methyl-2-undecyl-1,3-dioxolan-4-
yl)methoxyl]-1-propanesulfonate, commercialized by Waters under the name RapiGest, 
which can be used to improve protein solubility and are easily removed prior to LC-MS 
analysis by solution acidification and centrifugation [47, 78]. Several groups have reported 
improved membrane proteome recovery after using RapiGest. Nevertheless, the acid 
hydrolysis of the surfactant leads to the formation of hydrophobic residues, which must be 
removed by centrifugation in order to avoid interference with the mass spectrometric 
analysis and the pelleting step can result in co-precipitation of hydrophobic peptides of 
interest [47, 78].  
Another obstacle for membrane proteomics identification is the fact that many plasma 
membrane associated proteins are not optimally digested by trypsin. The problem can either 
arise from the existence of large spanning hydrophobic sequences, or from the abundance 
of PTMs, such as glycosylations, masking the protease’s substrate [47, 66]. Improved 
digestion of transmembrane domains can be achieved by using distinct proteases such as 
proteinase K or Lys-C, or cyanogen bromide (which cleaves peptide bonds at the C-
terminus of methionine residues) [47]. Masked trypsin cleavage sites can be better exposed 
by using techniques such as filter aided sample preparation (FASP), or enzyme-immobilized 
reactors, both allowing a more rapid and efficient sample preparation, with an increased 
tolerance for high urea and detergent concentrations in the sample to be digested [47, 66]. 
 
2.2.5 Using mass spectrometry to identify secreted protein biomarkers 
The secretome can be defined as the subproteome including all proteins released by a cell, 
a tissue, or an organism through different secretion mechanisms [46]. The secretome of a 
certain cell/organ includes cytokines, chemokines, hormones, other paracrine signaling 
molecules, but also extracellular matrix proteins and proteins shed from the cell surface [79, 
80]. Typically, proteins can be secreted via classical mechanisms, involving the ER/Golgi 
pathway, via non-classical pathways (for e.g. involving caspase 1), exosomes, or be simply 
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shed from the cell surface by extra-cellular proteases [46, 81]. It is speculated that 
approximately 10% of the human genome encodes secreted proteins [46] 
The secretome of a particular cell/tissue is extremely dynamic and can suffer significant 
changes during organ development, pathological transformation and in response to 
environmental stimuli, including organ or tissue damage [80]. Tapping into the pool of 
differentially secreted proteins in response to disease onset and progression is desirable 
for the field of biomarker discovery, with an increased interest being manifested in the area 
of cancer biomarker research. Sources for cancer secretome analysis are plasma, 
conditioned cell culture medium, and tumor proximal liquids – such as ovarian cancer 
associated ascites, pancreatic juice collected from tumor bearing patients, etc. [80]. 
Secreted protein biomarkers are often found in very low concentrations and require 
concentration steps prior to their analysis, such as solvent precipitation or ultrafiltration, 
which unfortunately lead to partial loss of the proteins contained in the supernatant [82]. 
Each source has distinct advantages and disadvantages for MS-based identification and 
validation methods.  
Plasma and serum are easy to collect through non-invasive procedures and carry potential 
markers able to elucidate organ confined events or to evaluate the overall state of health 
[46, 83]. Unfortunately, the plasma sample’s appeal is diminished by the presence of highly 
abundant proteins – such as serum albumin and transferrin, which mask the signal of less 
abundant proteins. Depletion of serum abundant proteins is however critical, since it can 
lead to the pull down of some of the putative biomarkers, but it is often necessary, as the 
detection range of most mass spectrometers is inferior to the dynamic range of serum 
proteins [54, 83]. Biomarker candidate concentrations in plasma are typically in the range 
of low ng/mL. Targeted MS approaches, such as selected reaction monitoring (SRM) of 
unfractionated plasma can only detect proteins in the low µg/mL range, making depletion 
steps mandatory, even for sensitive targeted MS approaches [48]. The storage and 
processing of blood samples, as well as the age, sex and ethnicity of biofluid donors can 
also significantly affect protein identification experiments, and accurate controls must be 
established in order to avoid experimental artifacts [32].  
The collection of tumor proximal fluids diminishes the problem of abundant proteins 
eclipsing low abundant biomarkers, but it represents an invasive procedure, and limited 
blood contamination can still occur (for e.g. during fine needle aspiration) [46, 80]. The 
problem of serum contamination when collecting tissue fluids can be partially circumvented 
by using capillary ultrafiltration probes, implanted into various tissues, which can collect 
secreted and ECM proteins. Once ultra-filtration probes are implanted in the tissue of 
interest, a vacuum is applied to a semi-permeable filter, leading to the collection of tissue 
fluids [80]. Pancreatic juice has been identified as a rich source of putative PDAC associated 
biomarkers. It is secreted by the exocrine pancreas and represents a bicarbonate based 
solution (produced by the ductal cells) containing digestive enzymes (secreted by the acinar 
cells) [46, 84]. The presence of secretory enzymes complicates proteomic analysis and 
rigorous procedures need to be employed for sample collection and processing to prevent 
the proteolytic degradation of the juice protein components [84]. 
Conditioned cell culture medium is often a preferred source for secreted biomarker 
evaluation, since it represents a stabilized, easy to handle model and it includes the 
possibility of comparing primary and metastatic cell lines with different aggressiveness or 
metastatic behavior [46, 81]. However, cell lines are an artificial isolated system, depleted 
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for e.g. of niche stimuli. The dependency of cultured cells on added mammalian serum 
complicates proteomic discovery, similarly to the way abundant serum proteins hinder the 
identification of low abundant proteins in the blood. Two strategies are typically employed 
to deal with the added serum contamination: either pre-fractionation procedures are added 
to the proteomic work flow – which increases the number of experimental steps and can 
compromise the accuracy of protein quantification, or cells are cultured in serum deprived 
medium prior to collection – leading to cell death and the artificial alteration of the secretome 
profile by apoptotic and pre-apoptotic cells [45, 79, 85]. Attempting to address the problem 
of secretome contamination with serum proteins, Eichelbaum et al. developed a method of 
labeling newly synthesized proteins with azide-containing amino acids, thus allowing the 
use of added serum for cell cultures without affecting the subsequent identification and 
quantification of secreted proteins. Newly synthesized secreted proteins can be captured 
from complex cell culture media by using click chemistry, eliminating the need for laborious 
concentration and pre-fractionation techniques [79].  
Villarreal et al. have analyzed to which extent serum starvation affects the quality of cell 
culture derived secretomes. By evaluating the secretome profile of various breast cancer 
cell lines grown in serum free medium for various amounts of time, they were able to 
establish a list of proteins associated with increased apoptosis of cultured cells, thus 
establishing an internal control. The apoptosis reporter protein list included mostly tRNA 
synthetases and chaperones [81]. Additionally, the group investigated if some of the 
intracellular annotated proteins identified in the conditioned medium were released in the 
extracellular space after cell lysis, or if they were truly secreted via an unconventional 
pathway specific to cancer cells. To their surprise, upon performing IHC on breast cancer 
tissue samples, they observed that a number of the nuclear/cytoplasmic proteins relocated 
in the neoplastic tissue and could therefore be detected in the extra-cellular environment 
[81]. Hence, they cautioned against discarding typically intra-cellular proteins from the 
subsequent cancer biomarker validation steps, and acknowledged the need for further 
investigations of unconventional secretion pathways and their role in mammalian cell 
biology [81]. The group also expressed interest in proteins secreted via exosomes, since it 
has been shown that tumor released exosomes represent more than a simple source of 
cancer biomarkers [81, 82]. In the particular case of melanoma, exosomes alone have been 
shown to prime their future metastatic site, ensuring the hospitability of the new niche to the 
invading cancer cells [82]. 
CA19-9 is the most widely used FDA approved serum biomarker for PDAC. The protein, a 
sialylated Lewis A antigen, is normally present on the surface of cells, but can also be 
secreted. However, CA19-9 is also elevated in benign diseases such as chronic pancreatitis 
and obstruction of the biliary duct [84]. Genetic variations in some individuals resulting in 
the inability to shed CA-19-9 antigen additionally complicate its use as a PDAC biomarker 
[46, 86]. For these reasons, several attempts have been made by the proteomic community 
to identify novel protein biomarker candidates secreted in pancreatic juice or cell culture 
medium that can lead to improvements in the diagnostic and disease monitoring capacity 
[46, 84]. This subchapter will not detail individual experiments and proteins of interest 
selected by the authors; an overview of these approaches can be found in the reviews of 
Pavlou et al. [46] and Makridakis et al. [85]. Very few attempts have been made to discover 
novel PDAC markers in the serum of cancer bearing patients or patients diagnosed with 
preneoplastic lesions. One such interesting discovery experiment has been performed by 
Nie et al. The authors selectively enriched circulating glycoproteins, using a lectin resin, and 
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proposed a panel of three protein markers, namely α-1-antichymotrypsin, thrombospondin-
1,and haptoglobin, to be used in combination with CA19-9, which could distinguish between 
cancer, diabetes, obstructive jaundice and chronic pancreatitis patients [77]. 
 
2.2.6 Validation methods and targeted proteomics 
Once the postanalytical data interpretation has been completed and a number of protein 
biomarker candidates has been selected, the next step of the biomarker development 
pipeline is the preclinical validation.  
Multiple techniques have been employed over the years. Historically, antibody based 
techniques such as ELISA, IHC and western blot (WB) have been preferred as convenient, 
rapid, sensitive and high-throughput solutions, despite the fact that they are difficult to 
multiplex [48]. However, the availability of suitable antibodies is often a limiting factor for the 
development of such validation method. The cross reactivity of commercially available 
antibodies needs to be taken into consideration when the aim is to quantify proteins with 
high sequence similarities between species (when animal xenografts samples are used), or 
between members of a certain protein family [48]. IHC validation is complicated by the 
obligatory sample fixation protocols, which additional to being time consuming, can also 
affect the availability of the antigen of interest. Moreover, IHC can only be used for 
semiquantitative evaluations of protein abundances [31, 48]. Novel technological advances 
have been developed in order to increase the specificity and sensitivity of antibody based 
validation methods. A novel immunoassay supported by ErennaTM Immunoassay Systems 
(Singulex, Alameda, CA, USA) utilizes photon fluorescence detection and paramagnetic 
microparticles to increase precision and sensitivity, being able to quantify and report 
concentrations below 1 pg/mL [31]. Another new development is the digital ELISA 
(Quanterix Corporation, Cambridge MA, USA), which can detect single enzyme-linked 
immunocomplexes on beads packed in arrays consisting of femtoliter wells, and can detect 
proteins present at sub-fM concentrations, thus being three orders of magnitude more 
sensitive than a conventional ELISA [31]. New affinity based techniques which are replacing 
antibodies with affibodies and aptamers, are also being considered [31, 54]. 
RT-qPCR is also commonly used in the validation phase of proteomics based biomarker 
discovery experiments, despite it mostly being regarded as a transcriptomic tool. The 
method interrogates whether the changes in protein expression levels observed between 
samples can be correlated with mRNA levels, or if a post-translational mechanism is more 
likely to be responsible for the recorded variations. Briefly, total RNA extracts need to be 
first reverse-transcribed, using oligo-dT, random, or specific primers. The resulting cDNA is 
interrogated for the amount of a specific mRNA of origin, based on the fluorescent signal 
detected in the sample. The fluorescence is either generated by a TaqMan hydrolysis probe, 
or most commonly by the SYBR green DNA intercalating agent [87]. The moment when the 
overall fluorescence detected in the sample surpasses the statistically defined background 
noise is called the threshold cycle (Ct), and it is an indicator of the amount of cDNA 
molecules present in the sample. The higher the initial number, the quicker can the Ct be 
reached [87]. Specific primers can be designed for the genes of interest, including the 
possibility to recognize species specific mRNA reverse transcribed sequences. Therefore, 
RT-qPCR can be used for the relative quantification of the genes of interest also in 
xenografted tissues, making it possible to exclude the signal originating from the host’s 
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stromal cells present in the tissue sample/contaminating the pre-sorted cells. For TaqMan 
probe detection protocols, an additional step for the selection of the oligonucleotide probe 
needs to be included [87, 88]. However, when designing a pair of primers for RT-qPCR, 
one needs to consider putative signals originating from potential pseudogenes, sometimes 
transcribed, although usually not translated into a functional proteomic entity [89, 90]. 
Properly designed RT-qPCR primers could also distinguish between splice isoforms [89]. 
However, as previously mentioned, gene expression experiments cannot always predict 
accurate protein levels, nor can they offer information on the wealth of PTMs associated 
with a specific protein marker or accompanying pathologic transformations [40].  
Mass spectrometric approaches represent an appealing alternative to antibody and other 
affinity compound based validation strategies. Targeted MS methods have been developed, 
aiming to allow multiplexed analysis, validation and quantification of specific protein 
biomarkers, while circumventing the traditional limitations of shot-gun discovery proteomics 
[48].  
The main caveat of traditional MS discovery designed instruments is their limited sensitivity 
when analyzing complex samples [31]. First, problems can arise from stochastic sampling, 
which is an intensity dependent effect. Secondly, ion suppression effects can arise 
depending on the presence of compounds in the sample altering the efficiency of gas ion 
formation. Finally, informative ion species can be excluded from the analysis, due to their 
elution within a predefined dynamic exclusion filtering window, designed to avoid 
resampling of the same ions [48, 54, 91]. Novel MS strategies, such as SRM (also known 
as multiple reaction monitoring or MRM), parallel reaction monitoring (PRM), or accurate 
inclusion mass screening (AIMS) have been developed to increase selectivity and improve 
MS quantification [48].  
SRM is a targeted proteomic approach, usually conducted on a triple quadrupole 
instrument, in which the first and the third quadrupoles act as mass filter, while the second 
quadrupole performs the CID fragmentation. In SRM, a specific peptide (the precursor) is 
selected in the first mass filter, fragmented, and a single fragment ion is filtered by the third 
mass analyzer. The number of fragment ions is counted by the instruments detector, 
allowing for precise quantification of the precursor peptide and therefore its corresponding 
protein of origin [48, 54]. A schematic representation of shotgun vs SRM proteomics is 
outlined in Figure 6. The pair of precursor and fragment ions selected during the analysis 
are referred to as transitions [48]. Alternatively, all product ions of a certain peptide can be 
analyzed in parallel, thus increasing the confidence rate for the identified peptide and 
providing a higher tolerance for co-isolated background peptides. This technique has been 
termed PRM [54, 92]. Proteotypic peptides as well as species specific peptides can be 
selected as precursors for the transitions, thus allowing for the accurate quantification of the 
protein of origin in complex samples and samples isolated from xenografts models [93]. 
SRM’s sensitivity also allows the detection of highly similar peptide sequences, such as 
somatically mutated and disease associated proteins [39]. However, optimization of 
transitions is not trivial and implementing the method requires significant technical 
knowledge, which can be a deterrent for clinical applicability [54]. Nonetheless, SRM has 
been proven to be a highly reproducible quantification method across different laboratories 
and it is currently used in the clinics for evaluating the concentration of small molecules [48]. 
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Figure 6: Comparison of the MS principles in shotgun proteomics and SRM analysis – schematic 
representation for ESI-quadrupole systems. Enzymatically digested peptides are loaded on a 
chromatographic column for prefractionation, and eluted. A: In shotgun proteomics, all eluting 
peptides are screened in the first quadrupole (Q1), and a full MS spectrum is created. Peptides with 
the highest MS intensity are selected for dissociation (Q2) and all fragment ions are screened in the 
second mass filter – Q3, thus obtaining the MS2 spectra which will be searched against available 
data bases. B: In SRM, Q1 selects only one prespecified precursor ion, with a defined m/z, and the 
peptide is fragmented in the second quadrupole. Q3 acts as a mass filter for a single fragment ion 
and the respective intensity is recorded. Further, relative or absolute quantification is achieved by 
comparing peak intensity between different samples or internal standards, respectively. Modified 
from Gilette et al. and Liu et al. [48, 54]. 
 
For a better quantification, SRM analysis is often performed in the presence of stable 
isotope labeled peptides corresponding to the precursor peptides to be analyzed. These 
internal standards allow a reliable evaluation of protein level differences in distinct samples. 
However the spike in of stable isotope labeled peptides cannot predict the effect of sample 
prefractionation protocols on the availability of the precursor peptides for the MS analysis, 
nor can it predict the efficiency of the enzymatic digestion [48]. Thus, for absolute 
quantification, the use of synthetic labeled whole proteins, undergoing the same 
preanalytical procedures, is recommended [39, 54].  
The complexity of the sample needs to be considered, since it affects the method’s limit of 
detection. Plasma often needs to be depleted for the most abundant proteins, using 
immunoaffinity depletion columns prior to the MS analysis, despite the risk of losing lower 
abundant proteins in the process [48]. The detection limit for unfractionated plasma is in the 
range of 0.3 – 1 µg/mL and therefore above the required level for distinguishing potential 
protein biomarkers. The detection boundary can be decreased to 1 – 10 ng/mL in 
fractionated plasma [48]. When analyzing unfractionated whole cell lysates, SRM allowed 
the detection of proteins present in as low as 7500 copies per cell [39].  
Sample handling is also highly important and hemolysis should be avoided, since it can 
negatively affect the mass spectrometric subsequent analysis [93]. SRM can also be used 
in combination with antibody based enrichments protocols, allowing for a better limit of 
detection in complex biological samples. Protein or peptide enrichment can be carried out 
A: Shotgun proteomics
B: SRM
Electrospray emitter Q1 Q2 Q3
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prior to the MS based analysis, using high affinity antibodies. The sensitivity of the antibody 
is not as important as its affinity, since the quadrupole filtering can distinguish between the 
isolated species. However, the method is limited by the existing of commercially available 
antibodies with high affinity for the peptide or protein of interest [48].  
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2.3 Current knowledge about novel PDAC biomarker candidates 
 
The following subchapters will summarize important information about the four main 
putative PDAC biomarker candidates of interest, identified in the current study. A short 
overview is presented in Table 1. 
Table 1: Short overview of the top four novel putative PDAC markers 
Protein name 
Phylogenetic 
distribution 
Cellular 
localization 
Organ 
distribution (adult 
humans) 
Function 
Cadherin-17 
Vertebrates 
and 
invertebrates 
Plasma 
membrane 
Small and large 
intestine 
Cell-cell 
interaction. 
Cell adhesion 
Galectin-4 
Animals and 
plants 
Cytoplasmic 
+ secreted 
Digestive tract and 
associated glands, 
excepting liver and 
pancreas 
Carbohydrate 
domain 
recognition. 
Protein-protein 
interaction 
Protocadherin-1 
Vertebrates 
and 
invertebrates 
Plasma 
membrane 
Central nervous 
system, airway 
epithelial cells 
Cell-cell 
interaction 
Lipocalin-2 
Eukaryotic 
organisms, 
mostly 
vertebrates 
Secreted 
Bone marrow, 
spleen, tonsils, 
respiratory + 
digestive track, 
kidney, prostate, 
uterus 
Iron transport. 
Innate immune 
response 
 
 
2.3.1 Cadherin-17 
Cadherins represent a family of calcium dependent adhesion proteins, typically involved in 
cell recognition, cell signaling, morphogenesis, angiogenesis, migration and tumorigenesis 
[94, 95]. All family members contain a series of extra-cellular amino terminal domains, 
termed cadherin repeats; most cadherins are trans-membrane proteins, including a carboxi-
terminal cytoplasmic domain, varying in size and composition significantly between different 
cadherin families, responsible for intra-cellular signaling [94-96]. The cadherin repeat 
consist typically of approximately 110 amino acids arranged in seven β-strands and two 
short α helixes, resulting in a β barrel structure similar to that of an immunoglobulin domain 
[97]. In the presence of calcium ions, the extra-cellular domain is stabilized and adopts a 
rod like structure; the binding of ions takes place at the junction between cadherin domains 
(also known as ectodomains) [98].  
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The cadherin family members can be classified in at least six sub-families, based on the 
composition of their extra and intra-cellular domains [96]: 
a) Classical cadherins: containing five extra-cellular cadherin domains, and a 
cytoplasmatic tail of 120-150 amino acids 
b) Desmosomal cadherins 
c) Seven domains cadherins: containing seven extra-cellular cadherin repeats and a 
very short cytoplasmatic tail, consisting of approximately 20 amino acids 
d) Seven transmembrane cadherins 
e) Truncated cadherins: containing no transmembrane domain, instead GPI anchored 
to the cell membrane 
f) Protocadherins (which will be discussed in greater detail in a following subchapter) 
Cadherin-17 (CDH17) belongs to the sub-family of seven domains cadherin, as it contains 
seven extra-cellular cadherin repeats, and it was first described as a proton dependent 
peptide transporter in the intestinal CaCo2 cell line [96, 97, 99].  
Phylogenetic analysis have suggested that the first two cadherin domains of CDH17 
resulted as a duplication of the first two ectodomains described in classical cadherins [97]. 
In support of the duplication theory comes also the observation that the calcium binding 
motif between cadherin domains two and three is incomplete [97]. The cytoplasmic domain 
of CDH17 is very short and no direct intra-cellular partners of interactions could be 
described so far [96, 100].  
Cadherins expression is highly regulated during embryogenesis and adulthood [101]. In 
mouse and human, CDH17 has been reported at the baso-lateral level of enterocytes and 
goblet cells of the intestine, while in adult rat it is also present in hepatocytes, which is the 
reason why the initial name for the protein was Liver-Intestine Cadherin [96, 100]. Some 
authors have reported occasional scattered weak expression in ductal cells of the healthy 
pancreas [95, 96].  
Classical cadherins are known to mediate cell adhesion via their cytoplasmatic tail, which 
interacts with β-catenin, plakoglobin and α-catenin [94]. However, in the case of CDH17 the 
adhesion mechanism is unknown. Not only that the 20 amino acids intracellular domain is 
insufficient for direct β-catenin interaction, but a GPI anchored engineered form of the 
protein was capable of mediating cell-cell adhesion to the same extent as the native CDH17 
[96, 100]. It has been however suggested that CDH17 could dimerize with E-cadherin, 
although this type of interactions are more likely to occur during embryogenesis, since the 
two cadherins are located at different junctions in the adult cell [96, 97]. It has been 
suggested that the interaction with E-cadherin can lead to the release of β-catenin from the 
cytoplasm, thus potentially implicating CDH17 in Wnt signaling [96]. Takamura et al. 
reported galectin-3 as a potential partner of interaction for CDH17, using a pancreatic ductal 
adenocarcinoma cell line [95]. The interaction would occur via the extra-cellular domains of 
CDH17, which have been shown to be subject to N-glycosylation [95, 96]; they could show 
that washing the cells with a lactose solution lead to a decrease in association between the 
two proteins (evaluated via co-immunoprecipitation – co-IP) in a dose dependent manner, 
but it was not affected upon washes with a sucrose solution [95]. Of interest is the fact that 
galectin-3 has also been described to be involved in Wnt signaling, based on its ability to 
interact with β-catenin in the nucleus and axin in the cytoplasm [96]. Recently, Bartolomé 
et al. described α2β1 integrin as an interaction partner for CDH17, based on co-IP 
experiments and mass spectrometric determination of the pulled down proteins [102]. 
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Interaction between the two adhesion molecules lead to activation of focal adhesion kinase 
(FAK) in a metastasising colorectal cancer cell line, and initiated Ras signaling. 
Interestingly, silencing of either the α2 or the β1 integrins resulted in loss of colocalization 
of the remaining chain with CDH17, leading to the conclusion that both α and β subunits 
were necessary for the proper interaction to occur. Moreover, CDH17 knock down could be 
correlated with a decrease conformational activation of β1 integrin [102]. Thus it appears 
as if CDH17 might mediate cell adhesion exclusively via key interactions of its extracellular 
domain. 
The CDH17 gene expression has been shown to be modulated by two major transcription 
factors – HNF1α and CDX2, based on chromatin-immunoprecipitation experiments and 
deletion/mutation analysis, using hepatocellular carcinoma cell lines [99].  
A summary of CDH17 mediated signaling and transcriptional regulation is presented in 
Figure 7. 
 
Figure 7: Schematic representation of signaling associated pathways and transcriptomic regulation 
of CDH17. The seven extracellular domains of the protein are predicted to be subject to N-
glycosylation, and the glycosyl chains are expected to mediate interaction with members of the 
galectin family, such as galectin-3. Galectin-4 and CDH17 co-expression has been reported in 
literature, however their putative interaction has not been tested. Wnt signaling (indicated by red 
arrows) and activation of FAK pathway via integrin β1 – CDH17 interaction (indicated by green 
arrows) are the main signaling pathways in which CDH17 has been shown to participate so far. 
Purple arrows indicate transcriptional events. ITGA2 = integrin α2; ITGB1 = integrin β1. 
CDH17 expression has been reported to be disregulated in malignant tissues, with different 
prognosis depending on the carcinoma type – in hepatocellular carcinoma, CDH17 
overexpression has been associated with bad prognosis [96, 103], while in PDAC it has 
been linked to improved prognosis, enhanced differentiation of the tumor and increased 
survival [96, 104].  
In the case of gastric carcinoma, CDH17 together with LGALS4 have been reported as 
markers for a molecular subtype (termed by the authors G-Intestinal), defined by better 
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response to 5-FU therapy, the corresponding group of patients showing a moderate survival 
benefit compared to patients who did not express the two markers (G-diffuse subtype) [105].  
In hepatocellular carcinoma, a splice variant of CDH17 has been described, where exon 7 
is excluded from the mature mRNA. This mutation seems to be specific to hepatocellular 
carcinoma and is associated with shorter survival, increased tumor recurrence and tumor 
venous infiltration [96]. In one study, knockdown of CDH17 in highly metastatic 
hepatocellular carcinoma cell lines lead to reduced proliferation, and was associated with 
cytoplasmic relocalization of β-catenin and a decrease in cyclin D1 levels, linking it 
potentially to Wnt signaling [103]. In another study, CDH17 was also shown to cross-talk 
with Met signaling [96].  
On the other hand, in the case of intrahepatic cholangiocarcinoma, the second most 
common type of liver cancer, CDH17 seems to have a protective role. Takamura et al. down 
regulated CDH17 and observed an increased expression of Metal Responsive Transcription 
Factor 1 (MTF1) and its downstream target Placental Growth Factor (PIGF) [106]. PIGF has 
been shown to be essential for angiogenesis and plasma extravasation in ischemia, 
inflammation and cancer [106]. In addition, MTF1 loss in Ras-transformed cells lead to 
reduced tumor growth, increased matrix deposition and reduced angiogenesis [106].   
In conclusion, CDH17 is an intriguing adhesion molecule, potentially linked to Wnt and Ras 
signaling [95, 96, 102], whose role in cancer progression appears highly dependent on the 
tissue of origin [106]. 
 
2.3.2 Galectin-4 
Galectins represent a class of animal lectins that typically bind β-galactose containing 
glycoconjugates [107, 108].They were initially named S-type lectins, due to the fact that 
they seemed to require reducing conditions in order to maintain their lectin-binding activity, 
thus indicating that a free cysteine residue was vital for the biological function of the protein. 
However,  galectin-4 activity is independent of the existence of reducing conditions in the 
environment [108]. All galectins contain a carbon recognition domain (CRD), of usually 
around 130 amino acids arranged in a β-sandwich completely lacking an α-helix, domain 
responsible for the recognition of and interaction with specific sacharides [108]. 
The galectin family has been subclassified in three major groups [108, 109]: 
a) Prototypical galectins: contain a single CRD, often forming dimmers 
b) Chimeric galectins: more common in invertebrates, contain a single CRD and a large 
Pro-Gly-Tyr rich domain, which is often very sensitive to metalloproteinases. The 
only vertebrate galectin described in this class is galectin 3 
c) Tandem repeat galectins: they contain at least 2 CRDs, linked together by an amino-
acid chain of 5-50 amino acids long. The linker peptides are often sensitive to 
proteolytic activity. This class includes galectin-4. 
Galectin-4 (LGALS4) is a 323 amino acid long protein (approximately 32 kDa), containing 
two CRDs (consisting each of approximately 130 amino acids), linked by a 34 amino acid 
sequence similar to the Pro-Gly repeats described for galectin 3 [110]. The two CRDs of 
LGALS4 display only 40% sequence similarity, and although they bind lactose with equal 
affinities, they exhibit different affinities for larger sacharides. This had led scientists to 
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hypothesize that it can act as a cross-linker and potential stabilizer of complex structures 
[110].  
In development and adulthood, LGALS4 is expressed at high levels in the digestive tract 
from mouth to rectum, but is not expressed in accessory digestive glands such as liver and 
pancreas [110]. It can be found either intracellulary, associated with adherens junctions, 
microvilli or lipid rafts [107, 110], or in the extracellular environment, where it is expected to 
act as a cross-linker for various glycoproteins [110]. No classical secretion signal peptide 
could be identified for any member of the galectin family, and therefore it can only be 
suspected that their export is done via a non-canonical secretion pathway [108, 111]. The 
exact mechanism is unknown, but it is believed to have evolved in order to avoid interaction 
between the galectins and the glycosylated proteins found in the Golgi classical secretion 
pathway, especially since the CRD is already active prior to externalization [107, 108, 111].  
The CRD seems to be essential only for the extracellular functions of galectins [107]. In the 
intestine, LGALS4 forms soluble high molecular weight complexes with brush border 
enzymes in lipid rafts [107, 112]. Upon LGALS4 depletion, proteins normally localized at the 
apical level were trapped intracellulary, thus indicating a sorting defect caused by the 
absence of the lectin [107, 112]. Sulfatides with long chain hydroxylated fatty acids, which 
are typically enriched in lipid rafts, were described as high affinity ligands for LGALS4 [107, 
113], leading to the conclusion that that the lectin is important for the apical delivery of 
proteins upon interaction with the sulfatides clustered on the lipid rafts [107, 113]. LGALS4 
has been shown to also play a role in the development of inflammatory bowel disease, since 
it stimulates CD4+ T cells to produce the pro-inflammatory cytokine IL6 [107, 109]. The IL6 
production is induced by a PKCθ signaling pathway, through the immune synapse [107, 
109]. The simple administration of a LGALS4 antibody to mice developing intestinal 
inflammation could lead to suppression of disease progression [107]. 
Two c-Rel binding sites could be identified at the promoter region of LGALS4, leading to 
suggestions that LGALS4 could be induced in inflammatory gut disease as part of the innate 
immunity response triggered by NF-kB [110, 114]. The promoter region of LGALS4 has also 
been suggested to be under control of Myo-D transcription factor, as well as multiple 
transcription factors belonging to the Hepatocyte Nuclear Factor 3/HNF3/fork transcription 
factor family, such as HNF3β, HNF4, HFH2 [110]. Thus, described putative transcription 
binding sites upstream of the LGALS4 promoter suggest that the gene is controlled by 
regulators of epithelial development, differentiation, as well as malignant transformation 
[110]. 
In fact, LGALS4 has been found to be associated with a number of malignancies. In colon 
cancer, a loss of supra-nuclear LGALS4, concomitant with increased cytoplasmatic 
expression could be described during cancer progression [110]. In one study, increased 
expression of LGALS4 in colon carcinoma was correlated with poor prognosis, although in 
early colon carcinogenesis, LGALS4 mRNA expression has been reported to decrease 
compared to the expression observed in the surrounding normal tissue [115]. Another 
example of abnormal expression has been described in breast cancer: although the healthy 
breast tissue is devoid of LGALS4, abnormal areas of benign tumors and especially 
carcinomas show high levels of the protein [110].  
The exact function of LGALS4 in human malignancies has however been insufficiently 
investigated, with reports sometimes reaching contradictory conclusions for distinct 
malignancies. A study using ovarian and lung carcinoma derived cell lines has reported that 
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poorly differentiated epithelial cancer cells not capable of forming polarized layers express 
less LGALS4, tend to migrate more and express higher levels of galectin-1, typically 
associated with tissues of mesenchymal origin [110]. Another study investigated the 
localization of LGALS4 in the colon metastasis derived cell line T84. The investigators 
observed accumulation of the lectin of interest at the cell-substrate interaction for freshly 
seeded cells, at the basal membrane for confluent cells, and at the leading edge of 
lamellipodia in the case of sub-confluent cells [115, 116]. They therefore concluded, that at 
least in the case of colon carcinoma, LGALS4 plays a role in cell-substrate interactions and 
may be important to cell migration and metastasis [115]. Of great importance was the report 
showing that LGALS4 may help cells survive in nutrient depleted environments. Thus 
MDCK cells transfected with LGALS4 were able to survive in serum starved medium for 7-
8 weeks, in stark difference to the mock transfected cells who became apoptotic after one 
week in the same conditions [110]. Considering that for PDAC the microenvironment is 
reported to be severely hypoxic and under-perfused [13], LGALS4 overexpression might 
therefore represent a survival advantage for these cancer cells. 
In 2011, Tan et al. reported that co-expression of CDH17 and LGALS4 can be correlated 
with better survival prognosis for gastric cancer patients, as well as increased responses to 
5-FU and oxaliplatin, despite showing augmented resistance to cisplatin treatments [105]. 
No attempts to functionally link the two proteins has been made. However, previous studies 
have identified ‘stalked’ brush border enzymes – containing only a small cytoplasmatic tail 
and large, heavily glycosylated extracellular domains, similar to the general organization of 
CDH17 – to be partners of interaction for LGALS4 [96, 112]. It would be of interest to 
investigate if the two proteins interact in vivo (as mentioned is Figure 7) and if this 
interaction plays a role in cancer progression and response to chemotherapy.  
To sum up, LGALS4 is a versatile carbohydrate binding protein, involved in inflammatory 
response and cancer progression. LGALS4 activation in cancer tissues can often be 
associated with improved overall survival. However, its upregulation seems to give a 
survival advantage for cancer cells living in nutrient deprived media [110].  
 
2.3.3 Protocadherin-1 
Protocadherins represent the largest subfamily of the cadherin family, briefly discussed 
earlier. The term protocadherin was introduced by Sano et al., when they identified a 
subclass of proteins containing cadherin ectodomains, holding different features from those 
of classical cadherins. The new class of proteins was highly expressed in the brain and their 
presence in a wide range of vertebrate and invertebrate species inspired the name 
protocadherin, from the Greek ‘protos’= first [117, 118].  
Based on their molecular and genetic features, protocadherins have been subdivided into 
several clusters: α-, β-, γ- protocadherins, flamingo cadherins, large protocadherins 
(including FAT cadherins) and nonclustered protocadherins δ and ε [117, 119].  
Protocadherin-1 (PCDH1) belongs to the δ protocadherin subfamily, which has been further 
subdivided in δ1 and δ2 protocadherins [119, 120]. Based on the latter subclassification, 
PCDH1 is a δ1 protocadherin, first identified under the name of PC42 in human brain [118]. 
δ1 protocadherins contain seven cadherin repeat domains, and three intracellular 
conserved motifs (CM), termed CM1, CM2 and CM3; CM3 is specific for δ1 protocadherins, 
Introduction 
 
37 
 
located adjacent to the CM1 domain, and seems to be responsible for interaction with 
Protein Phosphatase 1α (PP1α) [119, 120]. PCDH1 has been shown to be subject to 
alternative splicing, with at least two major isoforms often reported in literature: isoform 1 
expresses a short cytoplasmatic tail, while isoform 2 has a long cytoplasmatic region [118, 
119]. Several additional splice isoforms have been described as well by Koning et al., their 
inclusion/exclusion from the mature mRNA being most likely dictated by the differentiation 
state of the investigated cells; several alternative transcription initiation sites have also been 
suggested [119]. The exact function of the different splice isoforms has been so far 
insufficiently investigated. 
Protocadherins are currently regarded as proteins expressed mostly in the central nervous 
system, developmentally regulated and their expression tends to be higher in adult 
compared to fetal and neonatal tissues [117, 118]. Additionally to the brain localization, first 
reported for PCDH1 [118], the protein has also been reported to be expressed by airway 
epithelial cells, at the apical border, and in macrophages [121]. 
Very little is known about the function of PCDH1. Protocadherins in general have been 
shown to both promote, and inhibit cell adhesion, but the exact mechanisms of adhesion 
have not been explained [117]. PCDH1 is known to express a PDZ domain binding site at 
the C terminal end of the cytoplasmic domain. PDZ is a structural domain found in many 
different signaling proteins of many regna, responsible for helping transmembrane proteins 
anchor to the cytoskeleton and hold together signaling complexes [119]. Their defined 
expression by distinct subpopulations of functionally connected neurons as well as their 
localization at the synaptic junctions, lead researchers to presume that protocadherins could 
be involved in modulation of synaptic transmission, synaptogenesis and synaptic plasticity, 
all important for learning and memory formation [117, 120]. Protein isoforms expressing the 
full CM3 cytoplasmatic domains include a RRVTF sequence responsible for interaction with 
Protein Phosphatase 1α [120]. PP1α has been involved in regulation of synaptic plasticity, 
but also in lung development [120, 121]. Other putative interaction partners for δ1 
protocadherins include TAF1/set (involved in cell cycle regulation) and Frizzeled 7 receptor 
[120, 122]. PCDH1 has been identified as a susceptibility gene for bronchial 
hyperresponsiveness and asthma [121], and the expression level is increased in highly 
differentiated bronchial cells. Additionally, the expression of splice isoforms may also be 
dependent on the differentiation status of the bronchial cells [119]. PCDH1 has been 
suggested to be involved in epithelial repair, since the mRNA and protein levels were 
upregulated in a keratinocyte wound repair model [119].  
References about protocadherins expression and involvement in cancer have been scarce. 
Protocadherin-7, a δ1 protocadherin family member showing many structural similarities to 
PCDH1 has been reported to be involved in non-small-cell lung cancer [119]. To our 
knowledge, no report has to date ever linked PCDH1 to PDAC. 
 
2.3.4 Lipocalin-2 
The lipocalin protein family belongs to the structural superfamily of calycins (together with 
avidins and Fatty Acids Binding Proteins), and consist of over 50 small molecules, usually 
involved in binding and transporting small hydrophobic molecules (such as prostaglandins, 
retinol, hormones, etc) [21, 123-125]. Despite the low level of structural similarities between 
family members (~20%), the three dimensional structure is common for all affiliated 
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proteins, consisting of a single eight-stranded, continuously hydrogen bounded anti-parallel 
β-barrel, which forms an enclosing cavity, responsible for binding specific molecules [124, 
125].  
Lipocalin-2 (LCN2), also known as neutrophil gelatinase (NGAL – since it was first isolated 
from human activated neutrophils), or siderocalin (due to its iron binding capacity) is a 
25 kDa protein (in its monomeric form), which can also be found as a disulphide linked 
homodimer (46 kDa in size) or a disulphide linked heterodimer with matrix 
metalloproteinase 9 (MMP9) (135 kDa) [124, 126]. In healthy tissues, LCN2 has been 
reported in the bone marrow, in the spleen and tonsils, as well as in organs prone to 
exposure to microorganisms such as epithelia of the respiratory and digestive tracks [127]. 
It can also be found in low levels in the kidney, prostate and uterine mucosa [124]. 
LCN2 is a versatile protein, performing a variety of functions, depending on the tissue, 
developmental stage and health status. It is involved in the innate immune response, as it 
is released by neutrophils at a site of infection and inflammation, where it binds iron and is 
involved therefore in the antibacterial iron depleting strategy [124]. Its iron binding and 
transport capacity has also been shown to contribute to the activation/repression of iron 
responsive genes and cell growth, after its cytoplasmic internalization followed by iron 
unloading in acidic endosomes [124]. Lipocalin has also been reported to be a regulator of 
apoptosis, through its iron binding and transporting function – it can block the induction of 
pro-apoptotic protein Bim and prevent pro-caspase 9 activation. Alternatively though, LCN2 
can bind several siderophores in the cytoplasm, reducing intracellular iron concentration 
and leading to Bim expression [124, 128]. Moreover, LCN2 can protect against acute 
ischemic injury and its expression level reflects the extent of tissue damage, making it one 
of the most promising markers for nephrologic pathological states [124, 126]. However, 
neutrophil gelatinase has been reported to be upregulated in several inflammatory 
conditions, including appendicitis, inflammatory bowel disease, diverticulitis, and it seems 
to be under transcriptional regulation of NF-kB [126]. LCN2 is also involved in differentiation 
of primordial cells during embryogenesis, its expression being highest before the onset of 
cellular differentiation [21]. A schematic overview of the LCN2 involvement in signaling 
pathways relevant for tumor progression is represented in Figure 8. 
In human malignancies, LCN2 is often upregulated compared to the normal tissue, but 
controversially it tends to be downregulated in metastatic tumors compared to the primary 
tumor [124]. Both pro- and anti-neoplastic functions have been described in literature for 
the protein, depending on the type of tumor and the differentiation status of the neoplastic 
cells studied. For example, in the case of esophageal cancer, LCN2 interaction with MMP9 
leads to a protected, more active gelatinase, favoring cancer cell invasion [124, 126]. 
However, in K-Ras mutated colon cancers and pancreatic ductal adenocarcinomas, or Ras 
transformed breast cancer cells, LCN2 over-expression lead to decreased migration and 
metastasis. This effect could be due to decrease of Ras dependent phosphorylation and 
subsequent inactivation of E-Cadherin, or in the case of PDAC, by altering FAK 
phosphorylation at tyrosine level 397 (critical for the kinase’s activation) and subsequent 
decrease of migration and metastasis of pancreatic cancer cells [126]. Its function in cancer 
progression is therefore controversial and may be highly dependent on the tissue of origin. 
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Figure 8: LCN2 (also known as NGAL) involvement in survival, motility, proliferation and 
angiogenesis. New acronyms presented in the picture include: NGAL-R = NGAL receptor; v-Erb-B2 
Avian Erythroblastic Leukemia Viral Oncogene Homolog = ErbB-2/HER2; IL-17: interleukin-17; IL-
1β: interleukin-1 beta; NF-κB: nuclear factor kappa B cells; IκBζ: Inhibitor of NF-κB zeta subunit; HIF-
1α = hypoxia inducible factor-1α. Adapted from Candido et al. [124]. 
In the particular case of PDAC, LCN2 has been reported to be significantly upregulated at 
both mRNA and protein level, compared to chronic pancreatitis samples [21]. It could also 
be detected in the blood of PDAC patients, using ELISA or Radioimmunoassay (IRA). For 
this reason, several groups studied its potential use as a diagnostic marker, suggesting that 
despite having similar sensitivity to the only so far approved PDAC marker, CA19-9, it might 
show increased specificity [129, 130]. Of interest is the report of Moniaux et al., showing 
that LCN2 is upregulated early in the progression of pre-cancerous lesions: PanIN- I lesions 
already show high expression of the protein, and this comes in agreement with earlier 
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studies showing LCN2 upregulation in IPMNs [21]. High LCN2 levels were however 
associated with early dysplastic lesions as well as better differentiated tumor cells. It is 
therefore believed that LCN2 plays a role in the initiation of pancreatic cell 
transdifferentiation [21, 131]. Several groups have reported that down-regulation of LCN2 
in PDAC cell lines usually leads to reduced attachment, invasion and decreased tumor 
growth, despite having no effect on tumor cell proliferation [126, 128]. However some 
reports suggested that LCN2 upregulation lead to downregulation of VEGF and HUVEC 
tube formation [126], while others have indicated an increased expression of both VEGF 
and HIF-1α in vitro and in vivo, as well as increased vascularization in vivo [128]. Whether 
or not LCN2 promotes chemoresistance is still controversial, and seems to depend on the 
cell line used, as well as the length of the cytotoxicity experiment [126, 128]. LCN2 over-
expression has also been associated with increased E-Cadherin expression and decreased 
vimentin presence in pancreatic cancer, indicating that it might play a role in preventing 
EMT [131].  
In conclusion, LCN2 has been already reported as a promising marker for pancreatic 
cancer, with potential diagnostic applications, although it does not optimally distinguish 
between pre-malignant lesions and PDAC. Clinical applications have already been 
suggested, and Xu et al. conducted early experiments, assessing the applicability of  an 
oncolytic virus harboring the LCN2 gene for PDAC treatment [132].  
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3. Aim of the study 
 
Pancreatic ductal adenocarcinomas remain the solid tumors with the worst overall survival 
and attempts to develop novel therapies for the disease have been without results. As for 
other solid tumors, the stratification of patients into subgroups with tumors featuring similar 
molecular characteristics might allow to better evaluate the treatment options. Recently, 
three molecular subtypes have been proposed for PDAC, based in transcriptomic profiling. 
These molecular subtypes predict patient overall survival and response to therapy. 
However, to date no clinical biomarkers distinguishing between the three molecular 
subtypes have developed. 
 
The aim of our current study was the identification and validation of novel pan-PDAC as 
well as subtype-specific protein biomarker candidates, which can be employed in the 
development of novel clinical applications, such as diagnostics and/or targeted PDAC 
therapies. 
For this purpose, we set out to investigate novel cell surface as well as novel secreted 
protein biomarker candidates using a mass spectrometric approach employing an in vitro 
system recapitulating all three PDAC molecular subtypes. In addition, we investigated 
vascular accessible biomarkers using an in vivo mouse xenogaft system. Promising 
biomarker candidates were selected and further validated using both antibody based and 
antibody independent methods.  
We show the identification and validation of two novel pan-PDAC as well as two novel 
exocrine-like subtype specific protein biomarker candidates. The new biomarker candidates 
can be employed for patient stratification and the development of alternative antibody-based 
therapies in PDAC, as well as the development of new non-invasive diagnostic tools. 
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4. Materials and methods 
 
4.1 Materials  
Cell lines 
Cell line Origin Medium 
HPDE 
Dr.C. Eisen, HI-
STEM/DKFZ; first isolated 
by Furukawa et al [133] 
Keratinocyte serum free + 
50 μg/mL bovine pituitary 
extract 
HPNE ATCC (CRL-4023) DMEM + M3 + 5% FBS 
PACO cell lines Dr.C. Eisen, HI-STEM/DKFZ Cancer Stem Cell medium 
 
Mouse strains 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ JAX (NSG) mice were obtained from the Jackson 
Laboratory (Bar Harbor, USA) and bred in the DKFZ animal facilities. Mice were kept under 
pathogen free conditions and males ages 10-12 weeks were used for the generation of 
orthotopic and metastasis tumor models. All animal handling and experiments followed 
German laws and were previously approved by the governmental review board of Baden-
Württemberg, Germany. Animal experiments were performed under the TVA number 
G25/12. 
 
Cell culture and xenograft work products 
Product Company Ordering number 
0.2 μm syringe filter Life sciences PN4612 
100 μm cell strainer BD 352360 
15 mL conical falcon tubes TPP Z707724 
20 mL Luer Lock syringes Terumo SS-20L1 
40 μm cell strainer BD 352340 
50 mL conical falcon tubes Greiner T2318 
50 mL reagent reservoir, sterile Corning 4870 
70 μm cell strainer BD 352350 
75 cm2 cell culture flasks 
polystyrene, vented cap 
TPP 90076 
75 cm2 primaria cell culture flasks BD 353810 
Acepromazin (Vetranquil) Ceva 233A6 
Cell culture system Inserts 1,0 µm Falcon 353102 
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Cryotube 1.8 mL sterile Nunc 375418 
Eppendorf tubes 0.5, 1.5, 2mL safe 
lock 
Eppendorf 13625, 12682, 12776 
Falcon Companion-Plattes 6-well Falcon 353502 
Gentle MACS C tube Miltenyi 130-093-237 
Ketamin (Ketavet) Parke-Davis 51913 
LD column Miltenyi 130 - 0 42-9 01 
MACS M tube Miltenyi 130-093-236 
Microvette 500K3E Sarstedt 20.1341 
Nalgene freezing container Mr 
Frosty 
Bunc 51000001 
Nunc MaxiSorb Plates Fischer Scietific 44-2404-21 
Primaria cell culture plate 6well BD 353846 
Serological pipettes 2, 5, 10, 25, 
50 mL sterile 
BD 
3565-0.7/-29/-30/-35/-
50 
TipOne 1000, 200, 20, 10μL filter tips StarLab 
14262, 12704, 12705, 
12706 
Vacuum filtration system 500 mL 
0.2 μm pore size 
TPP 99500 
Xylazin (Rompun) Bayer 02169592 
 
Cell culture media and media components 
Product Company 
Ordering 
number 
Accutase Life technologies A11105 
Advanced DMEM/F12 Life Technologies 12634010 
Ascorbic Acid Sigma A4544 
Basic FGF Peprotech 100-18B-1000 
Bovine Serum Albumin Sigma A2153 
Bromphenol Blue Sodium Salt Sigma B8026 
CO2 independent medium Invitrogen 18045088 
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Cryostore CS10 Sigma C2874 
DMEM Wo glucose, L-glutamine, phenol 
red, sodium pyruvate and sodium 
bicarbonate 
Sigma D5030 
DMEM/F12 Life Technologies 21041025 
EGF Peprotech AF-100-15-1000 
Fetal Bovine Serum Life Technologies 10270 
Glucose 45% solution (sterile) Sigma G8769 
Heparine sodium cell culture tested Sigma H3149 
HEPES Life Technologies 15630056 
IGF-R3 Sigma I1271 
Insulin recombinant chain Sigma I9278 
Iron Chloride anhydrous Sigma 451649 
Keratinocyte serum free medium (Kit) 
with L-Glutamine, EGF and BPE 
Invitrogen 17005075 
L-Glutathione Sigma G-6013 
Lipid MIX Sigma L-0288 
M3 Base F Culture Media Incell Corp M300F-500 
N2 supplement Invitrogen 17502048 
DPBS 1X Sigma P5368 
Progesterone Sigma P8783 
Puromycin Sigma P8833 
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Putrescine dihrydrochloride (cell culture 
tested) 
Sigma P5780 
Sodium bicarbonate Cell culture tested Sigma S5761 
Sodium pyruvate Sigma S8636 
Sucrose Sigma S0389 
Trace Elements A, B, C Cellgro 
MT-99-182-Clc; 
MT-99-175-CIc; 
MT-99-176-Cic 
Trypsin/EDTA solution 1X Sigma T3924 
Water (RNase, DNase free, sterile, for cell 
culture) 
Gibco 10977-035 
β-Mercaptoethanol Life Technologies 31350010 
 
Chemical and biological reagents 
Product Company Ordering number 
1-Butanol Chemosolute 2513.1000 
2-Propanon Sigma 33539 
Acetone Sigma 32201 
Acetonitrile ULC/MS purity Biosolve 01204101 
ACK lysis buffer Lonza 10-548E 
ACQUITY UPLC PST C18 
nanoAcquity 10K psi column 
Waters 186003545 
Agarose GE Healthcare 17-0554-02 
Bicine Sigma B3876 
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BM Blue POD Substrate 
Soluble 
Roche 11 484 281 001 
Bovine Serum Albumin Sigma A2153 
C18 OMIX tips 10-100 µL Agilent A57003100K 
Calcium Chloride Sigma C4901 
CHCA matrix Proteochem P9100 
Chlorophorm ROTH 7331.2 
DAKO fluorescent mounting 
medium 
DAKO S3023 
DAKO Glycergel mounting 
medium 
DAKO C0563 
DAKO pen DAKO S2002 
DAPI dihidrochloride Sigma D9542 
Dextrane powder 40000 MW US Biological D6030 
Diisopropyl ether AppliChem A4322,1000 
DNase (RNase free) Qiagen 14325 
Donkey Serum Th Geyer BW/S2170/000100 
DTl- Dithiothreitol Sigma D9779 
EDTA Sigma 036099 
EDTA tetrasodium salt Sigma 27261 
Ethanol absolute Sigma 32205 
Ficoll Paque Plus GE Healthcare 17-1440-02 
Formalin solution 10% Sigma HT50-1-2 
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Fungizone (Amphotericin B) Life Technologies 15290-018 
Glycine Sigma G8898 
Goat Serum Sigma G6767 
Hematoxylin Sigma 51275 
Histogel Thermo HG 4000-012 
Hydrochloric acid 37% Sigma 30721 
Iodoacetamide Sigma I1149 
L-Cysteine Sigma 30089 
Matrigel BD 354234 
Methanol Sigma 34860 
Midori Green Nippon Genetics MG04 
Milk (Skim) Powder Sigma 70166 
NP-40 Sigma 74385 
NuPAGE 4-12% Bis-Tris gells; 
1.5 mm, 10 wells 
Life Technologies NP0335 
NuPAGE 4-12% Bis-Tris gells; 
1.5 mm, 15 wells 
Life Technologies NP0336 
NuPAGE MOPS running buffer Life Technologies NP0001 
OCT embedding medium TissueTek 4583 
PBS tablets GIBCO 18912-014 
pH9 Antigen retrieval buffer DAKO S236784 
Protease inhibitor EDTA free 
tablets 
Roche 04-693132 001 
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PVDF membrane 0.45μm pore 
size Immobilon P 
Millipore IPVH00010 
Quick Load 100bp DNA ladder Bio Labs NO467G 
RapiGest Surfactant Waters 186001861 
RNA from total human 
pancreas 
Ambion AM7954 (Lot no: 1011005) 
ROCK inhibitor Y-27632 Selleck S1049 
Sodium chloride Sigma 31434 
Sodium citrate tribasic 
dihydrate 
Sigma C8532 
Sodium Dodecyl Sulphate Sigma L6026 
Sodium hydroxide Sigma S5881 
Streptavidin-Sepharose High 
performance 
GE Healthcare 175113-01 
Sulfo-NHS-LC-Biotin Proteochem B2103 
Sulfuric acid 95-98% Sigma 258105 
SYBR green mix Life technologies 4367659 
TCEP BioVision 1202 
Trifluoroacetic acid ProteoChem LC6203 
Triton X-100 Sigma X100 
Trizma Base Sigma T1503 
Trypsin Porcine sequencing 
grade 
Promega V511A 
Tween-20 Sigma P137-9 
Materials and methods 
 
49 
 
Ultrafree centrifugal filters 
PVDF 
Millipore UFC30SV00 
Urea Sigma 33247 
Water ULC/MS purity Biosolve 23214 1B1 
Xylol Sigma 33817 
β-Mercaptoethanol Sigma 63689 
 
Antibodies 
 Primary antibodies 
Antibody Clone/host Ordering number Company 
CD31 mouse rat 550274 BD 
CD326 Epcam 
human 
microbeads 
not specified/mouse 130-061-101 Miltenyi Biotech 
CDH17 3H2/mouse SAB1403654-100UG Sigma 
GAPDH 2D4A7/mouse ab37187 Abcam 
LCN2 MM0458-2G32/rat NBP2-11778 
Novus 
Biological 
LGALS4 1E8/mouse SAB1401230-100UG Sigma 
PCDH1 5D5/mouse ab55504 Abcam 
 
Secondary antibodies and staining reagents 
Antibody Clone/Lot no Ordering number Company 
Donkey anti-rat 
Alexa-488 labeled 
Polyclonal/110472 Jackson 712-546-153 
Donkey anti-goat 
Alexa-647 labeled 
Polyclonal/111792 Jackson 705-606-147 
Donkey F(ab’)2 anti-
mouse Alexa-488 
labeled, preabsorbed 
Polyclonal/GR126425-
1 
Abcam ab150101 
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Goat anti-mouse 
Biotin labeled pre-
adsorbed 
Polyclonal/GR36816 Abcam ab98725 
Goat anti-mouse 
HRP labeled 
Polyclonal/895492A Invitrogen 62-6520 
Goat anti-mouse-
IgG2a 
Polyclonal/GR11071-7 Abcam ab98694 
Goat anti-rat Alexa-
594 labeled 
Polyclonal/716827 Invitrogen A11007 
Rat anti-mouse-IgG1 
Monoclonal/clone 
SB77e (IgG2b) 
Abcam ab99601 
Goat anti-mouse FcR 
block 
Polyclonal/108592 115-007-003 Jackson 
Streaptavidin Alexa-
488 labeled 
-- S32354 Invitrogen 
Streptavidin-HRP -- RPN1231V GE Healthcare 
 
  
Isotype controls 
Antibody Clone Ordering number Company 
Mouse IgG1 isotype 
biotinylated 
P3 13-4714-85 eBioscience 
Mouse IgG1 isotype 
unconjugated 
P3.6.2.8.1 14-4714-82 eBioscience 
Mouse IgG2a isotype 
unconjugated 
eBM2a 16-4724-85 eBioscience 
Rat IgG2a isotype 
unconjugated 
RTK2758 400502 BioLegend 
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Peptides 
Peptide 
Molecular 
weight 
Source Application 
TVFDEAIR 951.06 PSL Peptide 
MALDI MS 
Quantification 
TGVFDEAIRTVGF 1411.72 PSL Peptide 
MALDI MS 
Quantification 
CLEHMYHDLGLVRDF 1846.87 PSL Peptide 
MALDI MS 
Quantification 
EEQPSTPAPKVEQQEEILC 2155.02 PSL Peptide 
MALDI MS 
Quantification 
VVFNTLQGGK 1071.61 JPT Galectin 4 – MRM 
VGSSGDIALHINPR 1446.78 JPT Galectin 4 – MRM 
DAYVFYAVAK 1155.60 JPT CDH17 – MRM 
AENPEPLVFGVK 1308.71 JPT CDH17 – MRM 
 
 
Real Time qPCR primers 
Target 
Gene 
Primer sequence 5’ – 3’ 
Amplicon 
size (bp) 
Accesion 
number 
CDH17 
FW: AGGCACACAGAGTTTGAGGAGAGG 
RV: GTGGGTATCCCAGTCTGGTG 
286 
NM_004063.
3 
GAPDH 
FW: ATGGCCTTCCGTGTCCCCACTG 
RV: GTGGGTGTCGCTGTTGAAGTCAG 
183 
NM_0012567
99.1 
LCN2 
FW: CAGCAGAACTTCCAGGACAAC 
RV: TTGCGGGTCTTTGTCTTCTC 
93 NM_005564.3 
LGALS4 
 
FW: ACCCGCCTGTGCCATATTTC 
RV: TGGGTTGTGGGTGATCTTCTT 
236 NM_006149.3 
PCDH1 
FW: GCTCCATCCCCAGGCCACG 
RV: GGGCACCCACCTCTAGCTTG 
140 NM_002587.4 
RPL13a 
FW:  AAGTACCAGGCAGTGACAG 
RV:  CCTGTTTCCGTAGCCTCATG 
80 NM_012423 
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Kits 
Kit name Company 
Ordering 
number 
BCA Protein assay kit Pierce 23227 
DAB Peroxidase substrate kit Vecto Labs 
VC-SK-4100-
KI01 
ECL Prime Western Blotting detection 
reagent 
GE Healthcare RPN2232 
MACS Tumor dissociation kit, human Miltenyi Biotech 130-095-929 
ProteoSpin Abundant Serum Protein 
Depletion 
NORGEN BIOTEK 
CORP 
17300 
QIAshredder (250) QIAGEN 79656 
Rneasy Mini Kit (250) QIAGEN 74106 
SuperScript VILO cDNA Synthesis Kit Invitrogen 11754-050 
Vectastain ABC reagent Biozol diagnostica VEC-PK-4000 
 
 
Laboratory equipment/tools 
Equipment Company 
Axioplan Wide Field Microscope Zeiss 
CanoScan 5600F scanner Alternate 
Centrifuge AvantiJ-26XP Beckmann Coulter 
Criotome Microm HM 525 Thermo 
Discofix Luer Lock 3SC 10 cm B Braun 
Eppendorf centrifuge 5424 Eppendorf 
Eppendorf centrifuge 5424 R with cooling Eppendorf 
Eppendorf centrifuge 5810 R with cooling Eppendorf 
Film developing machine Classic E.O.S AGFA 
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Flow hood 1300 series A2 Class II Thermo 
Heidelberger prolongation B Braun 
Heracell 240i CO2 Incubator Thermo Scientific 
Histo star embedding machine Thermo 
Homogenizor T10 S IKA 
Insulin syringes 1mL 29G BD 
Intas photo imager INTAS 
LSM 700 Confocal Laser Scanning Microscope Zeiss 
MALDI Spotter/micro fraction collector, 
SunCollect 
SunChrom 
MALDI TOF/TOF 5800 ABSciex 
Microtome Microm HM355S Thermo 
Mupid One electrophoresis unit Nippon Genetics 
Nano Drop ND1000 Thermo 
NanoACQUITY UPLC Waters 
nanoAcquity UPLC column Waters 
Operating table (with heating) 
Hugo Sachs Elektronik – Harvard 
Apparatus 
pH-meter 211 Hanna Instruments 
QTrap 6500 ABSciex 
Rotamax 120 Heidolph 
Sonicator W-250D Branson 
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SpectraMax M5 Plate reader Molecular Devices 
SpeedVac RVC 2-25 CD plus Christ 
Surgical clamps Fine Science Tools 
Syringe pump Landgraf Laborsysteme 
T3000 Thermocycler Biometra 
Thermomixer comfort Eppendorf 
Tuberculin syringes ½ CC 27G Becton Dickinson and Company 
Tumbler Cole Parmer 
UltraCentrifuge Optima L-90K Beckman Coulter 
Venofix 25G Luer Lock B Braun 
Vi-Cell XR Cell Viability Analyzer Beckman Coulter 
Viia7 Real Time PCR system Thermo 
Waterbath Julabo 
Western Blot CL-X Posure Films Thermo 
Xcell II Blot Module Invitrogen 
Xcell SureLoc Mini-Cell Electrophoresis System Invitrogen 
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Software tools 
Tool Version Source 
GraphPad Prism 6 www.graphpad.com 
Microsoft Office 2013 http://office.microsoft.com 
MSQBAT 1.0 
Developed in house (A. Kerner and Dr. 
C. Rösli, HI-STEM) 
NetPrimer – premier 
biosoft 
2014 http://www.premierbiosoft.com/netprimer 
ProteinPilot 4.0/4.5 http://www.absciex.com 
Viia7 1.0 https://www.lifetechnologies.com 
WebGestalt 2014 http://bioinfo.vanderbilt.edu/webgestalt/ 
ZEN lite 2011 http://www.zeiss.com 
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Solutions and media formulation 
Cancer Stem Cell medium: 
500 mL Advanced DMEM/F12 
5 mL N2 supplement 
0.25 mL Trace elements A 
0.5 mL Trace elements B 
0.5 mL Trace elements C 
1 mL Lipid-MIX 1 
2 mM L-Glutamine 
0.6% glucose (added to final concentration) 
5 mM HEPES 
2 μg/mL heparine 
100 μM β-Mercapto ethanol 
1 μg/mL GSH 
50 ng/mL hBasic FGF 
20 ng/mL hEGF 
10 ng/mL IGFR3 
+ 0.06% BSA (final concentration excluding BSA from the Advanced DMEM/F12) 
+25 mL H2O 
 
Cancer Stem Cell medium, BSA/Transferrin depleted: 
500 mL DMEM/F12 
0.25 mL Trace elements A 
0.5 mL Trace elements B 
0.5 mL Trace elements C 
1 mL Lipid-MIX 1 
2 mM L-Glutamine 
0.6% glucose (added to final concentration) 
5 mM HEPES 
2 μg/mL heparine 
1 mM Sodium pyruvate 
10 mg/L Insulin 
10.01 mM Putrescine 
0.002 mM Progesterone 
0.00863 mM  Ascorbic Acid 
0.05 mM Iron Chloride 
100 μM β-Mercapto ethanol 
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1 μg/mL GSH 
50 ng/mL hBasic FGF 
20 ng/mL hEGF 
10 ng/mL IGFR3 
+25 mL H2O 
 
DMEM + M3 medium: 
75% DMEM without glucose 
25% M3 medium 
1.5 mM L-glutamine 
1.125 g/L NaHCO3 
5.5 mM D-glucose 
10 ng/mL human recombinant EGF 
750 ng/mL  puromycin 
5% fetal bovine serum 
 
Keratinocyte medium: 
Keratinocyte serum free medium 
50 μg/mL bovine pituitary extract 
5 ng/mL EGF (Gibco) 
 
CO2 independent medium: 
CO2 independent medium 
2 mM L-Glutamine 
1% BSA 
 
2mM PEB/10mM PEB: 
2 mM EDTA/10 mM EDTA 
1x PBS 
1% BSA 
 
Wash buffer A: 
1% NP-40 
0.1% SDS 
1x PBS 
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Wash buffer B: 
2 M NaCl 
0.1%SDS 
1x PBS 
 
Trypsin digestion buffer (TDB): 
50 mM Tris-HCl 
1 mM CaCl2 
pH 8.0 
 
Cell lysis buffer: 
10 mM EDTA 
2% NP-40 
0.2% SDS 
1x PBS 
1x Protease inhibitor added before use 
 
RIPA (RadioImmunoPrecipitaion) lysis buffer: 
50 mM Tris-HCl pH 8.0 
150 mM NaCl 
1% NP-40 
0.5% sodium deoxycholate 
0.1% SDS 
pH 8.0 
 
Tissue lysis buffer: 
2% (wt/v) SDS 
50 mM Tris-HCl 
10 mM EDTA 
1x PBS 
pH 6.8 
1x Protease inhibitor added before use 
 
Antigen retrieval buffer pH6: 
10 mM Trisodium citrate 
0.05% Tween 20 
pH 6.0 
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Anesthetic mixture (surgeries): 
10 mg/mL Ketamin (Ketavet) 
1.6 mg/mL Xylazin (Rompun) 
Prepared in water 
 
Anesthetic mixture (terminal perfusions): 
20 mg/mL Ketamin (Ketavet)  
2 mg/mL Xylazin (Rompun)  
0.3 mg/mL Acepromazin (Vetranquil) 
Prepared in 0.9% NaCl solution 
 
SDS Loading buffer (5x): 
208 µM Tris, pH = 6,8 
33% Glycine 
5% SDS 
0,06% Bromphenolblau 
 
DNA loading buffer (6X): 
1.168 M sucrose 
3.6 mM Bromphenol Blue sodium salt 
In water 
 
Western Blot running buffer: 
25 mM Bicine 
25 mM Bis-Tris 
1 mM EDTA 
50 nM Chlorobutanol 
10% Methanol 
In water 
 
TBE buffer: 
0.089 M Tris 
0.089 M H3BO3 
20 mM EDTA pH8 
14 mM NaOH 
Final pH 8.3 
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4.2 Methods 
 
4.2.1 Cell culture methods 
Culturing of PACO cells 
A total of twelve primary pancreatic cancer cell lines were obtained from Dr. Christian Eisen 
(HI-STEM/DKFZ). Cells were grown on Primaria 75 cm2 flasks in serum free CSC medium 
developed and optimized by Dr. Martin Sprick and Dr. Christian Eisen, until ~80% 
confluence was reached. 
For the subculturing of the PACO cells, the medium was aspirated, washed the flask with 
PBS, and 5 mL of Accutase were added per 75 cm2 flask. Cells completely detach from the 
substrate in ~15 minutes, at which point the enzymatic activity was stopped using CO2 
independent medium (double amount compared to Accutase volume) and the cell 
suspension was transferred in a falcon tube. Cells were centrifuged (450xg/4°C/5 minutes) 
and the pellet was resuspended in 1mL CSC medium. The standard split rate for the PACO 
cells was 1:10; for the classical subtype cell lines, sometimes a split rate of 1:20 was 
necessary, due to their fast growth rate. 
 
Freezing of PACO cells 
For cryopreservation purposes, the cells were detached and span down as previously 
mentioned. Then, the pellet was resuspended in Crystor CS10 and aliquoted into cryovials. 
The vials were placed in a Mr. Frosty and transferred to -80°C for 1-2 days, prior to being 
long term stored in liquid nitrogen. 
 
Culturing of the control cell lines 
The two control cell lines were grown in the medium recommended by the provider. For the 
HPNE cells, the growth medium was DMEM-M3 supplemented with EGF and 5% FBS. For 
the HPDE cell line, the recommended medium was Keratynocyte medium supplemented 
with bovine pituitary extract and EGF [133]. All control cell lines were grown in TPP 75 cm2 
flasks. 
For the subculturing of the control cell lines, cells were detached using 3 mL trypsin-
EDTA/T75 flask. HPNE cells needed 5 minutes for complete detachment, while the HPDE 
cell line required 15 minutes. Trypsin was subsequently inactivated using the specific cell 
line medium, added in double amount compared to the volume of the detachment enzyme. 
Cells were later span down using the above described centrifuge parameters and the pellet 
was resuspended in 1mL of the respective growth medium. Split ratios were 1:10 for the 
HPNE cell line, and 1:6 to 1:10 for the HPDE cell line. 
 
Freezing of control cell lines 
For cryopreservation, cells were detached and centrifuged as previously mentioned, and 
the resulting pellet was resuspended in Crystor CS10 (for the HPDE cell line) or 95% 
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DMEM-M3 medium + 5% DMSO cryo-medium (for the HPNE cell line). Alliquoting, freezing 
and storage was performed identically as for the PACO cell lines. 
 
Counting of cells 
Cell numbers were dermined using the ViaCell counter. For this purpose, the cells were 
detached (depending on the subsequent experiment, using 10mM PEB buffer or Accutase), 
pellet and resuspended in 1 mL PBS. A 1:10 dilution was performed in a Beckman Counter 
4 mL sample cup (final volume 500 μL) and the cells were counted by the ViaCell counter. 
 
4.2.2 Generation of orthotopic pancreatic mouse tumors 
NSG male mice were anesthetized using the anesthetic mixture for surgeries (administered 
at a dose of 10 µL/g), injected intra-peritoneal. The abdominal cavity was opened and a 
mixture of 106 viable PACO cells and Matrigel (2 mg/mL final concentration) was injected in 
the head of the pancreas (injection volume 30 µL). The peritoneum was sutured and the 
skin was clipped and disinfected, after which mice were kept under observation for 24 hours.  
Tumor growth was monitored by regular palpation of the mice. The animals were sacrificed 
when the size of the tumor reached ~ 1 cm in diameter. Generally, classical derived tumors 
required two months to develop, exocrine derived tumors three to four months, while QM 
tumors required six to nine months. 
 
4.2.3 Discovery of novel protein biomarkers in vitro 
4.2.3.1 Discovery of novel cell surface biomarkers in vitro 
Biotinylation of cells in vitro 
Cells were grown in their recommended medium, until 70-80% confluence was reached. At 
this point, the medium was removed, cells were washed twice with PBS and a 0.5 mg/mL 
Sulfo-NHS-LC biotin solution in PBS was added to the flask (total biotin ester amount: 2 mg). 
The flasks were incubated on a shaker for 10 minutes at room temperature, and the excess 
biotin ester was inactivated using 100 μL of a 1 M Tris-HCl buffer. The solution was 
removed, cells were washed once with PBS and were later detached using a 10 mM EDTA, 
1% BSA in PBS solution. After ~20 minutes, the detached cells were resuspended and 
centrifuged.  
 
Cell lysis 
The resulting pellet of cells was washed once with PBS, and the cell number was 
determined. Cells were lysed using the cell lysis buffer. Briefly, cells were incubated in the 
buffer for 30 minutes on ice, vortexed and later sonicated (10% intensity, 3 x 30 seconds). 
Cell debris were pellet by centrifuging full speed for 20 minutes, and the supernatant was 
stored at -20°C. Protein concentration of the total lysates was determined using the BCA kit 
(Pierce), according to the instructions of the provider. 
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Enrichment of cell surface proteins and on resin tryptic digestion 
250 μg of total protein lysate were loaded onto a sepharose-streptavidin column, pre-
equilibrated in wash buffer A. SDS was added to the sample to a final concentration of 2%. 
The biotinylated fraction was captured for two hours, tumbling at room temperature and 
unspecific binders were removed by performing a series of stringent washes: two washes 
with wash buffer A (1% NP-40, 0.1% SDS in PBS), two washes with 10% SDS in PBS, two 
washes with the high salt buffer B (2 M NaCl, 0.1% SDS in PBS) and ten washes in the 
trypsin digestion buffer (TDB) (50 mM Tris HCl, 1 mM CaCl2 pH8). 
The sepharose-streptavidin slurry containing the captured biotinylated fraction was digested 
using 800 ng trypsin (Promega) dissolved in TDB (final reaction volume 210 μL) for ten 
hours at 37°C. 
 
4.2.3.2 Discovery of novel secreted biomarkers in vitro 
Collection of supernatants containing secreted proteins 
Cells were grown in their standard culture conditions until they reached ~60% confluence.  
At this point, the medium was removed, cells were washed twice with PBS and incubated 
with the CSC medium depleted of BSA and transferrin. The depleted medium was 
formulated to match the normal CSC medium, while completely excluding BSA and 
transferrin. After 48 hours, the medium was collected and underwent a series of 
centrifugations for the removal of cell debris (5 minutes/500xg/4°C), of intracellular 
organelles (20 minutes/20’000xg/4°C) and finally microvesicles (2 hours/100’000xg/4°C). 
The resulting cleared supernatant was aliquoted and stored at -20°C. 
 
In solution digest of secreted proteins 
Protein concentration of the supernatant fraction collected after the 100’000xg 
centrifugation step was determined using the BCA method. Due to high dilution of proteins 
in the supernatant and interactions from components present in the culture medium with the 
BCA reagent, proteins were precipitated prior to concentration evaluation using the 
chloroform-methanol method.  
Briefly, a sample aliquot was precipitated by adding four volumes of methanol, one volume 
of chloroform and three volumes of water (vortexed after each step). The mix was 
centrifuged at 15’000xg for 2 minutes, and the aqueous phase was discarded. The proteins 
located in the interface were precipitated by adding four volumes of methanol, and were 
subsequently pelleted by centrifugation. Finally, the pellet was dried using the SpeedVac. 
The precipitate was solubilized directly in the final BCA reagent volume suggested by the 
provider, and protein concentration determination was achieved by the standard method 
recommended by the manufacturer. 
For the in solution digest, 15 μg protein were precipitated using the above described 
chloroform-methanol method and resuspended directly in trypsin digestion buffer. Trypsin 
was added in a 1:50 ratio (trypsin: total protein) and enzymatic digestion was performed for 
10 hours at 37°C. 
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4.2.4 Evaluation of in vivo vascular accessible protein markers 
Whole body perfusion using reactive biotin esters 
Orthotopic pancreatic tumors were grown in NSG mice, according to the protocol mentioned 
above.  
The whole body perfusion was performed as described by Rösli et al [134]. When the 
palpated tumor reached ~ 1 cm in diameter, mice were anesthetized using a mixture of 
Ketamin, Xylazin and Acepromazin. After confirming loss of pain sensitivity in the 
anesthetized animals, the abdominal cavity was opened, followed by the opening of the 
thoracic cavity. A needle was inserted in the left ventricle of the heart, connected to an 
automated pumping system containing 1 mg/mL reactive biotin ester solution in 10% 
dextrane-PBS. A cut was made in the right atrium, to allow evacuation of blood and pumped 
liquid, and the solution was pumped at a rate of 1.1 mL/minute for 10 minutes. The thoracic 
and abdominal cavity were sprinkled with a 50 mM Tris-HCl solution prepared in PBS pH 
7.4 to prevent biotinylation due to the evacuating unreacted ester from the circulatory 
system. After ten minutes, the biotin ester solution was replaced with a quenching solution, 
containing 50 mM Tris in dextrane-PBS, and the mouse circulatory system was washed for 
an additional ten minutes, using the same flow rate. All solutions were kept at 40° C prior to 
use, and all operations were performed on a heated surgery table, in order to prevent 
capillary contractions as a result of hypothermia. 
Pancreatic tumors and any visible metastases were collected and snap frozen for proteomic 
analysis, or embedded in OCT for evaluation of biotinylation/analysis of expressed protein 
markers. Healthy liver and in the case of healthy controls normal pancreas samples were 
also collected. 
 
Evaluation of perfusion success using immunofluorescence on cryosections 
Pieces of biotinylated organs were snap frozen in OCT medium and cut in 8 µm thick 
sections using a Microm HM 525 cryotome. 
Cuts were fixed in acetone at -20°C for eight minutes, and later delineated with a DAKO 
silicon pen. Blocking was achieved using 20% goat serum in PBS for one hour at room 
temperature. Incubation with the primary antibody (rat anti-mouse CD31) was performed 
for one hour at room temperature. After rinsing the cuts with PBS, incubation with secondary 
antibody Alexa-594 goat anti-rat and additionally Streptavidin-Alexa488 (for the biotin 
detection) was carried out for one hour at room temperature. Negative controls were 
incubated only with the secondary goat anti-rat antibody. 
Cuts were thoroughly washed in PBS, mounted with DAKO fluorescent medium and stored 
at 4°C in the dark. Pictures were acquired and processed as described in the validation 
section below. 
 
Tissue lysis of biotinylated organs 
Collected tissues were weighted and minced carefully. Upon transferring the tissue in a 
15 mL tube, 20 μL of tissue lysis buffer was added per mg sample, and the tissue was 
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homogenized 3 x 2 minutes (for pancreas and liver samples) or 5 x 2 minutes (for tumor 
samples), using an TS10 tissue homogenizer at full power.  
Homogenized samples were sonicated (Vibra-cell) 21 x 5 sec at 25% intensity (5 sec off 
pause on ice) and heated to 95°C for 20 minutes. Tissue debris were removed by 
centrifugation at 21’000xg, for 20 min, at room temperature. The supernatant was aliquoted 
and stored at -20°C. 
 
Evaluation of biotinylation level using ELISA 
A standard biotinylation curve was designed, using biotinylated and native BSA. Briefly, a 
total of 6.65 μg BSA (corresponding to 10-5 M) were pipetted in each well, by summing native 
and biotinylated protein. The concentration range of the curve varied between 0 to 2.5 μg 
biotinylated protein.  
Total protein concentration was determined using the BCA kit, as recommended by the 
manufacturer. Based on the determined value, samples were diluted to allow coating of 
10- 5 M antigen (the average protein mass was considered to be 53 kDa). Samples were 
pipetted on a Nunc maxisorp plate, in parallel with the biotinylation standard curve, and 
allowed to bind overnight, at 4°C. The following morning, the wells were washed and 
blocked using 2% BSA in PBS for one hour at room temperature. All staining reagent 
dilutions were performed in the blocking solution. 100 μL streptavidin-HRP (diluted 1:1000) 
were added to the wells and incubated for one hour at room temperature. Wells were 
thoroughly washed using PBS containing 0.1% Tween and PBS and 100 μL BM Blue POD 
substrate (Roche) were added for detection. The samples were incubated with the substrate 
for a maximum of 20 minutes, depending on the intensity of the blue color observed, and 
the reaction was stopped with 70 μL of 1 M H2SO4.  
The plates were analyzed using the SpectraMax M5 plate reader, by measuring the 
absorbance at 450 nm and subtracting the absorbance observed at 690 nm.  
 
Streptavidin enrichment of vascular accessible biotinylated proteins, alkylation of 
cysteines and tryptic digestion 
The equivalent of 50 μg biotinylated protein was used for subsequent enrichment on a 
streptavidin column and tryptic digestion. 
Samples were diluted in buffer A containing 2% SDS and 2 mM TCEP and allowed to bind 
for two hours at room temperature, while tumbling. Alkylation was performed by adding 
100 μL iodoacetamide (50 mM in PBS, pH 7.4) and incubating for 30 minutes in the dark. 
The reaction was stopped by adding an excess of cysteine (300 μL of 100 mM cysteine 
solution in water) and incubating for an additional 15 minutes in the dark. 
A delipidation step was performed by adding 400 µl wash buffer A and 800 µl butanol-DIPE 
(di-isopropyl ether) solution (40:60 [v:v]). Samples were incubated for 30 minutes at room 
temperature under constant agitation and the solvent phase was later removed. 
Unbound proteins were removed by washing two times with wash buffer A and ten times 
with TDB. Tryptic digestion was performed as previously described for the in vitro discovery 
of biomarkers. 
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4.2.5 Mass spectrometric analysis 
Purification of tryptic peptides 
Following the tryptic digestion, the peptide containing aqueous fraction was acidified with 
trifluoroacetic acid (TFA) to a final concentration of 0.1%. The acidification of the solution is 
required for optimum purification and de-salting of peptides using C18 packed mini-columns 
(OMIX tips, Agilent).  
The C18 columns were activated by washing two times with a 50% acetonitrile (ACN) 
solution, and equilibrated by washing two times with 0.1% TFA solution. Peptides were 
captured on the C18 column by pipetting up and down twenty times. The column was 
washed three times with the equilibration buffer and peptides were afterwards eluted in a 
75% ACN, 0.1% TFA solution. The peptides were ultimately dried in a SpeedVac and stored 
at -20°C. 
 
Fractionation of the tryptic peptide mix using reverse phase UPLC and spotting of 
the eluted fraction 
The dried tryptic peptides were resuspended in 20 μL 5% ACN, 0.1% TFA and loaded on 
an Acquity UPLC BEH130 C18 column (Waters), 75 μm x 250 mm with 1.7 μm particles 
and an average pore size of 142 Å. 8 μL of sample were loaded directly on the analytical 
column and eluted using an ACN gradient. Buffer B (ACN containing 0.1% TFA) 
concentration was varied as follows: buffer B concentration was increased from 5% to 11% 
in 0.33 minutes, maintained for another 0.67 minutes, then increased to 14% in 2.66 
minutes. Elution was performed using two consecutive linear gradients, from 14% to 30% 
buffer B for 64 minutes, and from 30% to 40% for 13.34 minutes. The column was washed 
by first linearly increasing the concentration of buffer B to 85% in nine minutes, maintaining 
it for an additional five minutes, after which the concentration of buffer B was brought back 
to base line 5% in two minutes. The column was equilibrated with the standard 5% buffer B 
for an additional 13 minutes. Total running time was 110 minutes, the constant flow rate 
was 350 nL/minute and the temperature of the column was set to 35°C. 
The eluted fractions were mixed with α-Cyano-4-hydroxycinnamic acid (CHCA) matrix 
solution prepared in 80% ACN containing a mixture of four standard peptides spiked in and 
spotted onto a MALDI plate by an automated spotter, depositing a spot every 4 seconds, in 
a total of 1200 fractions (Sunchrom). The concentration of the spiked in standard peptides 
in the final CHCA matrix mixture is summarized in Table 2: 
Table 2: Concentration of internal standard peptides in final matrix mixture for MALDI analysis 
Peptide sequence Concentration (fmol/µL) 
CLEHMYHDLGLVRDF 107.2 
EEQPSTPAPKVEQQEEILC 214.3 
TGVFDEAIRTVGF 53.6 
TVFDEAIR 26.8 
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MALDI MS and MS/MS analysis 
The samples were analyzed by the AbSciex MALDI TOF/TOF 5800. The mass spectrometer 
was operated in positive ion reflector mode. The number of laser shots per spot was set to 
2000 and the acquisition rate was 400Hz. The velocity of the laser was 1000 µm/second 
and the intensity of the laser was optimized prior to each analysis. Data were acquired in 
DDA (Data Dependent Acquisition). The TOF/TOF Series Explorer software calculated the 
peaks on interest, and MS2 was performed using the Dynamic Exit processing method, with 
a maximum of 35 MS2 spectra analyzed per spot, weakest precursor first. The spectra 
acquisition would be completed after a maximum number of 3000 laser shots per precursor, 
or until the quality of the spectra was evaluated by the software as high. The acquisition 
rate was set to 1000 Hz and the velocity of the laser was 1200 µm/second. 
For the in vitro samples, the MS/MS spectra were processed using the ProteinPilot software 
version 4.0, or version 4.5, and the search against the human data base was performed 
using the Paragon algorithm version 4.0.0.0 or version 4.5.0.0. The Homo sapiens 
reference proteome data set was downloaded from UniProt on 16th September 2011, and 
the search data base included 71020 proteins. For the in vivo samples, searches were 
performed against a mix human and mouse data base. The reference proteome data set 
was also downloaded from UniProt, on the 15th of May 2013, and the combined data base 
contained 243244 proteins, including reverse sequences. For the in vitro samples, 
ProteinPilot searches were performed allowing for missed cleavages and no cysteine 
modification were defined. The search mode was set to Thorough ID, with ID focus on 
biological modifications and amino acid substitutions. A detected protein threshold of 1.3 
was chosen and peptides with a confidence interval greater than 95% were accepted. For 
the in vivo samples, the definitions for the search algorithm were identical to the ones 
previously mentioned, with one exception: cysteine modifications – namely alkylation, were 
specified for the search algorithm.  
 
4.2.6 Validation of protein biomarkers 
4.2.6.1 Antibody based validations 
 
4.2.6.1.1 Western Blot  
 
Total cell lysates obtained as previously described were incubated with the reducing buffer 
for 10 minutes at 95°C and loaded on a precasted NuPAGE Bis-Tris 4-12% gradient gel 
(Novex). Samples were ran in MOPS SDS running buffer for one hour, 200 V constant. 
Immunoblotting was performed using PVDF membranes (activated prior to transfer in 
methanol) according to the manufacturer’s instructions, for 1.5 hours at 30 V. Membranes 
were blocked with 4% milk-PBS solution over night at 4°C. Staining with the primary 
antibody was performed in 2% milk-PBS solution for one hour at room temperature, followed 
by incubation with a horse radish peroxidase (HRP) labeled secondary antibody diluted in 
2% milk solution for another hour. Membranes were developed using the ECL development 
kit, according to the instructions of the provider.  
Dilutions used for the primary antibodies were: PCDH1 1:2000, GAPDH 1:10000. The 
secondary goat anti-mouse – HRP labeled antibody was diluted 1:2000. 
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4.2.6.1.2 Immunocytofluorescence on methanol fixed cells 
First validation steps were performed in vitro using the cultured primary PDAC and control 
cells. For this purpose, cells were grown on special cell inserts for 6 well plates, representing 
an adherent porous membrane (pore size 1 μm). Cells were seeded at a density of 5 x 105 
cells per well and were allowed to grow for 48 hours (with the exception of PACO14 and 
PACO16 cell lines, requiring 96 hours to reach the desired confluence). Two milliliters of 
medium were added both on top, and in the six well plates holding the inserts, to insure 
sufficient amount of nutrients for the growing cells, as well as proper humectation of the 
membranes on both sides. Cells were later fixed with ice cold methanol for 10 minutes at -
20°C and washed with PBS. The membranes were cut in smaller pieces and then stored in 
0.1 M glycine in PBS at 4°C for 24 hours.  
The cut membrane inserts were later stained following the standard protocol. Inserts were 
incubated in 0.2% Triton X solution in PBS for 15 minutes for membrane permeabilization. 
The fixed cells were blocked with a 10% serum solution in PBS, depending on the nature 
of the secondary antibody for 30 minutes at 37°C. The primary and secondary antibodies 
were diluted in 3% BSA solution in PBS. Incubation with the primary antibody was 
performed for one hour, at 37°C, membranes were washed three times with PBS and 
incubated with the secondary antibody for another hour at 37°C. DAPI staining was 
performed in parallel with the secondary antibody incubation. After the final washing step, 
the cut membrane inserts were mounted using Fluorescence mounting medium (DAKO) 
and stored at 4°C in the dark awaiting visualization. Isotype controls were performed for 
each specific antigen. 
The individual dilutions used in the experiment were: CDH17 antibody 1:50; LGALS4 
antibody 1:30; PCDH1 antibody 1:20. Isotype controls were diluted to the same 
concentration as that of the corresponding primary antibodies. The dilutions for the 
secondary antibodies were: Goat anti-mouse biotin labeled (Abcam) 1:200 incubated with 
Streptavidin-Alexa488 (Invitrogen) 1:200 (for CDH17 detection); Donkey anti-mouse 
Alexa488 labeled (Jackson) 1:250 (for the LGALS4 and PCDH1 primary antibodies). DAPI 
dilution was 1:100. 
Fluorescence staining and localization of the antigen of interest was achieved using the 
LSM 700 confocal fluorescence microscope (Zeiss) and pictures were later processed using 
the ZEN lite 2012 software. Scale bars were added and contrast for individual channels 
were optimized identically for all samples stained for one specific antigen. 
 
4.2.6.1.3 Immunocytofluorescence on formalin fixed paraffin embedded cells 
For those antibodies that did not stain optimally when cells were fixed with methanol, 
immunofluorescence was performed on formalin fixed cells embedded in Histogel, and 
finally embedded in paraffin. For this purpose, cells were detached non-enzymatically using 
a 10mM EDTA, 1% BSA solution in PBS, and were later fixed in formalin for 10 minutes at 
room temperature. Fixed cells were resuspended in 300 μL Histogel (pre-warmed to 60°C), 
allowed to cool and stored in formalin until paraffin embedding was performed. Stainings 
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were performed using the protocol for immunohistofluorescence of formalin fixed, paraffin 
embedded mouse derived tumors, described below.  
Antibody dilutions were: LCN2 1:150; donkey anti-rat 1:250; DAPI 1:100. Pictures were 
acquired using the LSM700 (Zeiss) and processed as previously described. 
 
4.2.6.1.4 Testing colocalization of putative exocrine-like biomarkers using 
confocal microscopy 
In order to investigate if the two putative exocrine-like protein biomarkers interact, their 
localization was assessed using confocal laser microscopy after co-staining methanol fixed 
PACO cell lines. Isotype specific unlabeled secondary antibodies, raised in different hosts, 
were employed for the recognition of the primary antibodies previously used, taking 
advantage of the fact that they were of different isotypes. The final detection was achieved 
using fluorescently labeled tertiary antibodies, distinguishing the different species from 
which the secondary antibodies have been obtained. 
Briefly, the cells were grown on cell inserts and fixed as previously described. After 
permeabilizing the cells and blocking with 10% donkey serum + 10% goat serum (prepared 
in PBS), the cells were incubated with a mixture of CDH17 antibody (diluted 1:75) and 
galectin 4 (diluted 1:30) for one hour at 37°C. After washing the inserts, the cells were 
incubated (one hour/37°C) with a mixture of unlabeled secondary antibodies distinguishing 
between the isotypes of the primary antibodies. The secondary rat anti-mouse IgG1 
antibody (recognizing the CDH17 antibody) was diluted 1:200, while the goat anti-mouse 
IgG2a antibody (recognizing the LGALS4 antibody) was diluted 1:400. Cells were washed 
with PBS and incubated with the final tertiary antibodies using the following dilutions: 
donkey anti-rat Alexa-488 labeled (1:200) and donkey anti-goat Alexa-647 labeled (1:200). 
DAPI was added to the tertiary antibody mix to a final dilution of 1:100 and the cells were 
incubated for one final hour at 37°C. Mounting and image acquisition/processing were 
performed as previously mentioned. 
Appropriate controls were also stained in parallel, evaluating the specificity of the secondary 
and tertiary antibodies. For this purpose, either individual primary antibodies were excluded 
from the analysis (while using both secondary and both tertiary antibodies), or, each or both 
secondary anti-isotype antibodies were omitted, while using both primary and tertiary 
antibodies. A scheme of the appropriate staining controls is listed in Table 3. 
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Table 3: Staining controls for colocalization evaluation experiments. All samples were incubated 
with the same mixture of tertiary antibodies, while the primary (first row) or secondary antibodies 
(second row) were selectively excluded to assess the specificity of the secondary and respective 
tertiary immunoglobulins. Secondary and tertiary antibodies were color coded in the table 
representation. Legend: Ab = antibody 
Indirect IF strategy Individual stainings + control stainings 
Primary Ab 
+ 
Secondary Ab 
+ 
Donkey anti-rat & 
Donkey anti-mouse 
tertiary Ab 
CDH17 +LGALS4 
+ 
anti-IgG1 & anti-IgG2a 
+ 
Tertiary Ab 
CDH17 
+ 
anti-IgG1 & anti-IgG2a 
+ 
Tertiary Ab 
LGALS4 
+ 
anti-IgG1 & anti-IgG2a 
+ 
Tertiary Ab 
CDH17 +LGALS4 
+ 
anti-IgG1 
+ 
Tertiary Ab 
CDH17 +LGALS4 
+ 
anti-IgG2a 
+ 
Tertiary Ab 
CDH17 +LGALS4 
+ 
No secondary Ab 
+ 
Tertiary Ab 
 
4.2.6.1.5 Immunohistofluorescence 
Orthotopic PACO derived pancreatic tumors were fixed in 10% formalin for 48 hours at 4°C 
and embedded in paraffin. For staining, the tissues were rehydrated and antigen retrieval 
was achieved by boiling the tissue in pH 6 citric buffer (for LGALS4 and PCDH1 antigens) 
or pH9 retrieval buffer (DAKO) (for CDH17 and LCN2 antigens) for 15 minutes. After rinsing 
the slides, blocking was performed using a 20% donkey serum solution in PBS for one hour 
at room temperature, followed by an additional blocking step using FcR fragments goat anti-
mouse (Jackson) diluted 1:10 in 12% BSA prepared in PBS. Incubation with the primary 
antibody was carried out over night at 4°C, while the secondary antibody incubation was 
performed for one hour at room temperature. All antibody dilutions were performed in 12% 
BSA solution. Slides were rinsed and mounted using the Fluorescence mounting medium 
(DAKO). Isotype controls were performed at concentrations matching to those of the 
antibodies of interest. 
Individual dilutions used in the experiments were: CDH17 1:750; LGALS4 1:600; LCN2 
1:600; PCDH1 1:400. Secondary antibodies were diluted as follows: donkey anti-mouse – 
Alexa488 coupled 1:750 for CDH17 stainings, 1:250 for LGALS4 and PCDH1 stainings; 
donkey anti-rat Alexa488 coupled 1:300. DAPI dilution was 1:100. 
Picture acquisition and processing was performed as previously described. 
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4.2.6.2 Antibody independent validations 
4.2.6.2.1 MRM validations 
Multiple reaction monitoring was used to quantify and validate the presence of the markers 
of interest in both whole cell lysates and secreted fraction. 
For validation/quantification of proteins in PACO and control cell lines, cells were lysed 
directly on the flask using the RIPA buffer, and the total cell lysates were clarified by 
centrifuging 20’000xg for 20 minutes. The protein concentration was determined using the 
BCA method, and 100 μg proteins were precipitated using the chloroform – methanol 
method previously described, in order to further increase the protein concentration.  
The proteins were resuspended in 0.05% RapiGest solution in TDB for better 
resolubilisation. RapiGest surfactant allows for improved digestion, without inhibiting 
enzymatic activity, and can later be removed from the sample by acidification of the solution. 
Disulfuric bounds were reduced by adding DTT to final concentration of 5 mM and heating 
the samples to 60°C for 30 minutes. Alkylation was performed by adding iodoacetamide 
solution to a final concentration of 15 mM and incubating in the dark for 30 minutes. Tryptic 
digestion was performed overnight with a 50:1 protein: trypsin ratio, at 37°C, under agitation. 
RapiGest surfactant was removed by acidifying the sample using TFA to a final 
concentration of 0.5% and incubation for 45 minutes at 37°C, followed by precipitation of 
the detergent at 17’000xg for 10 minutes. The tryptic peptides present in the aqueous phase 
were desalted as previously described and the peptides were dried in the SpeedVac and 
stored at -20°C.  
For the validation/quantification of the proteins of interest in the secreted fractions, we used 
the collected supernatants of cells grown in BSA/transferrin depleted medium, fractionated 
by ultracentrifugation as detailed earlier. 50 μg of total protein from cleared supernatants 
were reduced using 5 mM DTT at 60°C/30 minutes, followed by alkylation with 15 mM 
iodoacetamide at 24°C/30 minutes.  
Alkylated proteins were precipitated using acetone, according to the following protocol: five 
times excess ice cold acetone was added to the protein solution and incubated at -20°C 
overnight. Proteins were pelleted by centrifuging at 20’000xg, for 30 minutes at 4°C. Pellets 
were washed with 80% ice cold acetone and centrifuged at 20’000xg for 5 minutes at 4°C, 
followed by complete solvent removal and drying of the protein precipitate at room 
temperature.  
Proteins were solubilized in 4 mM Urea in TDB, and digested with trypsin added in a 1:50 
(trypsin: protein) ratio for 10 hours/37°C. Digested samples were acidified with TFA (0.1% 
final concentration) and peptides were desalted using the standard OMIX protocol 
described earlier. 
For the MRM analysis, samples were diluted to a final concentration of 2 μg/mL. Analysis 
were performed on an ABSciex QTrap 6500 coupled online to a Waters online 
nanoACQUITY system, in collaboration with Dr.Christoph Rösli and Wiebke Nadler 
(Biomarker Discovery Group, HI-STEM). Sample fractionation was performed on Atlantis 
dC18 nanoACQUITY Column or Fortis HPLC column 1.7μ Fortic C18 capillary. Atlantis 
dC18 columns are silica based reverse phase C18 columns, with particles containing di-
functionally bonded C18 ligands, optimized for highly aqueous phases. The column was 
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15 cm long, with a diameter of 300 μm, a 3 μm particle diameter and 100 Å pore size.  In 
the case of Fortis HPLC column, recommended for their stability over a wide pH range (1-
12), the size characteristics were the following: 15 cm length, 200 μm diameter, with 1.7 μm 
particles. The buffers used for the nanoACQUITY system were: UPLC purity grade water 
with added 3% DMSO, 0.1% formic acid and 0.01% TFA (defined as buffer A) and ACN 
UPLC grade purity with DMSO, formic acid and TFA added in the previously mentioned 
percentages (defined as buffer B). The peptides were eluted using an 117 minutes gradient, 
with the following specifications: the concentration of buffer B (ACN based) was increased 
linearly from 3% to 15% over 30 minutes; a second linear gradient increasing the buffer B 
concentration from 15% to 25% was performed for the following 55 minutes, and a third 
linear gradient, raising the concentration of buffer B from 25% to 32% was applied for 
another 25 minutes. The column was washed by increasing the concentration of buffer B to 
90% in two minutes and the high ACN concentration was maintained constant for an 
additional four minutes. Finally, the column was re-equilibrated by returning the buffer B 
concentration to the base-line 3% within one minute. The flow rate of the mobile phase was 
4 μL/minute and the temperature of the column was set to 45°C.  
For each protein to be quantified, we optimized three transitions per proteotypic peptide, 
and we used two precursor peptides per protein. Heavy labeled corresponding peptides 
were ordered from JPT and spiked in the samples, to a final concentration of 15.6 
fmol/sample. The details regarding the mass filter of Q1 and Q3 quadrupoles, the optimized 
declustering potential, collision energy and the observed retention time of precursor 
peptides (light and heavy) are listed in Table 4. All selected precursor ions were double 
charged, while all fragment ions analyzed were single charged. 
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Table 4: Transition of Cadherin-17 and Galectin-4 peptides for SRM 
Legend: D P = declustering potentional; CE = collision energy; RT = retention time 
Protein Peptide 
Precursor 
mass 
Fragment 
ion 
Fragment 
mass/charge 
state 
DP 
(V) 
CE 
(eV) 
RT 
(min) 
C
a
d
h
e
ri
n
-1
7
 
DAYVFYAVAK 
light 
573.795 
y6 698.387 
72.9 29.5 44.2 
y7 797.455 
y8 960.518 
DAYVFYAVAK 
heavy 
577.802 
y6 706.401 
y7 805.469 
y8 968.533 
AENPEPLVFGVK 
light 
650.350 
y4 450.271 
78.5 32.3 44.56 
y7 759.476 
y9 985.571 
AENPEPLVFGVK 
heavy 
654.357 
y4 458.285 
y7 767.490 
y9 993.585 
G
a
le
c
ti
n
-4
 
VVFNTLQGGK 
light 
531.800 
y6 603.346 
69.9 28 29.12 
y7 717.388 
y8 864.457 
VVFNTLQGGK 
heavy 
535.807 
y6 611.360 
y7 725.403 
y8 872.471 
VGSSGDIALHINPR 
light 
718.386 
y5 636.357 
83.5 34.7 30.53 
y6 749.441 
y7 820.478 
VGSSGDIALHINPR 
heavy 
723.390 
y5 646.365 
y6 759.449 
y7 830.487 
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4.2.6.2.2 Gene expression analysis 
RNA isolation from cultured cells and total tumor tissue 
In order to evaluate the gene expression levels for the markers of interest, we performed 
first an in vitro analysis. For this purpose, cells were seeded on 6 well Primaria plates at a 
density of 5 x 105 cells/well and allowed to grow for 48 hours. Cells were lysed using the 
RLT Lysis buffer provided by the RNeasy Mini Kit (Qiagen) containing β-mercaptoethanol 
and passed through the QIAshredder spin column (Qiagen), according to the instructions 
of the manufacturer. RNA was isolated according to the recommended protocol of the 
provider and DNase treatment was also performed (Qiagen). RNA concentration and purity 
were evaluated using the NanoDrop analyzer. 
Gene expression levels were also evaluated in vivo. Therefore, 30 mg of pancreatic tumor 
tissue derived from the mouse orthotopic xenografts were placed into a MACS M Tube 
(Miltenyi) together with the aforementioned lysis buffer and the tissue was dissociated using 
a Gentle MACS dissociator (Miltenyi). RNA extraction followed the previously mentioned 
protocol. 
 
EpCAM+ cell isolation and lysis for RNA extraction 
Because the total tumor tissue contains epithelial human cancer cells together with mouse 
stromal cell, we performed an enrichment of EpCAM+ human cells and isolated RNA from 
the enriched epithelial fraction for qPCR analysis. Tumor tissue was cut into small pieces, 
resuspended in CO2 independent medium and enzymes were added from the MACS tumor 
dissociation kit together with ROCK inhibitor and fungizone. The mix was placed in a MACS 
C Tube (Miltenyi) and fixed in a MACSMix rotator for 45 minutes at 37°C, with regular 
vortexing. The enzymatic cocktail was inactivated with fetal calf serum (FCS) and the 
dissociated cells were filtered through a 40 μm mesh. Cell debris and dead cells were 
removed using a ficol gradient centrifugation. Erythrocytes were removed by incubating the 
pellet of cells with ACK lysis buffer for 1 minute. The remaining single cells were incubated 
with anti-human EpCAM beads (Miltenyi) for 30 minutes at 4°C. The cell suspension was 
loaded on an LD column (Miltenyi) placed in a MACS separator, and after discarding the 
flow-through representing the stromal fraction, the EpCAM positive fraction was recovered 
from the column with the use of the plunger provided by the manufacturer, in a 2mM EDTA 
– PBS buffer containing 1% BSA. Cells were lysed using the QIAshredder kit and RNA was 
isolated as previously described. 
 
qPCR reaction 
Human specific primers were designed using the Netprimer software. In order to assess the 
specificity of the selected primers, the melting curves of each individual pair of designed 
primers were investigated for the presence of more than one product of amplification. 
Additionally, qPCR products were run on a 2% agarose gel (containing Midori Green for 
DNA band detection) in TBE buffer. Thus, it was confirmed that only one band can be 
detected following amplification, and the size of the amplicon was also assessed and 
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confirmed to match the predicted length. Band size was evaluated with the help of a 100 bp 
DNA ladder (Bio Labs). 
One microgram of total RNA extracted was reverse transcribed using the SuperScript VILO 
cDNA kit according to the instructions of the manufacturer. Reverse transcription reaction 
was performed for one hour at 42°C. 10 ng of total cDNA were used for the qPCR reaction, 
and the final concentration of the forward and reverse specific primers was 10 μM. The 
qPCR reaction was performed on the Viia7 Thermo, using the 2x concentrated SYBR green 
master mix (Applied Biosystems). Final reaction volume was 10 μL and the reaction was 
performed in the following conditions: the reaction mix was heated for 2 minutes at 50°C, 
followed by the initial denaturation performed at 95°C for 10 minutes. The denaturation and 
annealing plus extension cycles were carried out at 95°C for 15 seconds and 60°C for 1 
minute respectively, and repeated 40 times. Melting curves were generated and triplicate 
threshold cycles (Ct) values for each sample were averaged and compared to the Ct 
average of the housekeeping genes for each sample. mRNA levels were determined by 
relative quantification using the Viia7 RUO software version 1.0, and reported to two 
housekeeping genes: glyceraldehyde 3-phosphate (GAPDH) (primers designed to be 
human specific and the amplicon to span between different exons) and 60S ribosomal 
protein L13a (RPL13a). In vivo qPCR reactions were reported to total human pancreas RNA 
available from Ambion, which was processed prior to quantification identically to the total 
RNA extracts obtained from cell culture and mouse xenografts. 
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5. Results 
 
We set out to uncover novel cell surface and secreted protein markers in PDAC, which 
could be later used in clinical application, such as the development of novel diagnostic tests 
or novel targeted therapies. For this purpose, we employed for our discovery and validation 
experiments twelve patient matched primary pancreatic cancer cell lines (PACO cells) 
developed by Dr.Christian Eisen, DKFZ. Among the developed cell lines, three were present 
in duplicate, as biological replicates developed from the same patient. The subclassification 
of the cell lines into the individual subtypes was done using the gene set enrichment 
analysis (GESA) using the pancreatic ductal adenocarcinoma assigner as recommended 
by Collisson et al [3] (analysis performed by Dr. Christian Eisen). However, two cell lines 
originating from the same patient – PACO19 and PACO20 were initially classified as 
belonging to different subtypes – classical and respectively QM. Using both transcriptomic 
data (Dr.Elisa Espinet and Elisa Noll, HI-STEM, Metastasis Initiating Cells group) and whole 
cell proteome data (Wiebke Nadler, HI-STEM, Biomarker Discovery group), we observed 
that the PACO20 cell line clustered together with PACO19 and the two other classical cell 
lines – PACO2 and PACO17 (data not shown). For this reason, we decided to list PACO20 
as a classical cell line in our validation experiments. The list of PACO cell lines and their 
subclassification is shown in Table 5. Cell lines derived from the same patient are: PACO3 
and PACO10 (exocrine-like subtype); PACO7 and PACO8 (QM PDAC). For microscopy 
based validation experiments we employed two additional exocrine-like cell lines: PACO25 
and PACO26, which were not part of the cell lines used for the mass spectrometric 
discovery phase. Novel exocrine-like cell lines were provided by Dr. Elisa Espinet (HI-
STEM).  
Table 5: Subclassification of PACO cell lines 
Molecular subtype Cell line Observations 
Exocrine-like 
PACO3 Derived from the same patient. With medium length cell 
cycle PACO10 
PACO14 Growing in three dimensional islands. Very slow cycling 
PACO18 Slow cycling 
Classical 
PACO2 Fast cycling 
PACO17 Fast cycling 
PACO19 
Derived from the same patient; fast cycling 
PACO20 
Quasimesenchymal 
PACO7 Derived from the same patient. With medium length cell 
cycle PACO8 
PACO9 With medium length cell cycle 
PACO16 Very slow cycling 
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Two control cell lines, derived from healthy pancreatic tissue, were used as healthy controls 
in both the discovery and in vitro validation steps of the project. The two control cell lines 
were HPNE (Human Pancreatic Nestin Expressing Cells) and HPDE (Human Pancreatic 
Ductal Epithelial Cells). HPNE cells were immortalized using hTERT polymerase, while 
HPDE cells were immortalized by transfection with the E6E7 gene [133].  
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5.1 Identification of novel protein biomarkers using mass 
spectrometry 
The project focused on the in vitro discovery of novel pancreatic cancer biomarker 
candidates located on the cell surface of tumor cells or secreted by the tumor cells into the 
local environment. Specific enrichment protocols were optimized for each sub-proteome of 
interest. Additionally, we started investigating vascular accessible biomarkers associated 
with orthotopic pancreatic tumors developed in immunodeficient NSG mice, by performing 
whole body perfusion with a reactive biotin ester and enriching the biotinylated fraction prior 
to mass spectrometric analysis. 
 
5.1.1 Identification of novel cell surface protein biomarkers for PDAC 
using in vitro cultured primary, patient-matched cell lines 
The cell surface proteome of PDAC primary cells was analyzed after chemically enriching 
the plasma membrane associated proteins, upon using a reactive biotin ester – in this 
particular case Sulfo-NHS-LC Biotin. Amino groups (including amino terminal aminoacids 
or lysine residues) of proteins accessible to the reagent were covalently labeled upon 
reacting with the N-hydroxysuccinimide ester. Cells were incubated with the biotinylation 
reagent for 10 minutes at room temperature, and the unreacted ester was quenched using 
a Tris-HCl solution (for details see Materials and Methods). Afterwards, cells were detached 
using non-enzymatic methods, and lysed. Biotinylated proteins, present in 250 μg total 
protein, were enriched on a streptavidin resin and digested with trypsin, as described in the 
methods chapter. In parallel, negative controls have been performed for each sample, by 
using the same total protein amount and performing identical enrichment, digestion and 
fractionation protocols on cell lysates without prior biotin labeling. A minimum of four 
biotinylated samples and two negative controls were analyzed per cell line. The complex 
peptide mixture was fractionated using a reverse phase UPLC column, and the eluting 
fractions were mixed with CHCA resin and spotted on a MALDI plate, prior to MS analysis 
on a MALDI TOF/TOF 5800 instrument. 
After each MS run, we created 2D peptide maps, which enable an overview of the 
complexity of the sample to be analyzed, as well as the quality of the chromatographic 
fractionation. Spotted samples for which the 2D peptide maps revealed tailed elutions, 
contaminations or significant delays in the start of elution, were excluded from further MS2 
analysis. Thus, the created 2D peptide maps served as a first level quality control for the 
UPLC fractionated samples. We selected two representative maps: one for the biotinylated 
fraction (Figure 9A) and one for an unbiotinylated negative control (Figure 9B). The y axis 
indicates the fraction number in which the peptide was detected, whereas the x axis 
indicates the m/z value of each peptide. The red arrow points to one of the constant signal 
of the spiked in peptide having a mass of ~1411 Da, which was used for the normalization 
of the peptide maps. The two selected maps indicate the general high level quality of the 
reverse phase UPLC fractionation performed. As it can be observed from Figure 9, the 
majority of the eluted peptides can be identified in only few fractions, and no significant 
elution tails could be reported for the majority of the fractionated peptides. Exceptions could 
be observed for very abundant peptides, such as the ones derived from streptavidin 
digestion (delineated in red). The number of peptides in the negative controls (Figure 9B) 
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is, as expected, significantly lower compared to the number detected in biotinylated 
samples. Biotin carboxilazes, present in both biotinylated samples and negative controls, 
are enzymes employing biotin as cofactor for their catalytic activity [135]. These proteins 
are therefore enriched upon streptavidin pull down, thus explaining the presence of positive 
signals (additional to the streptavidin tryptic peptides) in the 2D peptide maps of the negative 
controls. 
 
Figure 9: 2D peptide maps of cell surface proteome samples. A: PACO3 biotinylated sample – run 6. 
B: HPNE non-biotinylated negative control – run 4. Abundant streptavidin derived peptides are 
outlined in red. 
Tandem MS was performed and the resulting spectra were used for protein identification 
using the ProteinPilot software, by employing the Paragon algorithm and searching against 
a non-redundant human proteome data base, downloaded from UniProt. The resulting 
protein lists were manually curated in order to evaluate the presence of putative isoforms. 
Proteins identified at least once with two peptides were included in the final cell surface 
proteome list. 
In total, we analyzed 108 biotinylated samples, and 46 negative controls. 16 healthy control 
samples were compared to 30 exocrine-like, 33 classical, and 29 QM samples. The final 
total list of proteins identified (excluding one hit wonders, as previously mentioned), included 
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2567 proteins. 1295 of them were present in all cell lines analyzed, while 860 were detected 
exclusively in one or multiple PDAC derived cell lines and were completely absent from the 
healthy controls. 200 proteins could be identified in the negative (unbiotinylated) control, 
consisting mostly of biotin carboxylases and abundant intracellular proteins – such as 
proteins of the cytoskeleton, ribosomal proteins, etc (Supplementary Information – digital 
format). Subtype specific proteins could be identified. Additionally, some of the identified 
proteins were present in two or more PDAC molecular subtypes. The exact number of 
proteins belonging to each subtype is represented in the Venn diagram displayed in 
Figure 10. 
 
Figure 10: Venn diagram representing the number of proteins identified after performing 
the cell surface proteome analysis. The following color code was used to distinguish 
between the different subtypes analyzed: grey: healthy control; blue: classical subtype 
PDAC; green: exocrine-like PDAC; red: QM PDAC. 
 
In order to evaluate the localization of the identified proteins, we performed a gene ontology 
analysis, using the WebGestalt software. As shown in Figure 11, a significant number of 
proteins identified by MALDI MS after the enrichment of the cell surface proteome were 
localized at the plasma membrane (more than 800 proteins) or are expected to participate 
in the formation of anchoring junctions (96 proteins). More than 1300 of the proteins were 
expected to be associated with membranous fractions (both intracellular and extracellular). 
With regard to proteins predicted to reside in intracellular membranes, 389 were annotated 
to the ER membrane fraction. 
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Figure 11: Gene ontology (GO) analysis of the complete cell surface proteome: close up. 
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Furthermore, the GO analysis allowed investigating the involvement of the identified 
proteins with disease associated pathways. The list was enriched for proteins involved in 
adhesion, neoplasm invasiveness and metastasis, as well as the development of epithelial 
cancers (data not shown). We additionally investigated which disease associated pathways 
are enriched in each individual subtype, and we could observe the same pattern as 
previously described for the complete cell surface proteome list (data not shown). 
When analyzing the complete cell surface proteome list, we could identify multiple proteins 
present in all the analyzed PACO cell lines, but in none of the controls, thus representing 
putative pan-PDAC markers. A short list of the proteins identified with the highest number 
of peptides in all the PDAC derived cell lines is shown in Table 6. The maximum number of 
peptides identified for each molecular subtype and for the healthy controls is indicated in 
the last four columns. 
As it can be observed from the list, protocadherin-1 (PCDH1) represented one of the top 
proteins identified in the PDAC cell surface proteome analysis, being detected in all PACO 
cell lines analyzed, and in almost every biological replicate performed (the absence of 
PCDH1 identification in some of the biological replicates can be explained by stochastic 
sampling). Moreover, PCDH1 could not be identified in any of the healthy control cell lines. 
Other important hits, previously described in literature as being associated with PDAC are: 
mesothelin [6], mucin-1 (MUC1) [20], carcinoembryonic antigen-related cell adhesion 
molecule-5 and -6 (CEACAM5 and CEACAM6) [136], and putative cancer stem cell marker 
prominin-1 (also known as CD133) [137]. Novel putative pan-PDAC markers include 
PCDH1, Single IgIL-1-related receptor (involved in Toll receptor signaling [138]), 
podocalyxin (particularly enriched in QM samples), lipocalin-2 (also known as Neutrophil 
gelatinase-associated lipocalin) and prominin-2. Out of the list, we selected two putative 
pan-PDAC markers for further validations: PCDH1 and LCN2.  
We were also interested in identifying subtype specific markers, and for this reason we 
inquired the cell surface proteome list for proteins present exclusively, or significantly 
enriched (based on the maximum number of peptides identified), in one molecular subtype. 
In order for a marker to be considered as being putative subtype specific, the respective 
protein had to be identified at least once in all of the cell lines belonging to that particular 
subtype. 
 To our surprise, the exocrine-like cell lines stood out, expressing several subtype specific 
proteins (Table 7). As indicated in Table 7, the top hits for the exocrine-like subtype were 
cadherin-17 (CDH17) and galectin-4 (LGALS4), identified in every cell line belonging to the 
exocrine-like subtype, and we selected both markers for further validations. Not only did we 
identify the two proteins with the highest number of peptides, but they were also present in 
more than 95% of all analyzed samples (including biological replicates) from cell lines of the 
exocrine-like subtype. The exocrine-like enriched group included additional putative 
biomarkers of interest which we did not pursue further, such as: deleted in malignant brain 
tumors 1 protein (previously described as being enriched in PDAC [41]), firbroblast growth 
factor receptor 4, vilin-1, etc. 
For the classical and the QM subtypes we could not identify any protein expressed solely 
or significantly enriched in the individual subtypes. A short list of proteins most abundant in 
classical and QM PACO cells is available in Table 8. Some of the proteins identified in 
classical PDAC with the highest number of peptides could only be detected in on cell line 
alone: PACO2. Two of the proteins identified with the highest number of peptides in the QM 
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samples – Zinc transporter ZIP4 and Ephrin type-A receptor 3, were unfortunately only 
present in two of the QM assigned cell lines. For this reason, we did not select any putative 
marker for further validations. 
Several proteins appeared enriched in one or two distinct molecular subtypes: for example 
mucin-16, present in classical and QM cells, but completely absent in exocrine-like PACOs, 
or metalloreductase STEAP1, enriched in the classical subtype, but also present in 
exocrine-like cells. STEAP1 could be identified in all cell lines belonging to the classical and 
exocrine-like subtype at least once, and appeared to be slightly enriched in classical cells. 
We considered STEAP1 for future validation experiments, which will not be presented in 
this report.  
The complete list of proteins identified in the cell surface proteome and corresponding 
secretome is available in the Supplementary Materials, in digital format.   
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Table 6: Putative pan-PDAC markers identified exclusively in PACO cell lines. The maximum number of peptides identified for each subtype is represented in 
the right columns (in brackets – number of cell lines in which the protein was identified/out of the number of cell lines belonging to the respective molecular 
subtype). Proteins are listed dependent on the percentage of PACO samples (including biological replicates) positive for the respective protein 
Protein Name Gene Name 
% 
positive 
PACO 
Max 
Ctrl 
Max 
Exocrine 
Max 
Classical 
Max  
QM 
Protocadherin-1 PCDH1 97.83 0 22 (4/4) 15 (4/4) 22 (4/4) 
Mucin-1 MUC1 91.3 0 19 (4/4) 11 (4/4) 15 (4/4) 
Probable G-protein coupled receptor 110 GPR110 89.13 0 5 (4/4) 6 (4/4) 11 (3/4) 
Single Ig IL-1-related receptor SIGIRR 83.7 0 8 (4/4) 10 (4/4) 7 (4/4) 
Carcinoembryonic antigen-related cell adhesion molecule 6 CEACAM6 82.61 0 7 (4/4) 7 (4/4) 6 (3/4) 
Neutrophil gelatinase-associated lipocalin LCN2 81.52 0 10 (4/4) 9 (4/4) 11 (3/4) 
Carcinoembryonic antigen-related cell adhesion molecule 5 CEACAM5 79.35 0 12 (4/4) 16 (4/4) 10 (3/4) 
Periplakin PPL 78.26 0 21 (4/4) 15 (4/4) 22 (4/4) 
Sodium- and chloride-dependent neutral and basic amino acid transporter 
B(0+) 
SLC6A14 77.17 0 6 (4/4) 7 (4/4) 4 (3/4) 
Canalicular multispecific organic anion transporter 2 ABCC3 72.83 0 17 (4/4) 8 (3/4) 16 (4/4) 
Cadherin EGF LAG seven-pass G-type receptor 1 CELSR1 69.57 0 20 (4/4) 13 (4/4) 7 (4/4) 
Mesothelin MSLN 65.22 0 6 (2/4) 8 (3/4) 7 (4/4) 
Poliovirus receptor-related protein 4 PVRL4 65.22 0 6 (4/4) 5 (4/4) 9 (3/4) 
Amyloid-like protein 2 APLP2 61.96 0 5 (4/4) 3 (4/4) 5 (4/4) 
Prominin-1 PROM1 58.7 0 19 (4/4) 4 (3/4) 4 (2/4) 
Epiplakin EPPK1 58.7 0 44 (4/4) 11 (3/4) 12 (2/4) 
Low-density lipoprotein receptor-related protein 8 LRP8 56.52 0 7 (3/4) 5 (4/4) 7 (4/4) 
Tumor necrosis factor receptor superfamily member 21 TNFRSF21 56.52 0 5 (2/4) 5 (4/4) 7 (3/4) 
Intercellular adhesion molecule 2 ICAM2 45.65 0 3 (3/4) 5 (4/4) 3 (3/4) 
Prominin-2 PROM2 44.57 0 18 (4/4) 10 (3/4) 6 (2/4) 
Envoplakin EVPL 42.39 0 4 (2/4) 12 (4/4) 10 (2/4) 
Podocalyxin PODXL 39.13 0 3 (1/4) 4 (2/4) 10 (3/4) 
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Table 7: List of proteins enriched in the exocrine-like subtype. The percentage of samples positive for a given protein is included in parallel with the maximum 
number of peptides identified for each molecular subtype. In brackets: number of cell lines in which the protein was identified/out of the number of cell lines 
belonging to the respective molecular subtype 
 
  % positive samples 
Maximum number of peptides 
identified 
Protein Name 
Gene 
Name 
% 
Exocrine 
% 
Classical 
% 
QM 
Max 
Ctrl 
Max 
Exocrine 
Max 
Classical 
Max 
QM 
Cadherin-17 CDH17 100.00 0.00 0.00 0 46 (4/4) 0 0 
Galectin-4 LGALS4 96.67 3.03 0.00 0 12 (4/4) 1 0 
Claudin-2 CLDN2 66.67 0.00 0.00 0 2 (4/4) 0 0 
Endothelial cell-selective adhesion molecule ESAM 56.67 51.52 0.00 0 4 (3/4) 3 0 
Semaphorin-4G SEMA4G 56.67 27.27 0.00 0 7 (3/4) 3 0 
Ly6/PLAUR domain-containing protein 2 LYPD2 46.67 0.00 0.00 0 3 (2/4) 0 0 
Receptor-type tyrosine-protein phosphatase H PTPRH 46.67 0.00 0.00 0 7 (3/4) 0 0 
Lysozyme C LYZ 40.00 12.12 0.00 0 2 (4/4) 1 0 
Protein KIAA1199 KIAA1199 40.00 9.09 0.00 0 5 (4/4) 1 0 
Alpha-2A adrenergic receptor ADRA2A 36.67 0.00 0.00 0 4 (2/4) 0 0 
Cadherin-12 CDH12 36.67 0.00 0.00 0 6 (1/4) 0 0 
Fibroblast growth factor receptor 4 FGFR4 33.33 0.00 0.00 0 4 (2/4) 0 0 
Glutathione peroxidase 2 GPX2 33.33 0.00 0.00 0 6 (4/4) 0 0 
Protein phosphatase 1 regulatory subunit 1B PPP1R1B 33.33 0.00 0.00 0 2 (3/4) 0 0 
Deleted in malignant brain tumors 1 protein DMBT1 30.00 0.00 0.00 0 3 (2/4) 0 0 
Probable G-protein coupled receptor 125 GPR125 26.67 0.00 0.00 0 3 (2/4) 0 0 
Villin-1 VIL1 23.33 0.00 0.00 0 5 (2/4) 0 0 
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Table 8: List of proteins enriched in the classical and QM subtypes. The percentage of samples positive for a given protein is included in parallel with the 
maximum number of peptides identified for each molecular subtype In brackets: number of cell lines in which the protein was identified/out of the number of 
cell lines belonging to the respective molecular subtype 
 
 
  % positive samples Maximum number of peptides identified 
Protein Name 
Gene 
Name 
% 
Exocrine 
% 
Classical 
% QM 
Max 
Ctrl 
Max 
Exocrine 
Max 
Classical 
Max  
QM 
Protocadherin Fat 2 FAT2 0.00 24.24 0.00 0 0 12 (1/4) 0 
Contactin-1 CNTN1 0.00 24.24 0.00 0 0 8 (2/4) 0 
Interferon-induced GTP-binding protein Mx2 MX2 0.00 24.24 0.00 0 0 4 (3/4) 0 
MICAL-like protein 1 MICALL1 0.00 24.24 0.00 0 0 3 (1/4) 0 
Pirin PIR 0.00 18.18 0.00 0 0 3 (1/4) 0 
Matrix metalloproteinase-28 MMP28 0.00 15.15 0.00 0 0 3 (1/4) 0 
Metalloreductase STEAP1 STEAP1 33.33 69.70 3.45 2 (1/2) 4 (3/4) 5 (4/4) 1 (1/4) 
Mucin-16 Q8WXI7 0.00 75.76 58.62 0 0 25 (3/4) 14 (3/4) 
Chloride intracellular channel protein 3 CLIC3 0.00 0.00 48.28 0 0 0 4 (3/4) 
Zinc transporter ZIP4 SLC39A4 0.00 0.00 44.83 0 0 0 3 (2/4) 
Syndecan-2 SDC2 0.00 0.00 24.14 0 0 0 4 (1/4) 
Ephrin type-A receptor 3 EPHA3 0.00 0.00 20.69 0 0 0 10 (1/4) 
Latrophilin-3 LPHN3 0.00 0.00 20.69 0 0 0 4 (1/4) 
Keratin-81-like protein -- 0.00 0.00 20.69 0 0 0 3 (2/4) 
Protein Wnt-11 WNT11 0.00 0.00 17.24 0 0 0 2 (1/4) 
Toll-like receptor 5 TLR5 0.00 0.00 10.34 0 0 0 2 (1/4) 
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5.1.2 Identification of novel secreted protein biomarkers for PDAC in 
vitro 
Putative novel diagnostic cancer biomarkers are expected to be proteins either secreted by 
the tumor cells into their microenvironment, or enzymatically shaved off plasma membrane 
components. In order to investigate putative novel PDAC diagnostic biomarkers, we 
employed the conditioned cell culture medium of the twelve PACO cell lines. The CSC 
medium for the PDAC derived cell lines has the advantage that it does not contain any 
added serum, which normally hinders mass spectrometric protein identification. However, 
the CSC PACO medium did contain high amounts of albumin and transferrin, which could 
have masked the signal of less abundant peptides originating from putative protein 
biomarkers. For this reason, together with Dr. Martin Sprick (HI-STEM/DKFZ), we optimized 
a novel CSC based medium, completely devoid of albumin and transferrin. Iron was 
supplemented to the new medium, in order to satisfy the metabolic needs of the growing 
cells. Since the new medium was not depleted in nutrients or growth factors (supplemented 
separately), we expected that the new formulation would not significantly impact the 
metabolism, phenotype and secretion pattern of the investigated cells.  
All cell lines were grown for 48 hours in the new chemically defined CSC albumin/transferrin 
depleted medium (termed secretome CSC medium), including the two healthy control 
references: HPDE and HPNE. The medium was later collected and underwent a series of 
centrifugation steps, meant to remove organelles released in the growth medium by 
apoptotic cells and microvesicles (for the full protocol see Materials and Methods). A 
minimum of three technical replicates were performed for each sample. We did not observe 
any changes in the cell morphology and division rate of the PACO and HPNE cells, which 
was to be expected, since the secretome CSC medium formulation is highly similar to their 
original cell culture medium. However, for the HPDE cell line (grown in a Keratinocyte cell 
medium), slight morphological changes could be observed, and the cells appeared more 
elongated than the counterparts grown in their native medium after the 48 hours incubation 
period (Figure 12). 
 
Figure 12: Microscopy pictures of HPDE cell line grown in regular Keratinocyte culture medium and 
in secretome optimized CSC medium are shown on the left and on the right side respectively. 
Secreted proteins were precipitated and digested with trypsin, and the peptide mixture was 
fractionated by reverse phase UPLC. Two representative 2D peptide maps (for HPNE and 
PACO19 collected supernatants) are shown in Figure 13. We observed once again that the 
majority of peptides were eluted in only a few fractions.  
Results 
 
87 
 
 
Figure 13: 2D peptide maps of secretome samples. A: HPNE – run 2. B: PACO19 – run 4. 
 
 
We analyzed a total of 47 supernatant samples, including 6 healthy controls, 13 exocrine-
like, 12 classical, and 16 QM PDAC samples. After manually curating the list of proteins 
identified (as previously mentioned for the cell surface proteome), we could confirm the 
presence of 1781 proteins in the secreted fractions, identified at least once with a minimum 
of two peptides. 786 of the identified proteins were common for the control and PDAC cell 
lines, while 175 detected proteins were identified in all PACO subtypes, but were absent in 
the healthy control cell line secretome. The number of secreted proteins identified and their 
distribution among the different subtypes is summarized in the following Venn diagram 
(Figure 14). 
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Figure 14: Venn diagram representing the number of proteins identified in the secretome analysis. 
The following color code was used to distinguish between the different subtypes analyzed: 
grey: healthy control; blue: classical subtype PDAC; green: exocrine-like PDAC; red: QM PDAC. 
 
We investigated the predicted cellular localization of the secreted proteins identified, by 
performing gene ontology analysis. Figure 15a shows a close up of the GO enrichment 
analysis results, using the complete secretome list for investigation. A clear enrichment of 
proteins annotated to the GO term “extracellular region” and “extracellular matrix” can be 
observed (more than 500 proteins in total). Over 100 of the discovered proteins were 
predicted to be located on the cell surface. Some of the intracellular proteins identified were 
described to be enriched in membrane bound and cytoplasmic vesicles. When analyzing 
the involvement of identified secreted proteins in disease associated pathways, we 
observed similar enrichments to the ones previously described for the cell surface 
proteome, with adhesion, neoplasm invasiveness and metastasis representing some of the 
most relevant disease associated pathways (data not shown).  
Interestingly, the secretome of individual subtypes revealed some relevant differences, 
compared to the whole secretome. For example, the secretome of the exocrine-like cells 
expressed a subset of proteins enriched in cell junctions, additionally to the already 
predicted extracellular and cell surface proteins (Figure 15b, close-up). In contrast, the 
classical and the QM subtype’s secretome were enriched in proteins expressed at the 
basement membrane level. For simplification purposes, we only represented close ups of 
the classical secretome GO analysis (Figure 15c).  
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Figure 15 (a): Gene ontology analysis of the complete in vitro secretome: close up.  
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Figure 15 (b): Gene ontology analysis of the exocrine-like in vitro secretome: close up.  
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Figure 15 (c): Gene ontology analysis of the classical in vitro secretome: close up. 
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We screened the complete secretome list for proteins associated exclusively with the PACO 
cell lines, but absent in the healthy control secretome. A short list of the most important hits 
is listed in Table 9. Several of the top hits identified in the cell surface proteome could also 
be detected in the secreted fraction. LCN2, one of the putative pan-PDAC markers detected 
during the cell surface analysis, was identified in the secreted fraction of all PACO cell lines 
as well, with a high number of peptides. Mesothelin, PCDH1, MUC1, CEACAM6 were also 
identified in the secretome of PDAC cancer cell lines. Among the secreted proteins present 
throughout the whole molecular subtype repertoire, we could discern remodeling agents of 
the ECM, such as matrilysin (MMP7) (appearing to be enriched in the exocrine-like subtype 
based on the maximum number of peptides identified and the percentage of positive cells) 
and ADAM8. Interestingly, trypsin-2 was secreted by exocrine-like and QM PACO cell lines.  
Several of the previously mentioned exocrine-like cell surface proteins could be detected in 
the secreted fraction as well, including the two putative biomarkers we had selected for 
further validations (Table 10). Among the top hits of exocrine-like specifically secreted 
proteins we noticed several proteins involved in mediating cell adhesion (such as cadherins-
6, -12 and -17). Interestingly, the pair ligand-receptor fibroblast growth factor 19 (FGF19) 
and fibroblast growth factor receptor 4 (FGFR4) were both secreted by exocrine-like cells.  
A short list of proteins enriched in the supernatant of classical and QM cell lines is presented 
in Table 11. Among the proteins highly expressed in the classical subtype are: contactin-1 
(previously observed on the cell surface proteome of PACO2 cells), C-X-C motif 
chemokine 14 and 16, GMCSF receptor subunit alpha. The top hit for QM specific secreted 
proteins was matrix-remodeling-associated protein 5, detected in half of the samples 
analyzed.  
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Table 9: Putative pan-PDAC secreted markers identified exclusively in PACO cell lines. The maximum number of peptides identified for each subtype is 
indicated in the right columns (in brackets: number of cell lines in which the protein was identified/out of the number of cell lines belonging to the respective 
molecular subtype) 
Protein Name 
Gene 
Name 
% 
positive 
PACO 
max 
ctrl 
max 
exocrine 
max 
classical 
max  
QM 
Neutrophil gelatinase-associated lipocalin LCN2 100.00 0 87 (4/4) 25 (4/4) 51 (4/4) 
Retinoic acid receptor responder protein 1 RARRES1 87.80 0 18 (4/4) 9 (4/4) 11 (4/4) 
Retinal dehydrogenase 1 ALDH1A1 80.49 0 16 (3/4) 9 (4/4) 8 (4/4) 
Mesothelin MSLN 80.49 0 19 (3/4) 10 (4/4) 7 (4/4) 
Insulin-like growth factor-binding protein 3 IGFBP3 75.61 0 6 (3/4) 11 (3/4) 12 (4/4) 
Na(+)/H(+) exchange regulatory cofactor NHE-RF1 SLC9A3R1 73.17 0 3 (4/4) 13 (3/4) 8 (4/4) 
Semaphorin-3B SEMA3B 70.73 0 14 (3/4) 5 (2/4) 19 (4/4) 
Protein-glutamine gamma-glutamyltransferase 2 TGM2 70.73 0 3 (2/4) 22 (3/4) 39 (4/4) 
Calcyphosin CAPS 65.85 0 9 (3/4) 5 (2/4) 7 (4/4) 
Pterin-4-alpha-carbinolamine dehydratase PCBD1 65.85 0 6 (4/4) 2 (4/4) 4 (4/4) 
Matrilysin MMP7 63.41 0 51 (4/4) 5 (4/4) 5 (1/4) 
Protocadherin-1 PCDH1 60.98 0 6 (2/4) 11 (4/4) 6 (3/4) 
Disintegrin and metalloproteinase domain-containing 
protein 8 
ADAM8 58.54 0 2 (2/4) 3 (4/4) 2 (4/4) 
CD2-associated protein CD2AP 58.54 0 9 (2/4) 9 (3/4) 3 (3/4) 
Mucin-5AC (Fragments) MUC5AC 58.54 0 15 (4/4) 18 (3/4) 2 (2/4) 
Periplakin PPL 58.54 0 11 (2/4) 13 (3/4) 17 (4/4) 
Protocadherin Fat 1 FAT1 56.10 0 10 (4/4) 14 (2/4) 7 (3/4) 
Carcinoembryonic antigen-related cell adhesion molecule 
6 
CEACAM6 46.34 0 11 (3/4) 6 (4/4) 2 (1/4) 
Mucin-1 MUC1 34.15 0 8 (2/4) 5 (3/4) 2 (3/4) 
Trypsin-2 PRSS2 26.83 0 10 (2/4) 7 (3/4) 0 (0/4) 
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Table 10: Putative exocrine-like secreted markers. The maximum number of peptides identified for each subtype is indicated in the right columns. Proteins 
are listed according to the percentage of samples in which the protein was identified (largest to smallest). In brackets: number of cell lines in which the protein 
was identified/out of the number of cell lines belonging to the exocrine-like molecular subtype 
 % positive samples Maximum number of peptides identified 
Protein Name 
Gene 
Name 
% 
Exocrine 
% 
Classical 
% QM 
max 
ctrl 
max 
exocrine 
max 
classical 
max  
QM 
Annexin A4 ANXA4 61.54 0.00 0.00 0 4 (4/4) 0 0 
Cathepsin E CTSE 61.54 0.00 0.00 0 4 (3/4) 0 0 
Regenerating islet-derived protein 4 REG4 61.54 0.00 0.00 0 9 (4/4) 0 0 
Galectin-4 LGALS4 46.15 0.00 0.00 0 8 (3/4) 0 0 
Fibroblast growth factor 19 FGF19 38.46 0.00 0.00 0 13 (2/4) 0 0 
Fibroblast growth factor receptor 4 FGFR4 38.46 0.00 0.00 0 4 (3/4) 0 0 
Kallistatin SERPINA4 38.46 0.00 0.00 0 4 (3/4) 0 0 
Nephronectin NPNT 30.77 0.00 0.00 0 4 (2/4) 0 0 
Complement C5 C5 23.08 0.00 0.00 0 16 (1/4) 0 0 
Cell adhesion molecule 4 CADM4 23.08 0.00 0.00 0 6 (2/4) 0 0 
Cadherin-6 CDH6 23.08 0.00 0.00 0 10 (1/4) 0 0 
Interleukin-1 receptor accessory 
protein 
IL1RAP 23.08 0.00 0.00 0 3 (1/4) 0 0 
Adseverin SCIN 23.08 0.00 0.00 0 3 (2/4) 0 0 
Angiotensinogen AGT 15.38 0.00 0.00 0 3 (1/4) 0 0 
Alkaline phosphatase, placental-like ALPPL2 15.38 0.00 0.00 0 10 (1/4) 0 0 
Cadherin-12 CDH12 15.38 0.00 0.00 0 2 (1/4) 0 0 
Cadherin-17 CDH17 15.38 0.00 0.00 0 4 (1/4) 0 0 
Macrophage metalloelastase MMP12 15.38 0.00 0.00 0 4 (1/4) 0 0 
Neurotensin/neuromedin N NTS 15.38 0.00 0.00 0 4 (1/4) 0 0 
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Table 11: Selected proteins secreted by the classical and QM cell lines. The maximum number of peptides identified for each subtype is indicated in the right 
columns. Proteins are listed according to the percentage of samples in which the protein was identified (largest to smallest) In brackets: number of cell lines in 
which the protein was identified/out of the number of cell lines belonging to the exocrine-like molecular subtype 
 % positive samples Maximum number of peptides identified 
Protein Name 
Gene 
Name 
% 
Exocrine 
% 
Classical 
% QM 
max 
ctrl 
max 
exocrine 
max 
classical 
max  
QM 
Polypeptide N-acetylgalactosaminyltransferase 6 GALNT6 0.00 58.33 0.00 0 0 9 (4/4) 0 
Catalase CAT 0.00 41.67 0.00 0 0 5 (3/4) 0 
Contactin-1 CNTN1 0.00 33.33 0.00 0 0 5 (1/4) 0 
Hematopoietic lineage cell-specific protein HCLS1 0.00 33.33 0.00 0 0 2 (1/4) 0 
Caprin-1 CAPRIN1 0.00 25.00 0.00 0 0 5 (2/4) 0 
Carboxypeptidase D CPD 0.00 25.00 0.00 0 0 2 (2/4) 0 
Granulocyte-macrophage colony-stimulating factor 
receptor subunit alpha 
CSF2RA 0.00 25.00 0.00 0 0 2 (1/4) 0 
C-X-C motif chemokine 14 CXCL14 0.00 25.00 0.00 0 0 2 (1/4) 0 
C-X-C motif chemokine 16 CXCL16 0.00 25.00 0.00 0 0 3 (1/4) 0 
Matrix-remodeling-associated protein 5 MXRA5 0.00 0.00 50.00 0 0 0 5 (2/4) 
Chloride intracellular channel protein 3 CLIC3 0.00 0.00 43.75 0 0 0 8 (2/4) 
Cellular retinoic acid-binding protein 2 CRABP2 0.00 0.00 43.75 0 0 0 6 (2/4) 
Protein kinase C-binding protein NELL2 NELL2 0.00 0.00 43.75 0 0 0 2 (2/4) 
Insulin-like growth factor-binding protein 5 IGFBP5 0.00 0.00 31.25 0 0 0 2 (2/4) 
Selenium-binding protein 1 SELENBP1 0.00 0.00 31.25 0 0 0 3 (2/4) 
Testican-2 SPOCK2 0.00 0.00 31.25 0 0 0 4 (2/4) 
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5.1.3 Overview of total protein list detected on the cell surface 
proteome and secretome of PDAC cell lines versus healthy controls 
After completing the in vitro analysis of both proteomic subsets, we decided to combine the 
two lists of identified proteins and analyze them together. The lists were again curated 
manually and only proteins identified at least once with two peptides in either the cell surface 
proteome or the secretome were considered for the final list. In total, we identified 3288 
proteins, out of which 1450 were common for both fractions (Figure 16). Only 546 proteins 
were selectively identified in the supernatant of cultured cells, while 1292 could be detected 
only in the enriched plasma membrane fraction.  
 
Figure 16: Venn diagram illustrating the total number of proteins identified at least once with two 
peptides in the cell surface and secreted proteome of cultured PDAC primary cells and healthy 
controls. 
The unified list of both proteomes is available in digital format in the Supplementary 
Materials. 
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5.1.4 In vivo biotinylation of tumor xenograft mouse models for the 
identification of novel subtype specific biomarker candidates  
In parallel we aimed to investigate protein markers associated with orthotopic pancreatic 
tumors, including proteins expressed on the surface of cancer cells, on the plasma 
membrane of stromal cells, as well as proteins present in the tumor associated ECM. For 
this purpose, 106 PACO cells were injected in the pancreas of immunodeficient NSG male 
mice. When the tumor reached ~1 cm in diameter (evaluated by weekly palpations), mice 
were anesthetized, the thoracic cavity was opened and the mice received a full body 
terminal perfusion with a reactive biotin ester prepared in dextrane-PBS solution. The 
perfusion protocol, performed in optimal temperature conditions to prevent vasoconstriction, 
leads to the covalent biotin labeling of proteins accessible from the blood stream, including 
vasculature associated proteins, as well as cell surface and ECM proteins expressed and 
secreted by the cancer cells or the tumor associated stroma. In vivo biotinylation is a 
powerful technique, as it allows the investigation of the tumor and the associated niche 
proteome, while at the same time offering potential valuable candidates for future targeted 
therapies. 
One cell line per molecular subtype was selected for the generation of orthotopic mouse 
tumors: PACO3 for exocrine-like PDAC, PACO17 for classical PDAC and finally PACO8 for 
QM PDAC (a minimum of 8 mice per experiment). Male mice were selected in an attempt 
to limit the influence of hormone levels variations (such as the ones associated with the 
female oestrous cycle) on the development of primary tumors. In total we perfused 33 tumor 
bearing mice, and nine healthy NSG male mice. For each experimental group we included 
a minimum of two negative controls – animals that were not perfused with the biotin ester. 
For PACO8 tumor bearing mice and the healthy control groups, we also performed a 
number of perfusions using the vector solution alone (dextrane-PBS) as additional negative 
controls. The number of mice used for the orthotopic tumor perfusion experiments are listed 
in Table 12. 
Table 12: Overview of the number of animals used for the in vivo proteomic discovery experiments 
Cell line 
Type of 
xenograft 
Number 
of  mice 
Number of non-
biotinylated 
contrls 
Number of 
biotinylated 
mice 
No of mice  
optimally 
perfused 
PACO3 Orthotopic 12 3 9 8 
PACO8 Orthotopic 13 1+1 Dextrane 10 7 
PACO17 Orthotopic 8 2 6 5 
Negative 
ctrl 
Healthy NSG 9 2 + 2 Dextrane 5 3 
 
The efficiency of the perfusion experiments was evaluated first visually: the color of 
optimally perfused organs shifted to a lighter shade as a result of washing out the blood 
from the vascular system. If no dark clotted spots could be reported in the liver and kidney 
of perfused animals, we expected an overall good biotinylation quality. If however large clots 
could be detected, we labeled the organs as only partially perfused. An example of a 
successfully perfused mouse is presented in Figure 17. 
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Figure 17: Mouse after receiving terminal whole body perfusion. Tissue discoloration can be 
observed for liver and kidney, indicating complete organ perfusion. The mouse had been injected 
intra-splenic with the PACO17 cell line and developed liver malignant lesions (metastases model). 
 
The primary pancreatic tumor (for tumor bearing mice), or total pancreatic tissue was 
collected and snap frozen in liquid nitrogen. Some tumor bearing mice developed in the 
incubation time liver metastases, which were also collected for further proteomic analysis. 
Liver tissue was collected as controls for the assessment of the whole body perfusion’s 
success. Small tissue samples were additionally embedded in OCT cryomedium and used 
for further experiments, evaluating the biotinylation efficiency. Frozen samples were stored 
at -80°C. Mice received number codes, which included the number of the PACO cell line 
from which they were derived, the acronym O (for orthotopic model) and a two number code 
indicating the identifier of the cage and the mouse number within the cage.  
 
5.1.4.1 Evaluation of perfusion success using immunofluorescence 
Prior to the proteomic analysis, a quality control check evaluating the biotinylation efficiency 
was performed, using the collected frozen OCT embedded tissues. Biotinylated areas were 
revealed by using a streptavidin-A488 conjugate, while the CD31 positive endothelial cells 
were visualized by means of secondary immunofluorescence (for details see Materials and 
Methods). For each sample we performed negative staining controls, from which the 
streptavidin conjugate and the primary anti-CD31 antibody were omitted. 
We evaluated the perfusion efficiency on PACO3 and PACO17 derived pancreatic tumors 
(Figure 18).  
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Figure 18: Orthotopic PACO derived pancreatic tumors: evaluation of biotinylation efficiency on 
frozen tissue. In green: biotin staining. In red: CD31 staining. A: PACO3.O.1.1 biotinylated tumor; 
B: PACO3.O.1.2 biotinylated tumor; C: PACO3.O.2.2 biotinylated tumor; D: PACO3.O.2.3 
biotinylated tumor; E: PACO3.O.2.3  liver metastases – biotinylated; F: PACO3.O.1.4 suboptimal 
perfusion; G: PACO3.O.2.1 suboptimal perfusion; H: PACO3.O.1.3 non biotinylated control; 
I: PACO17.O.2.2 biotinylated tumor; J: PACO17.O.2.4 biotinylated tumor;  K: PACO17.O.2.3 
biotinylated, tumor with liquid cyst;  L: PACO17.O.2.5 biotinylated, tumor with liquid cyst; 
M: PACO17.O.1.1 non biotinylated control;  N: PACO17.O.2.1 non biotinylated control; 
O: PACO3.O.1.1 staining negative control;  P: PACO3.O.2.3 liver metastases stainings negative 
control;  Q: PACO17.O.2.2 staining negative control; R: PACO17.O.2.4 staining negative control. 
(Scale bars: 100 μm). 
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Figure 18 includes representative immunofluorescence stainings of the analyzed samples. 
As it can be observed, tumors which had been estimated as optimally perfused exhibited a 
strong biotin signal (Figure 18 A  E for PACO3 tumors; I and J for PACO17 tumors). The 
biotinylation positive signal was not restricted to areas in the immediate vicinity of the CD31 
positive cells, thus indicating a good level of penetration for the reactive biotin ester used 
for the experiment. The spontaneous liver metastasis collected from one of the PACO3 
tumor bearing mice was also optimally perfused (Figure 18 E). For the mice with suspected 
suboptimal perfusion, the biotin signal was indeed very low or absent, independent on the 
CD31 staining (Figure 18 F  G PACO3 tumors). In the case of PACO17, two of the 
collected primary tumors harbored a large liquid cyst at the center of the cancerous lesions, 
and to our surprise, despite what appeared to be a good body perfusion, the biotinylation 
signal recorded within the tumor was either very low (Figure 18 K), or absent (Figure 18 L). 
In nonbiotinylated control samples we could not detect any biotin signal (Figure 18 H and 
M  N), thus confirming the specificity of our detection system. Negative staining controls 
(Figure 18 O  R) could confirm the specificity of our primary and secondary 
immunofluorescence detection system. We also performed IF stainings on biotinylated liver 
samples, for additional confirmation of the whole body perfusion efficiency. As expected, 
we could confirm a strong biotin signal in those liver samples collected from mice where a 
high biotin signal was also detected in the orthotopic pancreatic tumors, thus confirming the 
efficiency of the in vivo perfusion (data not shown).  
 
5.1.4.2 Evaluation and quantification of perfusion success using ELISA 
One of the first demands for optimal discovery and quantitative proteomics experiments is 
the proper normalization of the amount of starting material for each sample analyzed. As 
already discussed, the efficiency of the whole body perfusion of tumor bearing mice can 
vary between distinct animals, depending on the proficiency of the experimenter, the 
existence of biological impediments (a hypoperfused tissue area, a tendency of the animal 
to clot abnormally due to liver damage), the maintenance of constant physical parameters 
during the perfusion (temperature, homogeneous solutions), etc.  
In order to optimize the starting material for the mass spectrometric analysis, the amount of 
biotinylated protein needed to be determined in relation to the total protein concentration. 
For this reason we performed ELISA analyses, using a biotinylated albumin-based standard 
curve for quantification as described in Materials and Methods. Whole tumors where 
homogenized, and the total protein concentration was determined. 10-5 M total protein 
lysates were used for ELISA determination, as previously mentioned. We selected a 
number of tumors derived from each molecular subtype for this quantification experiment, 
based on the post perfusion evaluation of the biotinylation efficiency. Two classical 
(17.O.2.2 and 17.O.2.3), three exocrine-like (3.O.1.2, 3.O.2.2 and 3.O.2.3) and four QM 
(8.O.1.3, 8.O.1.4, 8.O.2.2 and 8.O.2.3) PDAC derived tumors were evaluated for the 
amount of total biotinylated proteins and the detected levels  are presented in Figure 19.  
Results 
 
101 
 
 
Figure 19: ELISA based evaluation of the biotinylation efficiency in PACO derived primary tumor 
xenografts. 
Figure 19 indicates that tumors derived from different cell lines might be perfused with 
different efficiencies. PACO3 exocrine-like tumors for example showed the lowest level of 
biotinylation (~5 µg/mg total protein). By contrast, PACO8 QM derived tumors showed the 
highest level of biotinylation, with more than 20 µg/mg total protein. PACO17 tumors had 
intermediate biotinylation levels. 
 
5.1.4.3 Identification of novel protein biomarkers in vivo using mass 
spectrometry 
50 µg total biotinylated protein were enriched on a streptavidin column and analyzed as 
mentioned in the materials and methods chapter. Unlike the previous in vitro based 
discovery experiments, cysteines were alkylated and the enriched fraction was also 
delipidated using an organic solvent mixture, as decided upon optimization experiments.  
For an initial proof of principle experiment, we selected two classical derived primary tumors 
(17.O.2.2 and 17.O.2.3) and one exocrine-like primary tumor (3.O.1.2). MS2 spectra 
obtained from each sample were searched against a mixed human and mouse data base. 
The assignment of one protein to the human or mouse proteome was dependent upon the 
identification of at least one species specific proteotypic peptide, as determined by the 
Paragon algorithm.  
In total, we identified 530 proteins in the three analyzed samples, out of which 177 were 
designated by the Paragon algorithm to be of human origin. Selected top hits and other 
interesting proteins identified are listed in Table 13. 
Some of the putative PDAC markers we had selected for future validations, based on the in 
vitro discovery experiments could also be detected in vivo, such as: LCN2 (present in all 
three analyzed samples) and LGALS4. Surprisingly however, we identified LGALS4 in only 
one sample, belonging to the classical subtype PDAC, namely PACO17 derived tumor 
17.O.2.3. Although the number of samples analyzed does not allow any generalized 
conclusions, it was reassuring to rediscover some of the top hits derived from the in vitro 
discovery experiment in the xenografted tumor material. Some proteins appeared to be 
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present only in the two classical PDAC tumors (such as integrin α-6), or only in the exocrine-
like sample (pancreatic alpha-amylase). The mouse form of the digestive enzyme 
pancreatic alpha-amylase could also be detected, this time in all three analyzed tumors. 
Some of the top mouse specific proteins included ECM proteins (various collagen chains, 
integrins – see also Supplementary Material). Complement proteins secreted by the 
mouse-derived stromal cells were also identified. This observation is in line with literature 
data, indicating that complement system proteins can be also produced by the pancreas 
[139]. Based on these preliminary data, it is too early to draw a conclusion whether the 
mouse tumor associated proteome features components exclusively associated with 
distinct PDAC molecular subtypes. Examples of such putative subtype associated proteins 
deduced upon a first in vivo analysis could be represented by: galectin-1 (identified in the 
two classical tumors), ferritin heavy chain and moesin (present in the stromal fraction of the 
PACO3 exocrine-like tumor). Further analyses are required to distinguish if these proteins 
are truly associated with distinct molecular subtypes, or only with the particular cell lines we 
took for analysis.  
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Table 13 Selected proteins identified in the course of the in vivo proteomic discovery experiments, using orthotopic pancreatic tumors grown in 
immunocompromised mice. Both human and mouse specific proteins are listed 
 Max number of peptides identified 
Protein Name Gene Name SwissProt Species 
PACO17 
17.O.2.2 
PACO17 
17.O.2.3 
PACO3 
3.O.1.2 
Collagen alpha-1(I) chain Col1a1 P02452 HUMAN  28 46 
Mucin-5AC (Fragments) MUC5AC P98088 HUMAN 8 2  
Pancreatic alpha-amylase AMY2A P04746 HUMAN   6 
Integrin alpha-6 Itga6 P23229 HUMAN 5 2  
Collagen alpha-1(IV) chain Col4a1 P02462 HUMAN  4 1 
Laminin subunit beta-1 LAMB1 P07942 HUMAN 3  2 
Laminin subunit gamma-1 Lamc1 P11047 HUMAN 3 2  
Galectin-4 LGALS4 P56470 HUMAN 3   
Integrin alpha-5 Itga5 P08648 HUMAN  3  
Neutrophil gelatinase-associated lipocalin LCN2 P80188 HUMAN 1 1 2 
Integrin alpha-V Itgav P06756 HUMAN   3 
Plectin PLEC Q15149 HUMAN  2 2 
Pancreatic alpha-amylase Amy2 P00688 MOUSE 7 4 16 
Complement C3 C3 P01027 MOUSE 50 35 69 
Collagen alpha-1(I) chain Col1a1 P11087 MOUSE 45 55 114 
Collagen alpha-2(I) chain Col1a2 Q01149 MOUSE 40 55 105 
Collagen alpha-1(III) chain Col3a1 P08121 MOUSE 21 28 61 
Ferritin heavy chain Fth1 P09528 MOUSE   3 
Galectin-1 Lgals1 P16045 MOUSE 2 1  
Complement C2 C2 P21180 MOUSE 4 1  
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Additionally, we also performed gene ontology enrichment analysis on the human specific, 
as well as the mouse specific protein fractions identified. An enrichment for proteins located 
in the extracellular compartment, basement membrane as well as basal lamina components 
could indeed be confirmed (Figure 20). However, for the human fraction, we identified 
several proteins with predicted intracellular localization.  
Gene ontology analysis of the mouse specific list confirmed an enrichment of extracellular 
and secreted proteins upon the biotinylation and subsequent streptavidin pull down 
experiments (Figure 21). ECM components, basement membrane associated proteins as 
well as plasma constituents (such as plasma lipoprotein particles) were also enriched in our 
list of mouse specific proteins. 
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Figure 20: GO analysis of human proteins identified in the NSG mouse tumor xengrafts, upon performing in vivo biotinylation.  
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Figure 21: GO analysis of mouse proteins identified in the NSG mouse tumor xengrafts, upon performing in vivo biotinylation. 
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5.2 Validation of detected pan-PDAC and exocrine-like PDAC 
protein biomarker candidates 
Based on the list of cell surface proteins identified in the course of the large-scale 
proteomics investigation on in vitro biotinylated cell lines, we selected two exocrine-like 
(CDH17 and LGALS4) and two pan-PDAC (PCDH1 and LCN2) protein marker candidates 
for further validations. The selection of the four candidates was based on the abundance of 
the proteins in the cell lines analyzed. We additionally evaluated their putative biomarker 
potential after consulting the available literature data about their localization in healthy and 
disease tissues, their known interactions and their novelty for the field of PDAC and 
biomarker discovery. 
For all proteins of interest we performed thorough validations including antibody based 
(Western Blotting, Immunofluorescence) and antibody independent (SRM, RT-qPCR) 
methods. After first validating the expression patter of the four markers of interest in vitro 
(on cell lines), we investigated their presence in orthotopic xenografts developed in 
immunodeficient mice and patient material. 
 
5.2.1 In vitro antibody based methods 
Antibody based techniques used for validations are versatile and allow the evaluation of 
cellular localization for the antigen of interest, potential interactions between different 
antigens, or enable the distinction between different protein isoforms [31, 67]. Additionally, 
antibody based detection methods are commonly employed in the clinic, for the evaluation 
of markers circulating in the blood (ELISA), or for investigating protein expression patterns 
in fixed tissue samples (IHC) [31]. 
 
5.2.1.1 In vitro validations 
5.2.1.1 In vitro validations using immunocytofluorescence 
We first investigated if the four proteins of interest are present exclusively on the subtype(s) 
of interest, and if they are localized on the cell surface of the cancer cells. For this reason, 
we performed immunocytofluorescence using cells grown on special cell inserts, as 
described in the methods chapter. With regard to the putative pan-marker LCN2, we 
performed the initial validations on EDTA detached cells, fixed in formalin and embedded 
in histogel, since the antibody of choice did not properly recognized the antigen after fixing 
the cells with methanol. 
 
For the two putative exocrine-like markers, IF stainings of methanol fixed cells showed a 
clear, exclusive expression of both CDH17 and LGALS4 on the exocrine-like cell lines: 
PACO3, PACO10, PACO14 and PACO18.  
In the case of CDH17, a clear and strong membrane staining could be observed on PACO10 
and PACO14 cell lines (Figure 22). PACO3 and PACO18 cells expressed CDH17 at lower 
levels, and in the case of PACO18 the staining pattern suggested the presence of some of 
the protein of interest in the cytoplasm of the cells. No distinguishable membrane staining 
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could be identified in classical or QM PACO cell lines, nor in the healthy and isotype 
controls. Potential back-ground staining could be reported in the case of some cell lines 
such as PACO19, PACO7 and the control cell line HPDE. We therefore performed 
additional experiments, in order to evaluate if the cytoplasmic signal reported in some of the 
non-exocrine-like cell lines could be attributed to background noise or atypical cellular 
localization. The complete panel of isotype control staining can be found in Supplementary 
Figure 1.  
 
Figure 22: In vitro IF validation of putative exocrine-like marker CDH17 on PACO and control cell 
lines. A: PACO3; B: PACO10; C: PACO14; D: PACO18; E: PACO2; F: PACO17; G: PACO19; 
H: PACO20; I: PACO7; J: PACO8; K: PACO9; L: PACO16; M: HPDE; N: HPNE; O: PACO10 isotype 
control; P: PACO14 isotype control (Scale bars: 50µm). 
 
LGALS4 immunocytofluorescence staining revealed a strong honey-comb pattern staining 
(indicating membrane localization of the protein) in all cell lines belonging to the exocrine-
like subtype (Figure 23). In accordance with literature data, we could also observe 
cytoplasmic staining in these cell lines, and some putative nuclear localization in the case 
of cell lines PACO10 and PACO3 (data not shown). But for the exocrine-like subtype, no 
relevant staining for LGALS4 could be reported, with the exception of weak cytoplasmic 
signals present in classical cell lines PACO17 and PACO20. However, based on the IF data 
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alone we cannot distinguish if the observed signal represents actual cytoplasmic staining, 
or simply a higher background. Additional isotype control stainings are available in 
Supplementary Figure 2. 
 
Figure 23: In vitro IF validation of putative exocrine-like marker LGALS4 on PACO and control cell 
lines. A: PACO3; B: PACO10; C: PACO14; D: PACO18; E: PACO2; F: PACO17; G: PACO19; 
H: PACO20; I: PACO7; J: PACO8; K: PACO9; L: PACO16; M: HPDE; N: HPNE O: PACO3 isotype 
control; P: PACO14 isotype control (Scale bars: 50µm). 
 
For putative pan-PDAC marker LCN2 we performed stainings using EDTA detached 
histogel-embedded cells, since our antibody of choice did not stain methanol fixed cells. As 
shown in Figure 24, all tested PACO cell lines were positive for LCN2 staining, although 
the level of expression as well as the preferential localization of the protein varied greatly 
between cell lines, and even between clones isolated from the same patient. A stronger 
staining could be reported for cell lines PACO3, PACO8, PACO9, PACO14, PACO17, 
PACO19 and PACO20, where a membrane localization of the signal could also be deduced. 
PACO10 and PACO18 displayed a less intense signal, although it seemed to be mostly 
localized on the cell surface of the proteins, or associated with the membrane. PACO2 and 
PACO7 cells displayed weak staining, which appeared to be mostly localized in the 
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cytoplasm. It is interesting to observe great differences in staining intensity between cell 
lines PACO3 and PACO10, isolated from the same patient, and an even more striking 
difference between genetically identical cell lines PACO7 (displaying very low staining) and 
PACO8. Despite the fact that we could not detect any LCN2 expression in control cell lines 
after performing MS analysis of membrane fraction enriched samples, our IF stainings 
revealed a positive staining in the cytoplasm of HPNE cell lines. However, in line with our 
proteomics data, no membrane staining could be observed. The complete set of negative 
controls (samples incubated with the secondary antibody only) can be found in 
Supplementary Figure 3.  
 
Figure 24: In vitro IF validation of putative pan-PDAC marker LCN2 on histogel embedded PACO 
and control cell lines. A: PACO3; B: PACO10; C: PACO14; D: PACO18; E: PACO2; F: PACO17; G: 
PACO19; H: PACO20; I: PACO7; J: PACO8; K: PACO9; L: PACO16; M: HPDE; N: HPNE O: PACO2 
negative control; P: PACO9 negative control (Scale bars: 50µm). 
 
In vitro fluorescent staining of the putative pan-PDAC marker PCDH1 showed variable 
levels of intensity in the investigated PACO cell lines (Figure 25). We could report the 
strongest stainings in QM cell lines, with PACO8 standing out with the most intense 
membrane signal observed among the investigated cell lines. Classical cell lines showed a 
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moderate staining, while the lowest staining intensity could be reported in exocrine-like cell 
lines, particularly PACO14 and PACO18. Besides weak cytoplasmic staining, a very clear 
sharp membrane staining could be easily detected in all PDAC cell lines, including the ones 
with the lowest overall level of staining. No clear membrane staining could be reported in 
the two control cell lines. The corresponding isotype controls confirmed the detected signal 
not to be the result of unspecific background (pictures O and P, Figure 25 and 
Supplementary Figure 4). 
 
Figure 25: In vitro IF validation of putative pan-PDAC marker PCDH1 in PACO and healthy control 
cell lines. A: PACO3; B: PACO10; C: PACO14; D: PACO18; E: PACO2; F: PACO17; G: PACO19; 
H: PACO20; I: PACO7; J: PACO8; K: PACO9; L: PACO16; M: HPDE; N: HPNE; O: PACO2 isotype 
control; P: PACO8 isotype control (Scale bars: 50µm). 
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5.2.1.1.2 Assessment of potential co-localization of exocrine-like protein 
biomarker candidates using confocal laser microscopy 
In order to evaluate if the two putative exocrine-like protein markers could be interacting 
partners, we performed co-staining of cells grown on cell inserts and evaluated their 
localization using confocal laser microscopy. For this purpose, we took advantage of the 
fact that the primary mouse monoclonal antibodies raised against CDH17 and LGALS4 
were of different isotypes. By using secondary antibodies raised against distinct mouse IgG 
isotypes, we were able to detect simultaneously the two antigens of interest. Fluorescent 
detection was achieved after using Alexa-dye labeled tertiary antibodies, recognizing the 
species of origin of the secondary antibodies. 
We investigated the potential co-localization of CDH17 and LGALS4 on two exocrine-like 
cell lines (PACO10 and PACO25), one classical cell line – PACO2, and the QM cell line 
PACO9. New exocrine-like cell lines PACO25 and PACO26 were obtained from Dr.Elisa 
Espinet (HI-STEM; Metastasis Initiating Cells group).  
In the case of the two exocrine-like cell lines, we observed strong membrane staining for 
CDH17 and cytoplasmatic as well as potential membrane staining for LGALS4 (Figure 26). 
In the classical and QM cell lines only weak background staining could be reported. 
Negative controls in which both secondary antibodies were excluded from the experiment 
were also performed in parallel, and revealed no unspecific background originating from the 
tertiary fluorescently labeled antibodies. After performing confocal laser microscopy of co-
stained cells, we could detect areas were the two antigens co-localize. The co-localization 
seemed to occur, as expected, at the cell surface level and not intracellular. 
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Figure 26: CDH17 and LGALS4 co-staining in vitro. From left to right: Alexa-488 and Alexa-647 
channel merge; Alexa-488 channel (CDH17); Alexa-647 channel (LGALS4); negative control (no 
secondary antibodies) Alexa-488 and Alexa-647 channel merge. From top to bottom: PACO10 (A); 
PACO25 (B); PACO2 (C); PACO9 (D). (Scale bars: 50 μm). 
 
In order to evaluate the specificity of the secondary antibodies, we performed control 
stainings, excluding one of the secondary antibodies. Similarly, we checked the specificity 
of the tertiary antibody by selectively excluding one tertiary antibodie and investigating if the 
corresponding fluorescent signal could still be detected. No cross reactivity of the secondary 
or tertiary antibodies could be detected after performing the above mentioned controls 
(Figure 27). 
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Figure 27: CDH17 and LGALS4 co-staining in vitro – control stainings assessing cross-reactivity of 
the secondary anti-mouse IgG1/anti-mouse IgG2a and tertiary anti-rat/anti-goat antibodies. 
A: PACO25 stained with CDH17 and LGALS4 primary antibodies + secondary rat anti-IgG1 
(detecting CDH17 primary antibody); B: PACO25 stained with CDH17 and LGALS4 primary 
antibodies + secondary goat anti-IgG2a (detecting LGALS4 primary antibody). C: PACO10 stained 
with CDH17 and LGALS4 primary antibodies + secondary isotype specific antibodies + tertiary 
donkey anti-rat (detecting CDH17); D: PACO10 stained with CDH17 and LGALS4 primary antibodies 
+ secondary isotype specific antibodies + tertiary donkey anti-goat (detecting LGALS4). (Scale bars: 
50 μm). 
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5.2.1.1.3 Assessment of isoform distribution of pan-PDAC biomarker 
candidate PCDH1 using Western Blotting 
Multiple isoforms have been reported in literature for PCDH1, although insufficient data exist 
about their distinct functions [119]. We wanted to investigate if PCDH1 expressed by PACO 
cell lines is represented predominantly by a single isoform, or if we can distinguish a subtype 
specific pattern of isoform expression. The monoclonal mouse anti-PCDH1 (clone 5D5) 
antibody employed was raised against a synthetic peptide, corresponding to the N-terminal 
domain of PCDH1. Therefore, the epitope recognized by the monoclonal antibody is 
common for both isoform 1 and isoform 2 of PCDH1. Although the 5D5 anti-PCDH1 
antibody cannot directly discriminate between the two major isoforms of the protein, 
molecular weight differences reported between the two splice forms can in the end be used 
to discern signals originating from different isofoms. 
Isoform 2 of PCDH1 contains an additional C-terminal domain, consisting of approximately 
200 aminoacids. After analyzing the peptide sequences identified by the Paragon algorithm 
with 99% confidence in our cell surface proteomics identification experiment, we were able 
to confirm the presence of peptides spanning the unique C-terminal domain of PCDH1 
isoform 2. Figure 28 shows the alignment of isoforms 1 and 2 for PCDH1, performed using 
the ClustalW alignment tool (for simplification purposes, we selected for representation only 
the C-terminal sequences starting at position 900 for both isoforms). Identified peptides, 
common for both isoforms are marked in green, whereas isoform 2 specific peptides are 
highlighted in yellow. Considering the complete list of PCDH1 peptides, identified with a 
99% confidence in all the samples analyzed during the cell surface proteome identification 
experiment, we could confirm a protein coverage of approximately ~28.5% for isoform 2 of 
PCDH1. The complete alignment of the two isoform sequences is presented in 
Supplementary Materials.       
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Figure 28: Alignment of isoform 1 (higher lane) and isoform 2 (lower lane) of PCDH1 performed 
using ClustalW tool. In green: peptides identified common to both isoforms. In yellow: isoform 2 
specific peptides identified. For simplification purposes, the presented alignment commences at 
position 900 for both isoforms. 
To further evaluate PCDH1 isoform distribution in the PACO cell lines, we performed WB 
analysis using whole cell lysates, as described in the methods section. GAPDH was 
employed as loading control. 
As presented in Figure 29, we detected in most PACO cell lines a single band with an 
approximate molecular weight of 135 kDa, corresponding most likely to isoform 2 of PCDH1. 
These observations were in line with the MS/MS data, which allowed the identification of 
peptides specific to isoform 2 alone in several of the cell lines analyzed (data not shown). 
In the case of PACO20, an additional band could also be detected, at a higher molecular 
weight. We could not determine if the additional band represents a hyper glycosylated form, 
or another splice isoform of the protein. No band corresponding to PCDH1 protein could be 
detected in either of the healthy control cell lines.  
According to the WB experiment, the highest PCDH1 signal could be detected in PACO20 
cell line. High amounts of the protein could also be detected in PACO8, PACO9 and cells 
belonging to the classical subtype, mostly confirming the observations of the in vitro IF 
experiments (see Figure 25). Surprisingly, we could not detect any PCDH1 signal in the 
cell line PACO16.  
 
Figure 29: Western Blot analysis of PCDH1 expression in PACO and control cell lines using whole 
cell lysates.  
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sp|Q08174|PCDH1_HUMAN        PSGKASKGNKSKGKKSKSPKPVKPVEDEDEAGLQKSLKFNLMSDAPGDSP 
sp|Q08174-2|PCDH1_HUMAN      PSGKASKGNKSKGKKSKSPKPVKPVEDEDEAGLQKSLKFNLMSDAPGDSP 
                             ************************************************** 
 
sp|Q08174|PCDH1_HUMAN        RIHLPLNYPPGSPDLGRHYRSNSPLPSIQLQPQSPSASKKHQVVQDLPPA 
sp|Q08174-2|PCDH1_HUMAN      RIHLPLNYPPGSPDLGRHYRSNSPLPSIQLQPQSPSASKKHQVVQDLPPA 
                             ************************************************** 
 
sp|Q08174|PCDH1_HUMAN        NTFVGTGDTTSTGSEQYSDYSYRTNPPKYPSKQVGQPFQLSTPQPLPHPY 
sp|Q08174-2|PCDH1_HUMAN      NTFVGTGDTTSTGSEQYSDYSYRTNPPKYPSKQLPHRRVTFSATSQAQEL 
                             *********************************: :     :. . .:   
 
sp|Q08174|PCDH1_HUMAN        HGAIWTEVWE---------------------------------------- 
sp|Q08174-2|PCDH1_HUMAN      QDPSQHSYYDSGLEESETPSSKSSSGPRLGPLALPEDHYERTTPDGSIGE 
                             :..   . ::                                         
 
sp|Q08174|PCDH1_HUMAN        -------------------------------------------------- 
sp|Q08174-2|PCDH1_HUMAN      MEHPENDLRPLPDVAMTGTCTRECSEFGHSDTCWMPGQSSPSRRTKSSAL 
                                                                                
 
sp|Q08174|PCDH1_HUMAN        -------------------------------------------------- 
sp|Q08174-2|PCDH1_HUMAN      KLSTFVPYQDRGGQEPAGAGSPSPPEDRNTKTAPVRLLPSYSAFSHSSHD 
                                                                                
 
sp|Q08174|PCDH1_HUMAN        ------------------------------------- 
sp|Q08174-2|PCDH1_HUMAN      SCKDSATLEEIPLTQTSDFPPAATPASAQTAKREIYL 
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5.2.1.2 In vivo immunohistofluorescence validations using mouse derived 
xenografts 
In order to evaluate if the markers present in vitro on the surface of the pancreatic cancer 
cells maintain their pattern of expression in vivo, we performed IF experiments using 
pancreatic tumor xenografts grown in immunocompromised NSG mice. As previously 
described, PACO cells were injected in the head of the pancreas of male mice and the 
tumors were allowed to grow until they reached ~1 cm in diameter. Mice were sacrificed 
and pancreatic tumors, as well as any growing liver or lung metastasis were preserved in 
formalin and latter embedded in paraffin. In addition, we received three novel xenografts 
from Dr. Elisa Espinet (HI-STEM, Metastasis Initiating Cells group), derived from the novel 
exocrine-like cell lines PACO25, PACO26 and PACO28. In parallel we also analyzed the 
pancreas of healthy NSG male mice and human healthy pancreas samples obtained from 
patients undergoing tumor resection (material provided by Dr. Elisa Espinet).  
When injected into NSG mice, PACO cells developed tumors with distinct histologies, 
depending on the molecular subtype to which they are annotated. Exocrine-like and 
classical xenografts often exhibited ductal like structures; whereas QM derived tumors 
usually display a poorly differentiated histology. One representative xenograft for each 
molecular subtype is shown in Figure 30 – slides were stained only with haematoxylin, and 
were selected from the panel of isotype controls performed for IHC experiments on paraffin 
embedded orthotopic tumors developed in NSG mice. 
 
Figure 30: Haematoxylin staining of mouse derived PDAC tumors, revealing histological differences 
between the different molecular subtypes. A: PACO3 derived tumor (exocrine-like); B: PACO19 
derived tumor (classical); C: PACO9 derived tumor (QM). (Scale bars: 100µm). 
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CDH17 expression in vivo confirmed most of the initial observations made in vitro. Primary 
tumors derived from exocrine-like PACO cell lines showed as expected a clear membrane 
staining. These observations were also true for the novel tested PACO25, PACO26 and 
PACO28 cell line derived xenografts. However, PACO26 expressed lower levels of the 
exocrine-like putative biomarker. As it could also be reported in vitro, PACO18 CDH17 
staining remained weak (Figure 31). Additionally, we could report CDH17 expression in 
some of the classical derived pancreatic tumors, with PACO19 showing the strongest 
expression, including a clear membrane staining. QM derived xenografts remained negative 
for the exocrine-like marker, despite showing a significant back ground, which could also 
be reported in the isotype controls (Supplementary Figure 5). We could not detect any 
expression for CDH17 neither in the two healthy human controls, nor in healthy mouse NSG 
pancreata. The signal contrast for the Alexa-488 channel was processed, after picture 
acquisition, using the same parameters for all samples, in the ZEN lite 2012 software, for 
better visualization. Due to significant back-ground staining, typical for the healthy mouse 
pancreas, the contrast of the acquired picture for the healthy NSG pancreata staining was 
not modified. 
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Figure 31: CDH17 staining in vivo using PACO derived pancreatic tumors in NSG mice and 
comparison to healthy pancreas isolated from human and mouse. A: PACO3, B: PACO10; C: 
PACO14; D: PACO18; E: PACO25; F PACO26; G: PACO 28; H: PACO2; I: PACO17; J: PACO19; 
K: PACO20; L: PACO7; M: PACO8; N: PACO9; O: PACO16; P: human healthy pancreas patient 
# 4984; Q: healthy mouse NSG pancreas; R: PACO3 isotype control; S: PACO28 isotype control. 
(Scale bars: 50 μm). 
We also investigated if CDH17 protein levels are up- or down-regulated in different 
metastatic lesions. For this reason, we employed PACO10 and PACO20 spontaneous lung 
and liver metastases, and compared the intensity of the staining to that of the primary tumor 
(Figure 32). As it can be observed in Figure 32 for the PACO10 derived tumors we could 
observe an increase in signal intensity in the metastasis compared to the primary tumor, 
indicating a stronger expression of CDH17 in the liver metastasis. A similar observation 
Results 
 
120 
 
could be made for PACO3 spontaneous liver metastases, when the tissue was embedded 
in OCT and stained for CDH17 (data not shown). However, in the PACO10 lung metastasis, 
CDH17 expression seemed to be completely absent, when compared to the isotype control 
(both positive and isotype staining had a high background). For the classical cell line 
PACO20, we could as well observe a significant increase in the intensity of CDH17 staining 
in the metastases, with a clear membrane pattern for lung metastases. Unfortunately, no 
liver metastasis was available for comparison staining. Additional experiments will be 
required to asses if CDH17 is typically up-regulated in metastatic cells, and if the organ 
harboring the secondary cancer and the molecular subtype dictate the expression pattern.  
 
Figure 32: CDH17 expression in primary tumor and metastasis. A: PACO10 tumor pancreas; 
B: PACO10 lung metastasis; C: PACO10 liver metastasis; D: PACO20 tumor pancreas; E: PACO20 
lung metastasis. The lower panel of pictures (F  J) includes the isotype controls corresponding to 
the A  E positive stainings. (Scale bars: 50 μm). 
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LGALS4 IF in vivo revealed a strong staining in all exocrine-like derived xenografts, with 
the signal localizing both in the cytoplasm and at the plasma membrane (Figure 33). In the 
case of PACO14 and PACO25 originating tumors, the cytoplasmatic staining appeared less 
intense, while most of the protein was either localized at the plasma membrane, or 
associated with the cell surface. As reported for CDH17, we could also observe an in vivo 
activation of LGALS4 in some xenografts derived from classical cell lines – PACO17 
showed a low expression, while the LGALS4 levels of PACO19 appeared to be comparable 
to the ones observed for the exocrine-like pancreatic tumors. QM derived cancers were 
mostly negative for LGALS4, with the exception of PACO16, where a moderate LGALS4 
expression could be detected. The pancreas of healthy NSG mice was negative for 
LGALS4, while we could detect a moderate cytoplasmic and potentially membrane staining 
in the healthy human pancreas sample obtained from resected pancreata. No unspecific 
signal could be detected in the appropriate isotype control stainings (Supplementary 
Figure 6). 
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Figure 33: LGALS4 in vivo staining using PACO derived pancreatic tumors in NSG mice and 
comparison to healthy pancreas isolated from human and mouse  A: PACO3, B PACO10; C: 
PACO14; D: PACO18; E: PACO25; F PACO26; G: PACO 28; H: PACO2; I: PACO17; J: PACO19; 
K: PACO20; L: PACO7; M: PACO8; N: PACO9; O: PACO16; P: human healthy pancreas patient 
# 4984; Q: healthy mouse NSG pancreas; R: PACO10 isotype control; S: PACO18 isotype control. 
(Scale bars: 50 μm). 
 
When investigating the presence of LGALS4 in PACO10 (exocrine-like) and PACO20 
(classical) spontaneously derived metastases (Figure 34), we could report similar patterns 
as earlier described for CDH17. LGALS4 staining was absent in lung metastases derived 
from the exocrine-like cell line PACO10. In the liver metastases however, the staining 
intensity was similar to that detected in the primary tumor and the likely originated from the 
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cytoplasm and the membrane of metastatic tumor cells. PACO20 primary tumor staining for 
LGALS4 was negligible. A strong activation of LGALS4 protein expression could be 
reported in the lung metastases, with the majority of the fluorescent signal originating from 
the cytoplasm (Figure 34). Isotype control staining confirmed that the observed signals 
were not the result of unspecific antibody binding. 
 
Figure 34: LGALS4 expression in primary tumors and metastases: A: PACO10 tumor pancreas; 
B: PACO10 lung metastasis; C: PACO10 liver metastasis; D: PACO20, tumor pancreas; E: PACO20 
lung metastasis. The lower panel of pictures (F  J) includes the isotype controls corresponding to 
the A  E positive stainings. (Scale bars: 50 μm). 
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For the putative pan-PDAC marker LCN2, in vivo IF results indicated that most pancreatic 
cancer cell lines continue to produce the protein at high levels after injection into NSG 
mouse pancreas (Figure 35). Some of the strongest expression could be detected for 
exocrine-like xenografts, as well as tumors derived from classical cell lines PACO19 and 
PACO20. Lower expression could be reported for the exocrine-like tumor PACO26 and the 
primary cancer derived from the PACO8 QM cell line. No clear signal could be detected for 
PACO2, PACO17 (classical PDAC) and PACO7 (QM PDAC) pancreatic tumors. For 
PACO2 and PACO7 the results are in agreement with previous in vitro validation 
experiments, where very low levels could be reported for the corresponding samples. LCN2 
staining was negative both in two healthy human pancreatic samples (only patient # 4984 
is presented in Figure 35), and in the pancreata of healthy NSG mice. With regard to the 
localization of LCN2 in mouse PDAC xenografts, we could observe that most staining 
appeared to be cytoplasmic and potentially membrane associated. A relatively clear extra-
cellular staining could be reported for PACO18 tumors (exocrine-like PDAC). For some 
xenografts, a stronger LCN2 staining became apparent for ductal like structures, at the 
apical level (in the case of PACO14, PACO16, PACO25). The complete panel of isotype 
controls is provided in Supplementary Figure 7. 
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Figure 35: LCN2 in vivo staining of PACO derived pancreatic tumors in NSG mice and comparison 
to healthy pancreas isolated from human and mouse  A: PACO3, B PACO10; C: PACO14; D: 
PACO18; E: PACO25; F PACO26; G: PACO 28;  H: PACO2; I: PACO17; J: PACO19; K: PACO20 
L: PACO7; M: PACO8; N: PACO9; O: PACO16; P: human healthy pancreas patient #4984; 
Q: healthy mouse NSG pancreas; R: PACO25 isotype control; S: PACO16 isotype control. 
(Scale bars: 50 μm). 
LCN2 expression in metastatic lesions appeared to vary greatly, depending on the 
originating cell line. For documenting the LCN2 IF in primary and secondary tumors in 
parallel, the intensity of the 488 nm laser was adjusted for optimal detection to the high 
fluorescence signal recorded for the PACO10 metastases samples. Thus, a significant 
upregulation of LCN2 can be clearly observed for both PACO10 derived liver and lung 
spontaneous metastases when compared to the primary tumor (Figure 36). In the PACO20 
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classical tumors on the other hand, the LCN2 signal disappeared in the lung metastases 
(metastatic areas are delineated in white). More samples need to be analyzed in order to 
appreciate if the metastases’s expression patterns currently reported can be extrapolated 
to the whole panel of secondary cancers originating from the same molecular subtype 
PDAC.  
 
Figure 36: LCN2 expression in primary tumor and metastases: A: PACO10 tumor pancreas; 
B: PACO10 lung metastasis; C: PACO10 liver metastasis; D: PACO20, tumor pancreas; E: PACO20 
lung metastasis. The lower panel of pictures (F  J) includes the isotype controls corresponding to 
the A  E positive staining. (Scale bars: 50 μm). 
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PCDH1 in vivo staining showed great variance in terms of expression levels in the different 
samples (Figure 37). Some of the highest signals could be detected for exocrine-like 
xenografts derived from the PACO3, PACO10 and PACO14 cell lines. A strong, likely 
membrane staining, could be detected for the majority of the analyzed xenografts, clearly 
exemplified by PACO14, PACO7, PACO8, PACO19 and PACO16 tumors. One of the best 
examples of strong localized PCDH1 membrane staining can be observed in Figure 37M 
where the positive staining pattern is clearly distinguishable from the isotype control 
(Figure 37R), especially when taking into consideration that the pictures were taken in 
identical areas of consecutive cuts made from the same paraffin block. The extent of the 
PCDH1 positive areas varied as well amongst samples: for example, in the case of PACO7 
samples, we could detect only small areas of clear membrane staining (data not shown). 
For PACO10 xenografts on the other hand, the majority of the primary tumor was positive 
for PCDH1. Despite being one of the highest PCDH1 expressing cell lines in vitro, PACO9 
showed no detectable staining after transplantation into NSG mice. PACO23 primary tumor 
appeared also negative for PCDH1 (compared to the staining with the isotype control, 
available in Supplementary Figure 8). PACO26 xenografts showed low staining for 
PCDH1, which appeared to be localized at the basal and apical level of the cancer cells. 
Healthy human and mouse pancreata were negative for PCDH1 (albeit a strong background 
could be detected in the case of the mouse pancreatic tissue). 
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Figure 37: PCDH1 in vivo stainings of PACO derived pancreatic tumors in NSG mice and 
comparison to healthy pancreas isolated from human and mouse A: PACO3, B PACO10; C: 
PACO14; D: PACO18; E: PACO25; F PACO26; G: PACO 28; H: PACO2; I: PACO17; J: PACO19; 
K: PACO20; L: PACO7; M: PACO8; N: PACO9; O: PACO16; P: human healthy pancreas patient # 
4984; Q: healthy mouse NSG pancreas; R: PACO8 isotype control; S: PACO10 isotype control. 
(Scale bars: 50 μm). 
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5.2.1.3 In vivo validations on patient material  
Original human primary pancreatic tumors from which the patient matched PACO cell lines 
were derived, was available for testing (courtesy of Dr.Christian Eisen, HI-STEM). We set 
out to investigate if the expression profile of the markers of interest identified in vitro 
matched that of the original tumor. Unfortunately we did not have original tumor material for 
all the derived cell lines and in some cases the tumor pieces stored in paraffin were highly 
necrotic, with very few and sometimes very small ductal-like tumor areas making the 
validation experiments difficult. Additionally, tumors with a high stromal component are 
associated with a higher tissue autofluorescence, thereby hindering the IF based validation 
experiments. At the time at which this report was written, no confocal fluorescent 
microscope including a spectral unmixing function, for the removal of the autofluorescent 
unspecific signal, was available for the analysis of the patient stainings. The molecular 
subtype for each patient primary tumor has been determined by Dr. Christian Eisen (HI-
STEM), even for those samples from which no cell line could be stabilized in vitro. 
CDH17 stainings of the original tumors revealed a clear signal in the respective patient 
material (PACO14, PACO18) with areas that could be interpreted as membrane restricted 
stainings. However, high back ground signals could be detected especially in the patient 
tumors from which the QM tumors had been derived (Figure 38). Due to lack of primary 
material not all the proper negative controls could be performed.  
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Figure 38: CDH17 stainings on patient original tumors. For simplification purposes, sample names 
were correlated to the PACO cell lines used in the proteomics investigation. A: PACO14; B: PACO18; 
C: Putative exocrine patient; D: PACO2; E: PACO17; F: PACO19; G: PACO7; H: PACO16. (Scale 
bars: 50 μm). 
LGALS4 staining profiles were less obvious for the patient material, compared to those 
described for its putative partner of interaction. As shown in Figure 39, patient samples 
from which PACO14, PACO19 and PACO16 samples were derived appeared to express 
medium and high levels of LGALS4, matching the mouse derived xenografts staining 
profiles previously presented. However, the nonspecific background signal observed in the 
isotype control staining renders the delineation of a clear conclusion impossible. Especially 
in the case of the QM patient from which the PACO7 cell line was derived, the background 
fluorescence was almost identical in intensity to that detected in the stained sample. 
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Figure 39: LGALS4 stainings on patient original tumors: Samples names were correlated to the 
PACO cell lines which had been stabilized in culture. A: PACO14; B: PACO18; C: Putative exocrine 
patient; D: PACO2; E: PACO17; F: PACO19; G: PACO7; H: PACO16; I: PACO7 isotype control; J: 
PACO19 Isotype control; K: PACO14 isotype control. (Scale bars: 50 μm). 
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In the case of putative pan-PDAC marker LCN2, the most intense staining could be 
observed in patients diagnosed with exocrine-like PDAC (Figure 40). A weaker LCN2 signal 
appeared to be present in the QM patients, while for the classical pancreatic cancerous 
lesions the back ground intensity did not allow the drawing of any relevant conclusion. 
 
 
Figure 40: LCN2 stainings on patient original tumors. Samples names were correlated to the PACO 
cell lines used in the proteomics investigation. A: PACO14; B: PACO18; C: Putative exocrine patient; 
D: PACO2; E: PACO17; F: PACO7; G: PACO16. (Scale bars: 50 μm). 
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5.2.2 Antibody independent methods: 
Pan-PDAC and exocrine-like subtype biomarker candidates were additionally validated by 
antibody independent methods. First, the markers of interest were quantified by MRM 
targeted proteomics, using species specific, proteotypic peptides. Second, the gene 
expression level for the putative biomarkers was evaluated by RT-qPCR, both in vitro and 
in vivo, using either total tumor lysate or EpCAM+ tumor cells.  
 
5.2.2.1 In vitro validation and quantification of exocrine-specific biomarkers 
using MRM 
We performed validations and quantifications for the two putative exocrine-like markers in 
vitro using MRM. The method combines the advantages of a high sensitivity with the 
possibility of performing the analysis of species specific proteotypic peptides [54]. Whole 
cell lysates prepared using the RIPA buffer and supernatants collected after 48 hour 
incubation and cleared by ultracentrifugation were digested with trypsin and processed as 
detailed in the materials and methods chapter. The selection of proteotypic precursor 
peptides was performed using the in house developed MSQBAT software (courtesy of 
Alexander Kerner and Dr. Christoph Rösli, HI-STEM), and the open source software 
Skyline. For the relative quantification of exocrine-like protein marker candidates, we added 
heavy labeled peptides corresponding to each of the selected precursor peptides. The raw 
data were normalized by dividing the relative protein intensity, as determined after the SRM 
analysis, to the average intensity value of exocrine-like samples. The normalized relative 
protein expressions are presented in Figure 41. 
As it can be observed in Figure 41, we could detect a clear upregulation of both putative 
exocrine-like markers CDH17 and LGALS4 in the exocrine-like cell lines compared to the 
classical, QM and control cell lines when analyzing the whole cell proteome. The expression 
difference for the two putative exocrine-like markers in the total cell proteome was 
statistically significant, as determined by the Mann-Whitney two-tailed test (p value < 0.05). 
An upregulation of secreted CDH17 and LGALS4 could also be reported for the secretome 
samples, albeit the results were not statistically significant due to the low number of 
analyzed samples. 
When investigating the relative expression levels of CDH17, the highest values could be 
reported in cell lines PACO3, PACO10 and PACO14, with PACO18 expressing significantly 
lower levels. The secreted protein levels reflected the profile of the total cell proteome, with 
PACO10 cell medium representing the most abundant source of secreted/shed CDH17. 
LGALS4 expression was the highest in the cell lines PACO18 and PACO14, followed by 
PACO10 and PACO3. The relative amount of secreted LGALS4 could (as for CDH17) be 
correlated with the relative expression levels detected in the total cell proteome (Figure 41).  
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Figure 41: In vitro evaluation of protein expression levels for the exocrine-like putative markers 
CDH17 and LGALS4 by SRM. The analysis was performed on total cell lysates and secretome of 
cultured PACO and healthy control cell lines. Error bars represent the standard error of mean (SEM), 
calculated with the Prism software. 
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5.2.2.2 Evaluation of gene expression levels for the markers of interest using 
RT-qPCR 
After validating the presence of the markers of interest on in vitro cultured cells and mouse 
xenografts, we wanted to evaluate if the upregulation of the putative pan-PDAC and 
exocrine-like markers was due to changes in gene expression, or a result of a post-
transcriptional event. For this purpose, we performed RT-qPCR using both in vitro cultured 
cells, as well as xenograft samples. Primers were designed using the NetPrimer software. 
After aligning the human and mouse gene, we selected oligonucleotides that bound human 
specific sequences in the gene to be quantified. The primer pair for the RPL13a human 
housekeeping gene was provided by Dr. Arnaud Descot (HI-STEM, Metastatic Niches 
group) and we did not investigate its cross-binding to the mouse equivalent mRNA. 
Additionally, whenever possible, we designed primers that would amplify multi-exonic 
sequences, thus allowing the identification of any potential genomic DNA contamination of 
the RNA sample prior to reverse transcription, based on the size of the resulting amplicon.  
 
5.2.2.2.1 In vitro evaluation of gene expression levels for pan-PDAC and 
exocrine-like biomarker candidates using RT-qPCR 
For the in vitro evaluation of the mRNA levels, cells were grown on Primaria 6-well plates, 
lysed and total RNA was extracted using the RNeasy kit. cDNA amplification was performed 
using the SuperScript Vilo cDNA kit. 10ng cDNA were used for the RT-qPCR reaction, 
performed in triplicates, using biological duplicates of each cell line. GAPDH and RPL13a 
were used as reference genes for the relative quantification performed by the Viia7 1.0 
software from Thermo. 
Quantification of the gene expression levels for the two putative exocrine-like markers 
revealed a major upregulation of CDH17 and LGALS4 mRNA levels in the cell lines 
belonging to the exocrine-like subtype (Figure 42), compared to either control, classical or 
QM PDAC cells.  CDH17 mRNA levels were clearly upregulated in all exocrine-like cell 
lines, compared to all other subtypes and the healthy controls. We could however observe 
that some QM PACO cell lines expressed higher levels of the LGALS4 mRNA, compared 
to classical PDAC and control cell lines. Nonetheless, the levels detected in these QM 
PACO cell lines were inferior to those reported for the exocrine-like cell lines. The increased 
gene expression reported was statistically significant, as shown by the results of the two 
tailed Mann-Whitney test (** p< 0.01; *** p< 0.001). 
 
Results 
 
136 
 
 
Figure 42: In vitro quantification of CDH17 and LGALS4 mRNA levels by RT-qPCR. Statistical 
relevance was evaluated with the two tailed Mann-Whitney test (** p< 0.01; *** p< 0.001). Error bars 
represent the standard error of mean (SEM), calculated with the Prism software. 
 
For the pan-PDAC marker candidates investigated we observed a significant upregulation 
of the corresponding mRNA levels in all PDAC subtypes compared to the healthy controls 
(Figure 43). In both cases, we could report a difference in the mRNA levels of individual 
healthy control cell lines as well: HPDE cell lines expressed higher mRNA levels of both 
pan-PDAC marker candidates compared to the HPNE cell line. Also, for LCN2, we could 
observe a similar level of mRNA expression in the QM cell line PACO7 compared to the 
control cell line HPDE. However the increase in the gene expression level was significant, 
as indicated by the two tailed Mann-Whitney test (* p< 0.05; ** p< 0.01).  
 
 
Figure 43: In vitro quantification of pan-PDAC marker candidates LCN2 and PCDH1 by RT-qPCR. 
Statistical relevance was evaluated with the two tailed Mann-Whitney test (** p < 0.01; *** p < 0.001). 
Error bars represent the standard error of mean (SEM), calculated with the Prism software. 
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5.2.2.2.2 In vivo evaluation of gene expression levels for pan-PDAC and 
exocrine-like biomarker candidates using RT-qPCR on total tumor tissue and 
EpCAM+ cells 
We evaluated the gene expression levels of the four biomarker candidates in vivo by 
analyzing both the mRNA levels in EpCAM+ sorted cells and in total tumor tissue. The 
relative gene expression quantification was performed again using the two house-keeping 
genes previously mentioned (GAPDH and RPL13a). EpCAM+ cell sorting was performed 
using anti-human CD326 magnetic beads from Miltenyi. Total tumor tissue was lysed and 
RNA extraction was performed as detailed in Materials and Methods. 
In the case of the two putative exocrine-like markers CDH17 and LGALS4, the gene 
expression levels confirmed the observations of the previous in vivo IF stainings. Both 
genes were up-regulated in classical and exocrine-like xenografts compared to QM derived 
tumors (Figure 44). The up-regulation was comparable in both EpCAM+ isolated cells and 
in total tumor mRNA. 
The highest CDH17 expression could be detected in PACO19 (classical), and exocrine-like 
PACO14, PACO28 and PACO10 EpCAM+ cells. Total tumor tissue analysis revealed 
similar CDH17 gene expression patterns as for the EpCAM+ cell analysis, with PACO19, 
PACO3, PACO10 and PACO28 derived tumors having the highest levels of CDH17 mRNA. 
When comparing the expression level of CDH17 in classical and exocrine-like pancreatic 
tumors, only two classical cell lines appeared to express similar mRNA levels to the 
exocrine-like cells – PACO19 and occasionally PACO2. PACO20 originating tumors 
(classical subtype) expressed very low CDH17 mRNA levels, similar to many QM 
xenografts. The in vivo gene analysis experiments confirmed PACO18 as a low expressing 
CDH17 cell line, with PACO10 and the new cell line PACO28 at the opposite end of the 
spectrum. The commercially available total RNA extracted from healthy human pancreas 
revealed CDH17 mRNA levels similar to those detected in QM derived tumors. 
Overall, the LGALS4 gene expression was comparable in all exocrine-like derived tumors, 
with a lower relative expression detected only in PACO3 cells. Classical tumors expressed 
typically inferior levels compared to the above mentioned exocrine-like samples, except for 
PACO19 derived xenografts. LGALS4 levels were the lowest in QM tumors and in human 
healthy pancreatic total RNA. However, PACO16 QM derived tumors occasionally appear 
to up-regulate LGALS4 mRNA, as observed in the course of the in vivo experiments (see 
Figure 33).  
 
Results 
 
138 
 
 
Figure 44: Relative gene expression of CDH17 and LGALS4 exocrine-like marker candidate. The 
analysis was performed on total RNA extracted from EpCAM+ sorted cells, or from whole tumor 
tissue. Error bars represent SEM. Statistical relevance was evaluated with the two tailed Mann-
Whitney test (* p < 0.05; ** p < 0.01). 
 
The mRNA levels for the two pan-PDAC marker candidates – LCN2 and PCDH1 – were 
clearly elevated in all the PACO derived tumor xenografts compared to the healthy 
pancreatic tissue, as shown in Figure 45. The overall expression intensity was similar for 
all the analyzed tumors and for the corresponding EpCAM+ isolated cells. In the case of 
LCN2, a moderate increased expression could be detected in the exocrine-like derived 
EpCAM+ cells, compared to the classical and the QM derived epithelial tumor cells. The 
highest LCN2 expressing tumors in vivo were PACO14 derived xenografts, while the lowest 
levels could be detected in QM derived xenografts PACO7 and PACO8. PACO2, PACO28 
and PACO14 derived tumors were expressing some of the highest PCDH1 mRNA levels. 
 
 
Figure 45: Relative expression of LCN 2 and PCDH1 pan-PDAC marker candidates. The analysis 
was performed on total RNA extracted from EpCAM+ sorted cells and from whole tumor tissue. Error 
bars represent SEM. Statistical relevance was evaluated with the two tailed Mann-Whitney test 
(* p< 0.05). 
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6. Discussions 
 
In summary, the presented study lead to the identification and initial validation of novel cell 
surface and secreted pan-PDAC as well as subtype specific protein biomarker candidates, 
which can prime the development of new diagnostic and/or therapeutic clinical applications. 
The discovery experiments made use of a panel of patient derived primary pancreatic 
cancer cell lines (PACOs), grown in a chemically defined cancer stem cell culture medium. 
These cell lines, developed by Dr. Christian Eisen (HI-STEM, DKFZ), maintain the 
transcriptomic profile reported in the original patient tumor, even after serial passages, and 
they recapitulate all three PDAC molecular subtypes described in literature – namely 
exocrine-like, classical and quasimesenchymal. Additionally, when injected in the pancreas 
of immunodeficient mice, the cell lines give rise to tumors histologically similar to the original 
patient tumor. 
The initial proteomic discovery experiments focused on the cell surface proteome of 
pancreatic cancer cells, aiming to identify novel candidates for future antibody based 
targeted therapies. The plasma membrane associated proteins of cultured cells were 
enriched after performing in vitro biotinylation, followed by streptavidin pull down of biotin-
labeled proteins and subsequent mass spectrometric analysis. This proteomic discovery 
experiment allowed the identification of proteins exclusively expressed on the surface of 
all/the majority of PACO cell lines, but completely absent in the healthy controls. 
Furthermore, proteins defining distinct molecular subtypes could also be identified. We 
selected the two pan-PDAC protein marker candidates PCDH1 and LCN2 for further 
investigations. Concerning individual molecular subtypes, the exocrine-like PDAC cell lines 
stood out, expressing several subtype specific proteins, of which we selected two of the top 
hits (CDH17 and LGALS4) for further validations. No definite classical or 
quasimesenchymal specific protein biomarkers could be defined after the in vitro proteome 
analysis.  
In addition, we investigated the secreted proteome of cultured PDAC and healthy control 
cell lines using shotgun proteomics. The secretome identification experiments indicated that 
the four biomarker candidates selected based on the cell surface proteome analysis were 
as well secreted by the cancer cells in the environment, and could therefore be considered 
for the development of novel diagnostic tools.  
Finally, vascular accessible proteins present on the surface of pancreatic cancer cells and 
the associated tumor stroma were investigated upon performing whole body perfusion of 
immunodeficient mice harboring PACO-derived tumor xenografts with a reactive biotin 
ester. A proof-of-principle experiment confirmed the presence of two of the putative 
biomarkers identified after the in vitro experiments (LGALS4 and LCN2) in the primary 
pancreatic tumors. In addition, the in vivo biotinylation experiments indicated that the two 
protein biomarkers are accessible from the blood stream, and could represent candidates 
for novel targeted PDAC therapies, such as antibody-based therapies.  
The presence of the four biomarker candidates in the corresponding cell lines was validated 
first in vitro, by employing both antibody based (IF, WB) and antibody independent (SRM, 
RT-qPCR) methods. IF experiments confirmed the presence of both PCDH1 and LCN2 on 
the surface of all cultured PDAC cell lines, while they could not be detected at the plasma 
membrane level of the healthy control cell lines. The initial mass spectrometric identification 
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revealed the presence of isoform 2 specific peptides for PCDH1 in several of the analyzed 
PACO cell lines, although the exclusive presence of isoform 2 in the cultured PDAC cell 
lines could not be clearly confirmed. Additionally, RT-qPCR experiments showed a clear 
increase in the corresponding mRNA levels of both candidates in all the PDAC cancer cell 
lines, compared to the control cell lines. Therefore, it appears as if the increased PCDH1 
and LCN2 expression in PDAC cells is the result of transcriptional activation of the 
corresponding genes. Regarding the two subtype specific biomarker candidates CDH17 
and LGALS4, IF could confirm their exclusive presence at the plasma membrane level of 
the corresponding exocrine-like cell lines. LGALS4 was also detected in the cytoplasm of 
exocrine-like PDAC cells. Moreover, IF experiments suggested that the two exocrine-like 
biomarker candidates might represent interaction partners, a finding which has been 
confirmed with appropriate methods. CDH17 and LGALS4 protein levels were also 
investigated using SRM, which could additionally validate their exclusive presence in the 
whole cell lysates and in the secretome of exocrine-like cell lines. The corresponding mRNA 
levels were also upregulated only in those cell lines belonging to the exocrine-like subtype, 
as detected by RT-qPCR. Therefore, CDH17 and LGALS4 protein expression in exocrine-
like PDAC cell lines is likely the result of transcriptional activation of the corresponding 
genes. 
Additionally, we investigated the presence of the four biomarker candidates in pancreatic 
tumor xenografts developed in immunodeficient mice and in the original patient tumors. In 
vivo IF experiments could confirm the presence of the two pan-PDAC protein biomarker 
candidates in the extracellular environment and at the plasma membrane level of cancer 
cells, while being completely absent from healthy human pancreata. The protein expression 
of PCDH1 and LCN2 in mouse xenografts could be associated with increased levels of the 
corresponding mRNAs in the tumor xenografts, compared to the healthy control. CDH17 
and LGALS4 association with the plasma membrane of exocrine-like cancer cells was also 
confirmed upon in vivo IF analysis. However, in contrast to the in vitro validation 
experiments, we could additionally detect the two biomarker candidates in some of the 
classical-derived tumor xenografts, although at levels usually inferior to those reported for 
the exocrine-like tumors. CDH17 was completely absent from healthy human pancreata. 
On the other hand, some LGALS4 expression could be identified in the normal appearing 
pancreatic tissue employed for the IF validation experiments. Since the normal human 
pancreatic tissue was isolated from macroscopically healthy areas of tumor bearing patients 
(as evaluated at the time of surgery), we could not clearly determine if the LGALS4 present 
in the selected healthy tissue was not in fact associated with undetected malignant lesions 
expanding beyond the apparent tumor boarder. Elevated levels of CDH17 and LGALS4 
mRNAs could be reported in the exocrine-like and some of the classical tumor xenografts. 
The four protein marker candidates were also detected in the corresponding original patient 
tumors, although the quality of the paraffin embedded material prohibited extended 
validation experiments.  
Recently, Lisa Becker, a master student in our lab, generated scFv antibody fragments 
against the two exocrine-like protein candidates CDH17 and LGALS4 using phage display 
technology. Initial validation experiments verified the ability of the selected antibodies to 
recognize the native proteins in ELISA experiments. Furthermore, the scFv fragments could 
also be employed for fluorescent detection of the corresponding proteins on formalin 
fixed/paraffin embedded samples. The selected antibodies can be further developed for 
diagnostic applications and/or novel PDAC immunotherapeutic approaches.   
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6.1 Mass spectrometric based analysis of the cell surface 
proteome and secretome of cultured cells reveal novel 
putative PDAC markers, with the potential to distinguish 
between molecular subtypes 
The study presented in this PhD thesis lead to the discovery and validation of novel cell 
surface and secreted biomarkers with potential future clinical applications for the diagnosis 
and treatment of pancreatic cancer. The high mortality and metastasis rate of the PDAC [5, 
41], combined with its notoriety for being one of the most resistant tumors to both chemo-
therapy and radio-therapy, has increased the demand for the development of accurate 
diagnostic tests as well as targeted therapies [7, 25].  
Starting from an in vitro disease system, we employed mass spectrometric based 
approaches to compare the cell surface proteome and the secretome of pancreatic cancer 
cells to the one of healthy control cell lines. The comparative proteomic approach made use 
of twelve primary patient derived pancreatic cancer cell lines, grown in serum-free 
conditions, developed by Dr. Christian Eisen (HI-STEM, DKFZ). These cell lines, termed 
PACOs, offer significant advantages over conventional serum dependent cell lines. First of 
all, for commercially available cell lines grown for multiple passages in FCS based medium, 
genetic alterations are often documented [140]. Second of all, FCS dependent cell lines 
have often been reported to diverge both from the original phenotype and the molecular 
characteristics of the original tumor, a phenomenon which aggravates with increasing 
number of passages [46, 140]. The transcriptomic profile of the original patient tumors 
matched that of tumor xenografts derived after injecting the corresponding PACO cell lines 
into immunodeficient mice (Pearson correlation coefficient > 0.8) [141]. Furthermore, the 
orthotopic mouse tumor generated by these cell lines showed histological features and 
molecular characteristics closely resembling those of the original malignant neoplasm (Noll, 
Eisen et al., manuscript in preparation). Thus, the serum-free PACO cell culture model is 
less likely to lead to the discovery of artifactual protein biomarkers, while at the same time 
offering the advantages of an easy to manipulate in vitro system. Additionally, Collisson et 
al. recently argued that PDAC tumors, far from reflecting a homogeneous disease, can be 
subclassified based on their transcriptomic profiling into three molecular subtypes: classical, 
exocrine-like and QM. The individual subtypes showed different responses to conventional 
therapies and could be correlated with distinct overall survivals [3, 141]. The PACO cell 
lines represent to our knowledge the only in vitro PDAC model to recapitulate all three 
molecular subtypes described by Collisson et al. (Noll, Eisen et al., manuscript in 
preparation).  
The dynamic range of protein concentrations in complex biological raw samples exceeds 
the detection capabilities of current MS instruments. For this reason, extensive sample 
subfractionation and/or enrichment of subcellular compartments is a prerequisite for an 
efficient proteomic discovery experiment [72]. In this study, novel cell surface markers for 
future diagnostics and targeted therapies were identified by a proteomics approach utilizing 
in vitro biotinylation of cell surface proteins, followed by streptavidin pull down of the tagged 
subproteome. Using this technique, we identified more than 2500 proteins with a minimum 
of two proteotypic peptides. GO enrichment analysis revealed that the subcellular 
fractionation strategy has successfully lead to the detection of a significant number of 
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proteins annotated to the plasma membrane and the ECM (Figure 11). The list also 
included proteins annotated to intracellular membranous structures, such as ER proteins. 
Although such intracellular hits are usually discarded as contaminants, it is important to 
keep in mind that cellular re-localization is an often described event in human malignancies 
[29]. Thus, ER membrane proteins often end up being expressed on the surface of cancer 
cells, making them interesting targets for antibody based therapies, since they would 
normally be inaccessible in healthy tissues [29].  
However, the list of proteins identified was not devoid of intracellular proteins, without 
membranous fraction annotations, such as ribosomal proteins, housekeeping proteins 
involved in glucose metabolism, components of the cytoskeleton and biotin carboxylases. 
Biotin carboxylases are enzymes known to require biotin as a cofactor [135]. Therefore, the 
identification of these proteins with a high number of peptides in non-biotinylated negative 
controls has to be expected. The remaining intracellular proteins have either unspecifically 
bound to the streptavidin column, or derive from intracellular proteins which have been 
released into the culture medium (e.g. by apoptotic cells). Additionally, despite the presence 
of an electrical charge on the sulfo-NHS moiety of the reactive biotin ester employed, some 
of the biotinylation reagent might still be internalized, especially by biotin transporters 
located on the plasma membrane. This can therefore lead to unspecific biotinylation of 
intracellular proteins [73, 142]. 
We interrogated the list of cell surface proteins for both universal PDAC biomarkers, as well 
as subtype specific markers, which could be used for the clinical subclassification of 
pancreatic cancer patients.  
Out of the list of proteins expressed on PACO cell lines, but completely absent in the 
negative controls (Table 6), we selected two putative pan-PDAC markers for further 
validations: PCDH1 and LCN2. PCDH1 has never been associated with malignancies prior 
to our study and is typically expressed in the adult central nervous system and in the 
respiratory tract, at the bronchi level [118, 119]. LCN2 on the other hand, has been 
described as a tumor associated marker for many malignancies, including pancreatic 
cancer [124]. It has however captured our attention, since it is a secreted protein, which 
could be employed for the development of a blood based diagnostic test for PDAC, 
optionally in a panel with other pancreatic cancer biomarkers.  
When searching for subtype specific biomarker candidates, we observed that the exocrine-
like PDAC cell lines could clearly be separated from the ones representing the other two 
subtypes, expressing several unique proteins (Table 7). Two of them, namely – CDH17 and 
LGALS4 – were identified in every patient matched cell line belonging to the exocrine-like 
subtype, with a significant number of peptides. Therefore we selected the two proteins for 
further validation. The two proteins are expressed in healthy tissues of the digestive tract, 
but are largely absent from auxiliary glands, such as the liver and the pancreas [96, 110]. 
Their expression pattern is often altered in malignant development, being associated with 
both aggressive cancer behavior, as well as more differentiated neoplasms. Their role in 
cancer progression appears to be highly dependent on the tissue of origin [96, 110].  
We could not identify any protein that could clearly distinguish the classical and QM 
molecular subtypes, as the proteins identified were often not present on all the patient-
matched cell lines belonging to one subtype, or they were detected in more than one 
subtype (Table 8). Since the purpose of our investigation was the identification of true 
subtype specific biomarkers, and not protein markers reflecting an individual patient, we 
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excluded from validation experiments those proteins who could not be detected in all 
patient-matched cell lines belonging to one PDAC subtype. We have considered validating 
a marker defining two molecular subtypes, STEAP1, being present on the surface of cell 
lines belonging to the exocrine-like and the classical subtypes. The validation data for this 
marker are however not presented in this report, as they require additional optimizations.  
The reason for the differences observed in the protein expression profiles between the 
exocrine-like and the other two molecular subtypes is unknown. One possible explanation 
could be that the different subtypes arise from different cells of origin. Both ductal and acinar 
cells (undergoing acinar to ductal metaplasia) have been hypothesized as the putative 
source of exocrine pancreatic neoplasms [143, 144]. However, no definite conclusion has 
been reached so far in the debate regarding the PDAC cell of origin [143].  
We investigated as well if the putative protein biomarkers, identified in the course of the cell 
surface proteome analysis, could be employed as potential diagnostic markers in non-
invasive screening protocols. In order for a marker to be eligible for such diagnostic 
purposes, it needs to be secreted or shed from the plasma membrane of cancer cell in 
amounts that would allow it’s identification in body fluids of patients, preferably in blood [32]. 
One suggested way of detecting putative secreted biomarkers is the investigation of the 
supernatant of cultured cells, and its comparison to that of healthy counterparts [46]. For 
this purpose, we optimized the serum-free CSC medium in which the PACO cells were 
grown, by removing albumin and transferrin from the formulation, and incubated the cells 
with the new medium, for 48 hours. Albumin and transferrin subtraction from the CSC 
medium was dictated by the need to improve the dynamic range of our discovery 
experiments, as the high concentration of the two proteins would prohibit proper 
identification of less abundant secreted proteins.  
The secretome analysis lead to the identification of more than 1700 proteins (excluding one 
hit wonders). Gene ontology analysis confirmed the enrichment of proteins with annotations 
containing the terms extracellular, ECM, plasma membrane, as well as vesicular systems 
in the list of secreted proteins (Figure 15a). We had previously reported that the GO 
enrichment analysis of the cell surface proteome revealed indistinguishable profiles 
between the three molecular subtypes. However, when enquiring the secretome profiles 
using GO annotations, we could observe some discrete, yet significant differences between 
the distinct PDAC subtypes (Figure 15b). Exocrine-like supernatants were enriched in 
proteins present in adherens junctions, whereas classical and QM secretomes were more 
likely to express proteins associated with the basement membrane. This observation could 
be complemented by the fact that the exocrine-like cell surface and secreted proteomes 
included multiple members of the cadherin family (Table 7 and Table 10), known to be 
involved in the formation of adherens junctions [94]. Furthermore, we could distinguish 
several intracellular constituents among the proteins identified in the supernatant of cultured 
cells. Generally the cytoplasmic and organelle specific hits would be discarded from future 
validation experiments of putative secreted biomarkers. However, recent reports have 
indicated that unconventional secretion might be a common event in tumors, and the 
extracellular localization of typically intracellular proteins has been confirmed through IHC 
experiments [81]. Thus future validation experiments do not need to automatically exclude 
proteins with a GO annotation suggesting their intracellular localization. 
It can be speculated if the cultured pancreatic cancer cells still express digestive enzymes 
specific to the exocrine pancreas (Table 9) and other proteases, potentially leading to the 
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release of non-tryptic peptides. Indeed, after investigating the non-tryptic peptides identified 
by the ProteinPilot software with higher than 95% confidence, we could determine that the 
percentage of non-tryptic peptides detected in all the secretome samples was almost double 
to the one detected for the in vitro biotinylated samples (7.6% versus 4.2%) (data not 
shown). Interestingly, the protein coverage of the secretome samples has been inferior to 
that observed in the cell surface proteome (data not shown). One possible explanation could 
be provided by the pre-digestion of the secreted proteins during the 48 hours incubation 
period, which is known to negatively affect the downstream proteomic analysis [84, 145]. 
Comparative analysis of PACO versus healthy control collected supernatants confirmed the 
presence of the previously selected putative pan-PDAC and exocrine-like protein 
biomarkers in the secretome of cultured cells (Table 9 and Table 10). LCN2, which is 
constitutively released in the extracellular environment [129], was identified as expected 
with a large number of peptides in the supernatants of all PACO cell lines, while being 
completely absent in the secretome of healthy controls. PCDH1 release in the extracellular 
fraction was confirmed in more than 60% of the analyzed samples, despite being described 
in the literature as a membrane bound protein [119]. Its presence in the secretome could 
be the result of the protease based shaving of extracellular domains of membrane proteins, 
or unspecific release of plasma membrane proteins upon cell lysis. Indeed, PCDH1 
peptides identified with a high confidence in the secretome samples mapped to the N-
terminal extracellular domain, but not to the C-terminal cytoplasmic tail (data not shown). 
However, we could not exclude the contribution of potentially apoptotic cells to the secreted 
proteome.  Future cell viability assays should therefore be performed, in order to evaluate 
the extent to which cell lysis products contribute to the overall secretome composition. Both 
CDH17 and LGALS4 were detected exclusively in the secretome of exocrine-like cells, thus 
confirming the initial cell surface discovery experiments (Table 10). LGALS4 was identified 
in more than half of the exocrine-like supernatant samples, whereas CDH17 signals were 
only detected in the secreted fraction of those cell lines with a high expression on the cell 
surface (PACO10 cells, Supplementary Information). These observation are in 
agreement with literature data, which confirm LGALS4 secretion in the extracellular 
environment through unconventional pathways [114]. The identification of CDH17 in the 
supernatant of exocrine-like cells could again be the result of protease mediated shaving, 
or unspecific lysis of cultured cells.  
The chemically defined, serum free CSC medium used for the cultivation of PACO cells has 
the advantage that the necessary growth factors are provided at known concentration. By 
contrast, commercially available cell lines require serum supplements, with unknown 
chemical composition. Hence, we expect that removal of albumin from the PACO culture 
medium would not have an effect as severe as FCS withdrawal for commercially available 
cells (which is known to induce apoptosis and cell cycle arrest [81]) and would therefore not 
compromise the quality of the proteomic discovery. On the other hand, the two control cell 
lines were initially cultured in medium containing either added FCS or bovine pituitary 
extract. The medium composition optimal for the HPNE cell line does not vary significantly 
from the one of the CSC PACO medium. Consequently, we did not expect major metabolic 
and transcriptomic alterations when culturing the HPNE cells in the new CSC secretome 
medium. For the HPDE cell line however, the medium formulation varied substantially from 
the PACO standard culture medium. We are not sure if the morphological changes 
observed under the microscope (Figure 12) were induced by differences in the chemical 
composition of the advanced DMEM/F12 versus the keratinocyte based medium, or if they 
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were the result of bovine pituitary extract removal, which might have provided additional 
essential hormones and factors for this immortalized pancreatic cell line.  
 
Following the completion of the discovery phase, we proceeded to validate the two pan-
PDAC and exocrine-like protein biomarkers candidates, by using antibody based and 
antibody independent methods, in vitro as well as in vivo.  
 
6.2 Validation of exocrine-like protein biomarker candidates 
6.2.1 In vitro validations 
We investigated the presence of CDH17 and LGALS4 on the cell surface and in the 
secretome of PACO cultured cells by means of both antibody based and antibody 
independent methods.  
IF in vitro experiments confirmed the exclusive expression of the two proteins on the cell 
surface of all patient matched exocrine-like cell lines (Figure 22 and Figure 23). As 
expected, cytoplasmic as well as limited nuclear staining could be reported for LGALS4 
(Figure 23) [107]. The intensity of the staining profiles for the two markers varied between 
cell lines. CDH17 staining was most intense in the PACO10 cell line, while the weakest 
staining could be observed in PACO18 cells. LGALS4 staining intensity was the highest in 
PACO14 and PACO18 samples. Occasionally we could observe cytoplasmic fluorescence 
in some of the classical and QM cell lines. We estimated that the signal could be the result 
of autofluorescence, weak unspecific binding of the antibodies employed for the experiment, 
or might indicate a potential cytoplasmic localization for the protein of interest in some of 
the classical and QM PDAC cell lines. Isotype control stainings indicated that for some of 
the QM annotated cell lines, an unspecific cytoplasmic signal could indeed be detected 
(Supplementary Figure 2). However, not all classical and QM PACO cell lines revealed 
unspecific fluorescent signals in the respective isotype controls. Therefore, we could not 
exclude a potential cytoplasmic localization of the two biomarker candidates in some of the 
non-exocrine-like cell lines, prior to performing additional validation experiments. 
In order to further validate the specificity of the two exocrine-like biomarker candidates, we 
performed antibody independent validation experiments, using a targeted mass 
spectrometric approach, termed SRM.  
SRM experiments of total cell lysates and supernatants confirmed the exclusive presence 
of the two protein biomarker candidates in exocrine-like PDAC cells (Figure 41). Moreover, 
the targeted MS approach lead to the conclusion that the cytoplasmic staining detected in 
some of the classical/QM PACO cell lines was the result of unspecific background 
(Figure 41 – absence of signals in whole cell lysates obtained from non exocrine-like cells). 
The presence of CDH17 and LGALS4 in the secreted fraction of exocrine-like cell lines 
(Figure 41, relative quantification achieved by SRM) makes the two proteins eligible for 
consideration as putative diagnostic biomarkers for patient stratification.  
The upregulation of CDH17 and LGALS4 on the cell surface of exocrine-like PDAC cell lines 
appears to be (at least partially) dictated by transcriptional activation of the corresponding 
genes, according to the RT-qPCR quantification (Figure 42). The CDH17 gene expression 
profiles could be correlated with previous experimental data of Noll, Eisen et al., which have 
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identified the Hepatic Nuclear Factor 1-alpha (HNF1α) transcription factor as a marker for 
the exocrine-like PDAC subtype (Noll, Eisen et al., manuscript in preparation). HNF1α is 
one of the two transcription factors known to regulate the expression of CDH17 in vivo [99]. 
Moreover, the gene expression levels of the transcription factor correlated with the profiles 
observed for CDH17 mRNA levels in the exocrine-like cell lines (data not shown). 
Tan et al. reported CDH17 and LGALS4 as markers describing the gastric carcinoma G-
intestinal molecular subtype, correlated with a better response to 5-FU therapy and slightly 
improved overall survival compared to patients whose tumors did not express the two 
proteins [105]. Additionally, Takamura et al. identified galectin-3 as a putative interaction 
partner for CDH17 [95]. Galectin-3 appeared to bind to the extracellular domain of CDH17, 
more specifically to the carbohydrate residues of the N-glycosylated protein, and the 
interaction was inhibited by the presence of lactose [95]. In light of the two studies, we 
examined if the two putative exocrine-like biomarkers might interact at the plasma 
membrane level of PDAC cancer cells. Confocal IF costaining experiments revealed that 
CDH17 and LGALS4 indeed co-localize on the surface of exocrine-like PACO cells 
(Figure 26). Nonetheless, further investigations are required to confirm the interaction of 
the two proteins – such as co-IP (in the presence and absence of lactose solutions) or 
Fluorescence Resonance Energy Transfer (FRET) experiments. In FRET experiments, a 
donor chromophore (excited by a laser) can only transfer energy to an acceptor 
chromophore if the two light sensitive molecules are situated in close proximity. FRET is 
sensitive to even small changes in the distance between donor and acceptor molecule, thus 
making it a reliable technique for confirming direct interaction between two molecules [146, 
147]. An additional method for detecting protein-protein interactions and pinpoint their 
subcellular localization is represented by the proximity ligation assay (PLA). The method 
combines antibody-based recognition of two protein targets with the amplification of a DNA 
reporter molecule, only possible if the two employed antibodies (containing attached 
oligonucleotides sequences) are located in close proximity. Ligated DNA molecules can be 
amplified via rolling circle amplification, and the corresponding products are visualized by 
hybridization [148, 149]. Nonetheless, to our knowledge, this is the first study ever to report 
a potential interaction between CDH17 and LGALS4. 
 
6.2.2 In vivo validations 
Next, we evaluated if the in vitro validated markers maintain their exclusive exocrine-like 
expression pattern in pancreatic tumors, when injected into the pancreas of 
immunodeficient NSG mice. Additionally, we also verified the expression levels of CDH17 
and LGALS4 in the original patient tumors, when primary tissue material was available.  
Tumor xenografts grown in NSG mice continued to express CDH17 and LGALS4 in 
exocrine-like malignancies, in patterns similar to those earlier described for the in vitro 
cultured cell lines. Thus, PACO10 CDH17 staining signal continued to be one of the most 
intense, whereas the PACO18 staining in vivo was once again very weak (Figure 31). In 
the case of LGALS4 staining, the signal was yet again highest in PACO18 samples. 
Moreover, the two exocrine-like marker candidates were also identified in novel exocrine-
like tumor xenografts not included in the initial proteomics discovery experiments, thus 
further confirming their association with the exocrine-like molecular subtype. However, we 
could observe activation of CDH17 and LGALS4 expression in several tumors belonging to 
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the classical subtype, in particular PACO17 and PACO19 derived tumors. Additional tests 
are planned to evaluate if the increased expression of CDH17 can be associated with 
elevated levels of HNF-1α transcription factor, described by Noll, Eisen et al. as a biomarker 
for exocrine-like PDAC (Noll, Eisen et al., manuscript in preparation). Tumors of the QM 
subtype were typically negative for the two markers. When comparing the staining 
intensities for the putative biomarkers, it became apparent that the signal detected in 
exocrine-like PDAC was typically higher than the one observed in classical tumors. 
Heterogeneity of PDAC tumors, including those derived in NSG mice from PACO cell lines, 
could present an explanation for the in vivo staining of some of the classical tumors. Thus, 
it is possible that one patient/cancerous growth harbors simultaneously two or more distinct 
PDAC molecular subtypes. Arguments supporting this theory can be partially provided by 
the PACO in vitro system. Based on the initial gene set enrichment analysis performed by 
Dr. C. Eisen (HI-STEM, DKFZ) using the PDA-assigner described by Collisson et al., two 
PACO cell lines isolated from the same patient – PACO19 and PACO20 – were annotated 
to distinct subtypes: classical and respectively QM [141]. The re-classification of PACO20 
as a classical cell line was based on more detailed transcriptomic and proteomic analysis, 
as mentioned in the Results chapter. Nonetheless, the exact classification of PACO20 will 
require additional investigations. Further analysis will therefore be required to determine if 
tumor heterogeneity represents a common event in PDAC.  
The healthy pancreatic tissue was, to our surprise, positive for LGALS4, although literature 
data have never reported LGALS4 expression in the adult human pancreas [110]. Since the 
healthy tissue was collected from the healthy appearing area of a resected tumor (as 
evaluated at the time of the surgical procedure) and as we only had a limited number of 
healthy controls, we cannot exclude that the positive signals detected in the ‘healthy’ tissues 
are in fact associated with PDAC precancerous lesions. Further evaluation from a 
pathologist would be required prior to drawing a definite conclusion.  
We thus turned our attention to the initial paper of Collisson et al., describing the gene 
expression patterns of the three molecular subtypes. We could observe that the original 
publication had listed both CDH17 and LGALS4 as genes whose transcription appears to 
be activated in tumors belonging to the classical subtype [3]. However, in vivo IF 
experiments indicated a strong expression of CDH17 and LGALS4 in the majority of our 
exocrine-like tumors, contradicting the data of Collisson et al. Furthermore, this upregulation 
could also be confirmed at mRNA level by RT-qPCR (Figure 44). The gene expression 
levels for the two targets were clearly higher in exocrine-like and some classical tumors 
(especially PACO19 derived xenografts), compared to healthy pancreas and QM tumors. 
Thus, it appears as if in vivo, both exocrine-like and classical tumors can selectively express 
the two protein markers.  
The reason for this in vivo activation of the two putative exocrine-like markers in the classical 
subtype requires further studies. One possible explanation could be provided by the in vitro 
culture medium in which the PACO cells were isolated and maintained. It could be 
speculated that both the chemical composition and the selection of the growth factors lead 
to the enrichment of specific subpopulations in vitro, which may or may not harbor stem cell 
like properties. Some low expression levels of LGALS4 could, for example, already be 
detected in vitro (PACO19 cell line), albeit with only one peptide (Table 7). We can suspect 
that the tumor microenvironment leads to the transcriptional activation of the two genes, 
probably a means to better adapt to the new conditions. The nature of the PDAC stromal 
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compartment has baffled scientists working in the oncology field, since it is one of the only 
tumors described to be associated with a highly abundant desmoplastic stroma. 
Additionally, tumor blood vessels are only sparsely present, and many of them are 
nonfunctional [8]. The increased interstitial fluid pressure (IFP) recorded in PDAC tumors is 
suspected to be the main reason for the collapsing of tumor associated capillaries, leading 
to the formation of extended hypoxic, nutrient deficient areas [13]. LGALS4 overexpression 
has been associated with improved survival of cells cultured in FCS depleted medium 
compared to cells not expressing the protein [110]. Thus, LGALS4 in vivo activation could 
represent a strategy employed by PDAC cells to adapt to the new environment and to adjust 
to the scarce availability of nutrients, compared to the cultured system. In contrast, CDH17’s 
role in cancer progression is more elusive, as very little is known about the signaling 
networks in which it participates. It has been linked to Wnt signaling and FAK activation 
after interacting with the β1 integrin receptor [102, 103]. We can therefore assume that 
CDH17 in vivo activation plays a role in cancer cell proliferation and migration. However, 
we cannot confirm whether the PDAC molecular subtypes described by Collisson et al. are 
stable or if they can transform into a new molecular subtype, based on environmental 
stimuli. As stated earlier, further investigations will also be required to evaluate if patients 
can harbor multiple molecular subtypes of PDAC in one malignant lesion. 
As previously mentioned, Tan et al. acknowledged that patients with CDH17 and LGALS4 
double positive gastric tumors have a better overall survival rate compared to patients 
whose tumors were double negative for the two proteins. Double positive tumors exhibited 
also a higher level of differentiation, consequently offering a possible explanation for the 
better prognosis associated with the disease [105]. Additionally, patients with PDAC tumors 
expressing high levels of CDH17 have been shown as well to have improved overall survival 
[95]. Collisson’s original data, which reported high expression levels of both CDH17 and 
LGALS4 in classical PDAC tumors, suggested that patients diagnosed with classical tumors 
have a slightly better prognosis compared to patients harboring cancers of the exocrine-like 
and QM PDAC subtypes [3]. On the other hand, Noll, Eisen et al. identified exocrine-like 
PDAC tumors as being associated with the best overall survival (Noll, Eisen et al., 
manuscript in preparation). The reasons behind such contradicting data are most likely 
rooted either in the size of the patient cohort used for the comparison analysis, or in the 
applied technique (genomic analysis of microdissected tumors vs histological analyses). 
Either way, based on our experimental data, both classical and exocrine-like tumors 
express high levels of the two putative biomarkers compared to QM malignancies. We 
suggest that CDH17 and LGALS4 expression might correlate with a higher level of tumor 
differentiation, leading to better overall disease prognosis. In fact, classical and exocrine-
like cancers typically develop ductal-like tumor structures, whereas QM tumors display a 
poorly differentiated histology (Figure 30). 
We observed that metastatic lesions can also express the two protein markers, depending 
on the organ that has been colonized and the tumor of origin. Both PACO10 and PACO3 
(originating from the same patient) exocrine-like liver metastases, expressed high levels of 
CDH17 (Figure 32 and data not shown). However the CDH17 staining was negative in lung 
metastases. The presence of CDH17 in liver metastases has previously been documented 
for colorectal carcinoma, being in fact suggested that its expression in the primary cancer 
might be a prerequisite for future liver colonization of the cancer cells [102]. This could 
suggest a dual role for CDH17 in PDAC tumors: it could represent a marker of more 
differentiated primary tumors, while at the same time indicating a phenotype more likely to 
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produce liver metastasis. For PACO20 derived tumors on the other hand, metastatic lung 
lesions appear to upregulate CDH17, in contrast to the PACO10 derived lung tumors 
(Figure 32). We unfortunately were not able to test the expression levels in liver 
metastases, derived from the same cell line. Interestingly, LGALS4 expression in 
spontaneous PACO derived metastases correlated with the one observed for CDH17 
(Figure 34). The observation that the two exocrine-like biomarker candidates are co-
expressed by the same metastatic lesions might indicate a functional association of the two 
proteins, first suggested by the in vitro colocalization experiments. Further in vivo analysis 
will be required, prior to drawing a conclusion about the functional roles of CDH17 and 
LGALS4 in primary and metastatic PDAC tumors.  
In addition, we investigated the presence of CDH17 and LGALS4 in the original patient 
tumors (Figure 38 and Figure 39). CDH17 expression was clearly upregulated in those 
tumors from which the exocrine-like PACO cell lines were derived from. For LGALS4 
however, the interpretation of the IF stainings was hindered by the high background 
detected in patient material, most likely originating from the tumor stroma. In the future, we 
would like to evaluate the IF stainings at a confocal microscope allowing spectral unmixing, 
which would therefore remove the autofluorescence signals from the high-stroma containing 
samples. 
Important for the development of potential targeted therapies, the in vivo biotinylation 
experiments followed by mass spectrometric analysis, detected LGALS4 in PACO17 
derived tumors with more than two peptides (Table 13). Albeit the in vivo experiments were 
to date performed on a small cohort, they do offer an initial confirmation that LGALS4 is 
accessible from the blood stream, depending on the size of the targeted therapeutical agent 
to be developed. 
 
6.3 Validation of pan-PDAC protein biomarker candidates 
6.3.1 In vitro validations 
We could confirm the presence of PCDH1 on the cell surface of all in vitro grown PACO cell 
lines, the highest levels being detected in cell lines belonging to the QM subtype 
(Figure 25). Some cytoplasmic staining was identified in the healthy control cell lines, but 
no clear membrane staining was present in either the HPDE or the HPNE cells. However, 
no PCDH1 signal could be detected in the whole cell lysates of the healthy controls, as 
determined by WB (Figure 29), indicating that the cytoplasmic signals detected in IF 
experiments might have derived from unspecific background staining. The high protein 
expression levels of PCDH1 in PDAC cells were associated also with increased abundance 
of the corresponding mRNA, as determined by RT-qPCR (Figure 43).  
IF experiments on paraffin embedded cells could confirm the presence of LCN2 associated 
with the plasma membrane or in the cytoplasm of PACO cell lines (Figure 24). The signal 
was highest in cells belonging to the exocrine-like and classical subtypes. We could detect 
some cytoplasmic staining in the HPNE control cell line. However, we could not detect LCN2 
in any of the healthy control cells lines in our MS identification experiments. Additionally, 
LCN2 has not been reported in literature as being expressed by healthy pancreatic tissue 
[127]. Therefore, it is possible that the positive fluorescent signal detected in the HPNE cell 
line might represent an artifact introduced by the staining procedure. mRNA expression 
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levels detected by RT-qPCR, correlated with the protein levels previously evaluated in IF 
experiments (Figure 43), indicating that transcriptional activation was (at least partially) 
responsible for the overexpression of LCN2 in PDAC cultured PACO cells. 
Isoform 2 of PCDH1 could be identified in several of the samples analyzed during the cell 
surface MS discovery experiment (Figure 28). Literature data report several splice isoforms 
for PCDH1, as well as multiple transcription initiating codons in the corresponding gene. 
The developmental status of the cell, as well as environmental signals from the niche, seem 
to influence the splicing pattern of the PCDH1 mRNA resulting in the expression of different 
PCDH1 protein isoforms [119]. Two main isoforms are most often reported for PCDH1, 
which are distinguishable by their molecular weight. Isoform 2 contains an additional 
cytoplain the asmic domain, which has been shown to mediate the interaction between 
PCDH1 and protein phosphatase 1-α [122]. WB analysis (Figure 29), revealed a single 
signal in the majority of cultured PACO cell lines, having a molecular weight of ~140 kDa. 
This molecular weight would correspond to isoform 2 of PCDH1 (molecular weight of 
polypeptide chain alone: ~120 kDa). However, we need to keep in mind that cadherins are 
often subject to N-glycosylation [94]. In the absence of data describing the extent of post-
translational modifications of PCDH1, we cannot draw a definite conclusion about the main 
isoform present in our in vitro system. Alternative glycosylation patterns could also hinder 
the antibody based detection of different PCDH1 isoforms. WB detection following 
deglycosylation treatment would help elucidate which of the isoforms is predominantly 
expressed by PACO cells. Additionally, we are considering performing SRM experiments, 
with optimized transition selection for isoform specific precursor peptides, and resulting 
fragment ions. For PACO20 cell lysates, an additional band, with a higher molecular weight 
compared to the predominant isoform could also be detected, albeit with a weaker intensity 
(Figure 29). Despite the fact that IF experiments indicated a high protein expression level 
for PCDH1 in PACO16 cells, we could detect any signal corresponding to the protein in the 
total cell lysates in WB (Figure 29). One possible explanation could be that the protein 
concentration in PACO16 total lysates is below the detection limit of the WB method, 
whereas the intense IF signal might have originated mostly from the plasma membrane of 
cultured cells. An additional explanation could be provided by the presence of limited mouse 
fibroblast contamination in some of the PACO16 batches we analyzed, which might have 
led to the dilution of PACO16 specific proteins in the whole cell lysates.  
 
6.3.2 In vivo validations 
IF stainings performed on primary tumor xenografts confirmed the presence of both PCDH1 
and LCN2 in pancreatic tumor mouse xenografts (Figure 35 and Figure 37). Exocrine-like 
PDAC appeared to express the highest protein and mRNA LCN2 levels (Figure 35 and 
Figure 45). In addition, LCN2 overexpression has often been correlated with improved 
disease prognosis [124], which could again be linked to the observations of Noll and Eisen, 
associating PDAC exocrine-like tumors with better overall survival (Noll, Eisen et al., 
manuscript in preparation). The PCDH1 signal in vivo was generally weak, with exocrine-
like tumors and several QM derived cancers expressing higher levels, as evaluated by IF 
(Figure 37). mRNA PCDH1 levels were clearly upregulated in all analyzed PDAC samples 
compared to healthy pancreatic tissue (Figure 45). 
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Lipocalin 2 expression is typically down-regulated in metastatic lesions [124]. We 
investigated the expression levels of LCN2 in spontaneous metastases developed by tumor 
bearing mice and could report that the expression level of the protein lesion varied 
compared to the primary cancerous lesion, depending on the cell line of origin. For example, 
in PACO20 derived lung metastases, LCN2 protein expression was completely absent, 
correlating with literature reports. However, for the exocrine-like subtype derived liver and 
lung secondary tumors however, we could report a significant LCN2 overexpression 
compared to the primary cancer (Figure 36). The significance of this activation in some of 
the secondary lesions needs further investigation. PCDH1 expression in metastatic lesions 
has not yet been tested.  
LCN2 could also be detected when performing the in vivo whole body perfusion of tumor 
bearing mice (Table 13). This again confirmed that LCN2 could represent a candidate for 
novel targeted PDAC therapies.  
LCN2 expression could as well be detected in the patient original tumors, with the exception 
of the patient from which the PACO17 cell line was isolated (Figure 40). However, our 
observations were once again hindered by the high background present in the patient 
tumors. Due to insufficient patient tumor material available, we did not investigate the 
expression levels of PCDH1 in the original patient PDAC samples. 
LCN2 activation in PDAC and its presence in the blood of pancreatic cancer patients has 
already been documented in literature [21]. The protein can be detected in the plasma of 
pancreatitis patients, as well as in asymptomatic individuals, harboring precancerous 
lesions [21]. Although this early activation might represent an impediment for developing 
LCN2 into a proper diagnostic tool, it is worth noting that both pancreatitis patients, and 
individuals bearing PanIN precursor lesions, have an increased risk of developing PDAC 
later in life [5] and could be better monitored if they are recognized as a high risk group.  
In order for a putative cancer biomarker to successfully enter the clinic, extended 
validations, on large patient cohorts need to be performed prior to its recognition as a 
valuable clinical tool [32, 70, 150]. In future experiments, we plan to investigate the presence 
of the four protein biomarkers described in tissue microarrays and the corresponding blood 
of patients, harboring malignant and benign diseases. Thus, one can investigate which 
panel of markers can be used for diagnostic applications and/or targeted therapies. 
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7. Conclusions and outlook 
 
We have validated PCDH1 as a novel marker for PDAC, and evaluated its applicability as 
a diagnostic tool, in combination with LCN2. Additionally we have identified molecular 
subtype specific protein markers – namely CDH17 and LGALS4, which can potentially be 
used for the stratification of patients and may help facilitate therapeutical decision making. 
CDH17 and LGALS4 were expressed exclusively on exocrine-like PDAC cells in vitro, and 
they maintained their expression in vivo. Additionally, we observed some ectopic activation 
of both CDH17 and LGALS4 in some of the classical mouse derived tumors, although 
generally the expression level was inferior to that documented for exocrine-like PDAC. Initial 
in vitro experiments revealed the colocalization of the two putative exocrine-like markers on 
the surface of cultured cells. So far, in vivo localization experiments have been hindered by 
the fact that the majority of our tissue samples have been fixed in formalin, and the 
commercially available antibodies we employed so far require distinct antigen retrieval 
protocols. For this reason, cryopreserved organ samples will be employed in the future, to 
evaluate if the putative interaction between CDH17 and LGALS4 can also be observed in 
tumor tissues.  
The two panels of pan-PDAC and subtype specific putative markers will need to be 
additionally validated on larger cohorts of patients. In collaboration with Dr. M. Sprick (HI-
STEM, DKFZ, Heidelberg) and Prof. Dr. W. Weichert (Pathology Department, 
Universitätsklinikum Heidelberg), we plan to investigate the four putative biomarkers on a 
PDAC TMA, originating from primary tumor material for which the molecular 
subclassification is already known.  
The two pan-PDAC and exocrine-like markers are also secreted by cancer cells in vitro, 
and could represent attractive diagnostic markers for clinical applications. We are currently 
investigating, using SRM and ELISA, if the presence of these markers can also be detected 
in the blood of tumor bearing mice.  
The final goal of the current study is the development of specific monoclonal antibodies, 
which could be used for targeted therapies in pancreatic cancer. Our lab has recently 
selected specific antibodies against the two putative exocrine-like biomarkers CDH17 and 
LGALS4, using phage display technology (work of Lisa Maria Becker and Dr. Katharina 
Frey, Biomarker Discovery Group, HI-STEM). The two antibodies recognized the native 
proteins, evaluated by ELISA tests using recombinant proteins. Additionally, the antibodies 
produced as single chain Fv (scFv) fusion proteins could also recognize the proteins against 
which they were raised, when using methanol or formalin as fixation methods for the 
biological material (data not shown). The selected antibodies will need to first undergo 
affinity maturation before establishing their clinical applications as diagnostic and/or 
therapeutic tools. Should the antibodies be eligible for therapeutical delivery, biodistribution 
experiments will need to be performed, evaluating which antibody format would localize 
most efficiently within the tumor. Combinational therapies with agents targeting the tumor 
stroma, aimed to alleviate the augmented IFP reported in some tumors, can also be 
considered for an improved delivery. As we have mentioned, exocrine-like tumors appear 
to upregulate liver specific transcription factors, which might be associated with increased 
clearance of xenobiotics. A targeted antibody based therapy, potentially combined with 
immunostimulatory strategies, might be considered as an alternative for those patients 
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whose transcriptomic signature indicate the potential failure of conventional cancer 
therapies.  
Due to time constraints, the current study did not investigate if the PDAC biomarker 
candidates discovered, are also associated with benign inflammatory pancreatic 
pathologies, such as pancreatitis. However, future experiments are planned interrogating 
the presence of the markers discussed in this work in healthy and diseased tissues, using 
both commercially available TMAs, as well as samples provided by the clinical hospital, 
Heidelberg. It is possible that some of the proteins for which we performed the early 
validation experiments are already present in precancerous lesions, which often progress 
to fully developed PDAC. If so, these biomarkers could be employed for the monitoring of 
high-risk patients. 
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8. Supplementary information 
 
 
Supplementary Figure 1: In vitro IF validations: CDH17 – isotype controls. A: PACO3; 
B: PACO10; C: PACO14; D: PACO18; E: PACO2; F: PACO17; G: PACO19; H: PACO20; 
I: PACO7; J: PACO8; K: PACO9; L: PACO16; M: HPDE; N: HPNE (Scale bars: 50µm)  
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Supplementary Figure 2: In vitro IF validations: LGALS4 – isotype controls. A: PACO3; 
B: PACO10; C: PACO14; D: PACO18; E: PACO2; F: PACO17; G: PACO19; H: PACO20; 
I: PACO7; J: PACO8; K: PACO9; L: PACO16; M: HPDE; N: HPNE (Scale bars: 50µm) 
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Supplementary Figure 3: In vitro IF validations: LCN2 – negative controls (without primary 
antibody). A: PACO3; B: PACO10; C: PACO14; D: PACO18; E: PACO2; F: PACO17; G: PACO19; 
H: PACO20; I: PACO7; J: PACO8; K: PACO9; L: PACO16; M: HPDE; N: HPNE; 
(Scale bars: 50µm) 
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Supplementary Figure 4: In vitro IF validations: PCDH1 – isotype controls. A: PACO3; 
B: PACO10; C: PACO14; D: PACO18; E: PACO2; F: PACO17; G: PACO19; H: PACO20; 
I: PACO7; J: PACO8; K: PACO9; L: PACO16; M: HPDE; N: HPNE; O: PACO10 isotype control; 
P: PACO14 isotype control (Scale bars: 50µm) 
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Supplementary Figure 5: In vivo validations - CDH17 isotype controls. A: PACO3, B: PACO10; 
C: PACO14; D: PACO18; E: PACO25; F PACO26; G: PACO 28; H: PACO2; I: PACO17; 
J: PACO19; K: PACO20; L: PACO7; M: PACO8; N: PACO9; O: PACO16; P: human healthy 
pancreas patient # 4984; Q: human healthy pancreas patient # 4985; R: healthy mouse NSG 
pancreas. (Scale bars: 50 μm) 
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Supplementary Figure 6: In vivo validations – LGALS4 isotype controls. A: PACO3, B: PACO10; 
C: PACO14; D: PACO18; E: PACO25; F PACO26; G: PACO 28; H: PACO2; I: PACO17; 
J: PACO19; K: PACO20; L: PACO7; M: PACO8; N: PACO9; O: human healthy pancreas patient 
# 4984; P: healthy mouse NSG pancreas. (Scale bars: 50 μm) 
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Supplementary Figure 7: In vivo validations – LCN2 isotype controls. A: PACO3, B: PACO10; 
C: PACO14; D: PACO18; E: PACO25; F PACO26; G: PACO 28; H: PACO2; I: PACO17; 
J: PACO19; K: PACO20; L: PACO7; M: PACO8; N: PACO9; O: PACO16; P: human healthy 
pancreas patient # 4984; Q: human healthy pancreas patient # 4985; R: healthy mouse NSG 
pancreas. (Scale bars: 50 μm) 
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Supplementary Figure 8: In vivo validations – PCDH1 isotype controls. A: PACO3, B: PACO10; 
C: PACO14; D: PACO18; E: PACO25; F PACO26; G: PACO 28; H: PACO2; I: PACO17; 
J: PACO19; K: PACO20; L: PACO7; M: PACO8; N: PACO9; O: PACO16; P: human healthy 
pancreas patient # 4984; Q: healthy mouse NSG pancreas. (Scale bars: 50 μm) 
  
Supplementary information 
 
162 
 
Supplementary Material: Complete alignment of isoform 1 (upper sequence) and isoform 2 (lower 
sequence) of PCDH1, using ClustalW. In green: identified peptides common to both isoforms. In 
yellow: identified peptides specific to isoform 2 of PCDH1 
 
sp|Q08174|PCDH1_HUMAN        MDSGAGGRRCPEAALLILGPPRMEHLRHSPGPGGQRLLLPSMLLALLLLL 
sp|Q08174-2|PCDH1_HUMAN      MDSGAGGRRCPEAALLILGPPRMEHLRHSPGPGGQRLLLPSMLLALLLLL 
                             ************************************************** 
 
sp|Q08174|PCDH1_HUMAN        APSPGHATRVVYKVPEEQPPNTLIGSLAADYGFPDVGHLYKLEVGAPYLR 
sp|Q08174-2|PCDH1_HUMAN      APSPGHATRVVYKVPEEQPPNTLIGSLAADYGFPDVGHLYKLEVGAPYLR 
                             ************************************************** 
 
sp|Q08174|PCDH1_HUMAN        VDGKTGDIFTTETSIDREGLRECQNQLPGDPCILEFEVSITDLVQNGSPR 
sp|Q08174-2|PCDH1_HUMAN      VDGKTGDIFTTETSIDREGLRECQNQLPGDPCILEFEVSITDLVQNGSPR 
                             ************************************************** 
 
sp|Q08174|PCDH1_HUMAN        LLEGQIEVQDINDNTPNFASPVITLAIPENTNIGSLFPIPLASDRDAGPN 
sp|Q08174-2|PCDH1_HUMAN      LLEGQIEVQDINDNTPNFASPVITLAIPENTNIGSLFPIPLASDRDAGPN 
                             ************************************************** 
 
sp|Q08174|PCDH1_HUMAN        GVASYELQAGPEAQELFGLQVAEDQEEKQPQLIVMGNLDRERWDSYDLTI 
sp|Q08174-2|PCDH1_HUMAN      GVASYELQAGPEAQELFGLQVAEDQEEKQPQLIVMGNLDRERWDSYDLTI 
                             ************************************************** 
 
sp|Q08174|PCDH1_HUMAN        KVQDGGSPPRASSALLRVTVLDTNDNAPKFERPSYEAELSENSPIGHSVI 
sp|Q08174-2|PCDH1_HUMAN      KVQDGGSPPRASSALLRVTVLDTNDNAPKFERPSYEAELSENSPIGHSVI 
                             ************************************************** 
 
sp|Q08174|PCDH1_HUMAN        QVKANDSDQGANAEIEYTFHQAPEVVRRLLRLDRNTGLITVQGPVDREDL 
sp|Q08174-2|PCDH1_HUMAN      QVKANDSDQGANAEIEYTFHQAPEVVRRLLRLDRNTGLITVQGPVDREDL 
                             ************************************************** 
 
sp|Q08174|PCDH1_HUMAN        STLRFSVLAKDRGTNPKSARAQVVVTVKDMNDNAPTIEIRGIGLVTHQDG 
sp|Q08174-2|PCDH1_HUMAN      STLRFSVLAKDRGTNPKSARAQVVVTVKDMNDNAPTIEIRGIGLVTHQDG 
                             ************************************************** 
 
sp|Q08174|PCDH1_HUMAN        MANISEDVAEETAVALVQVSDRDEGENAAVTCVVAGDVPFQLRQASETGS 
sp|Q08174-2|PCDH1_HUMAN      MANISEDVAEETAVALVQVSDRDEGENAAVTCVVAGDVPFQLRQASETGS 
                             ************************************************** 
 
sp|Q08174|PCDH1_HUMAN        DSKKKYFLQTTTPLDYEKVKDYTIEIVAVDSGNPPLSSTNSLKVQVVDVN 
sp|Q08174-2|PCDH1_HUMAN      DSKKKYFLQTTTPLDYEKVKDYTIEIVAVDSGNPPLSSTNSLKVQVVDVN 
                             ************************************************** 
 
sp|Q08174|PCDH1_HUMAN        DNAPVFTQSVTEVAFPENNKPGEVIAEITASDADSGSNAELVYSLEPEPA 
sp|Q08174-2|PCDH1_HUMAN      DNAPVFTQSVTEVAFPENNKPGEVIAEITASDADSGSNAELVYSLEPEPA 
                             ************************************************** 
 
sp|Q08174|PCDH1_HUMAN        AKGLFTISPETGEIQVKTSLDREQRESYELKVVAADRGSPSLQGTATVLV 
sp|Q08174-2|PCDH1_HUMAN      AKGLFTISPETGEIQVKTSLDREQRESYELKVVAADRGSPSLQGTATVLV 
                             ************************************************** 
 
sp|Q08174|PCDH1_HUMAN        NVLDCNDNDPKFMLSGYNFSVMENMPALSPVGMVTVIDGDKGENAQVQLS 
sp|Q08174-2|PCDH1_HUMAN      NVLDCNDNDPKFMLSGYNFSVMENMPALSPVGMVTVIDGDKGENAQVQLS 
                             ************************************************** 
 
sp|Q08174|PCDH1_HUMAN        VEQDNGDFVIQNGTGTILSSLSFDREQQSTYTFQLKAVDGGVPPRSAYVG 
sp|Q08174-2|PCDH1_HUMAN      VEQDNGDFVIQNGTGTILSSLSFDREQQSTYTFQLKAVDGGVPPRSAYVG 
                             ************************************************** 
 
sp|Q08174|PCDH1_HUMAN        VTINVLDENDNAPYITAPSNTSHKLLTPQTRLGETVSQVAAEDFDSGVNA 
sp|Q08174-2|PCDH1_HUMAN      VTINVLDENDNAPYITAPSNTSHKLLTPQTRLGETVSQVAAEDFDSGVNA 
                             ************************************************** 
 
sp|Q08174|PCDH1_HUMAN        ELIYSIAGGNPYGLFQIGSHSGAITLEKEIERRHHGLHRLVVKVSDRGKP 
sp|Q08174-2|PCDH1_HUMAN      ELIYSIAGGNPYGLFQIGSHSGAITLEKEIERRHHGLHRLVVKVSDRGKP 
                             ************************************************** 
 
sp|Q08174|PCDH1_HUMAN        PRYGTALVHLYVNETLANRTLLETLLGHSLDTPLDIDIAGDPEYERSKQR 
sp|Q08174-2|PCDH1_HUMAN      PRYGTALVHLYVNETLANRTLLETLLGHSLDTPLDIDIAGDPEYERSKQR 
                             ************************************************** 
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sp|Q08174|PCDH1_HUMAN        GNILFGVVAGVVAVALLIALAVLVRYCRQREAKSGYQAGKKETKDLYAPK 
sp|Q08174-2|PCDH1_HUMAN      GNILFGVVAGVVAVALLIALAVLVRYCRQREAKSGYQAGKKETKDLYAPK 
                             ************************************************** 
 
sp|Q08174|PCDH1_HUMAN        PSGKASKGNKSKGKKSKSPKPVKPVEDEDEAGLQKSLKFNLMSDAPGDSP 
sp|Q08174-2|PCDH1_HUMAN      PSGKASKGNKSKGKKSKSPKPVKPVEDEDEAGLQKSLKFNLMSDAPGDSP 
                             ************************************************** 
 
sp|Q08174|PCDH1_HUMAN        RIHLPLNYPPGSPDLGRHYRSNSPLPSIQLQPQSPSASKKHQVVQDLPPA 
sp|Q08174-2|PCDH1_HUMAN      RIHLPLNYPPGSPDLGRHYRSNSPLPSIQLQPQSPSASKKHQVVQDLPPA 
                             ************************************************** 
 
sp|Q08174|PCDH1_HUMAN        NTFVGTGDTTSTGSEQYSDYSYRTNPPKYPSKQVGQPFQLSTPQPLPHPY 
sp|Q08174-2|PCDH1_HUMAN      NTFVGTGDTTSTGSEQYSDYSYRTNPPKYPSKQLPHRRVTFSATSQAQEL 
                             *********************************: :     :. . .:   
 
sp|Q08174|PCDH1_HUMAN        HGAIWTEVWE---------------------------------------- 
sp|Q08174-2|PCDH1_HUMAN      QDPSQHSYYDSGLEESETPSSKSSSGPRLGPLALPEDHYERTTPDGSIGE 
                             :..   . ::                                         
 
sp|Q08174|PCDH1_HUMAN        -------------------------------------------------- 
sp|Q08174-2|PCDH1_HUMAN      MEHPENDLRPLPDVAMTGTCTRECSEFGHSDTCWMPGQSSPSRRTKSSAL 
                                                                                
 
sp|Q08174|PCDH1_HUMAN        -------------------------------------------------- 
sp|Q08174-2|PCDH1_HUMAN      KLSTFVPYQDRGGQEPAGAGSPSPPEDRNTKTAPVRLLPSYSAFSHSSHD 
                                                                                
 
sp|Q08174|PCDH1_HUMAN        ------------------------------------- 
sp|Q08174-2|PCDH1_HUMAN      SCKDSATLEEIPLTQTSDFPPAATPASAQTAKREIYL 
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Supplementary Material: Digital format content 
 
 Complete list of proteins identified on the cell surface and secreted proteome of in 
vitro cultured PDAC and healthy pancreatic cell lines (Office Excel sheet) 
 
 Complete list of cell surface and secreted proteins identified in vitro – combined data 
set 
 
 Complete list of in vivo accessible proteins identified after performing whole body 
perfusion on NSG mice bearing orthotopic tumors (Office Excel sheet) 
 
 
 
 Gene ontology complete pictures: 
 
 Gene ontology of the in vitro whole cell surface PDAC proteome 
 Gene ontology of the in vitro exocrine-like cell surface PDAC proteome 
 Gene ontology of the in vitro classical cell surface PDAC proteome 
 Gene ontology of the in vitro QM cell surface PDAC proteome 
 Gene ontology of the in vitro whole PDAC secretome 
 Gene ontology of the in vitro exocrine-like PDAC secretome 
 Gene ontology of the in vitro classical PDAC secretome 
 Gene ontology of the in vitro QM PDAC secretome 
 Gene ontology of the in vivo vascular accessible PDAC proteome – human 
proteome 
 Gene ontology of the in vivo vascular accessible PDAC proteome – mouse 
proteome 
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